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Summary 
Light as a trigger is ideal to perturb biological function due to its high spatial and temporal 
precision. This is evidenced by the ever-expanding arsenal of genetically-encoded optical tools 
available to scientists today. These tools are summarized by the umbrella term ‘optogenetics’ 
and have had an especially transformative impact on neuroscience, since light is able to match 
the high speed and precision of neuronal processes. Alternatively, ‘photopharmacology’ can 
be employed which describes the use of photoswitchable drugs acting on non-genetically 
modified targets to enable their optical control. As an extension of pharmacology, it offers the 
same advantages, such as acute onset and facile translatability from bench to bedside, but 
also suffers from some of pharmacology’s disadvantages, primarily from its lack of target 
selectivity. While this lack of selectivity is often regarded as an issue of ‘selectivity for one 
target over another’, side-effects also arise from a drugs’ action on the desired target but at the 
wrong site, i.e. the wrong cell or organ. While much effort in drug development is directed at 
identifying more and more selective drugs, many effective drugs that are widely prescribed 
have an extensive polypharmacology which we are only beginning to understand. This double-
edged sword of polypharmacology may offer huge untapped potential, as long as its effects 
can be limited to a certain area. One possibility to spatially confine a drugs’ effect lies in the 
combination with genetic methods that allow for precise targeting to specific populations of 
cells. To this end, an anchoring-site can be genetically introduced into the cell of interest and 
subsequently be provided with function by labeling it with a drug, an approach that is described 
as ‘tethered pharmacology’. The photoswitchable variant thereof, ‘tethered 
photopharmacology’, provides reversibility as well as an additional layer of temporal control. 
In this thesis, I will give a general introduction to the concept of tethered photopharmacology 
(chapter 1). Then, I will describe an approach that employs tethered photoswitches to render 
chimeric receptor tyrosine kinases light-sensitive (chapter 2). Next, I introduce an improved 
series of photoswitchable K+ channel blockers and elaborate on antibody-photoswitch 
conjugates that target K+ channels (chapter 3). I will then describe the design of a tethered 
photoswitch for the wild-type AMPA receptor, and show its preliminary biological 
characterization (chapter 4). Approaches towards expanding tethered photopharmacology to 
the μ-opioid receptor are described in chapter 5. The synthesis of a freely-diffusible 
photoswitch for the smoothened receptor is presented in chapter 6. In chapter 7, the synthesis 
of photoswitchable kinase inhibitors is described. Lastly, chapter 8 summarizes miscellaneous 
work on various biological targets. In summary, I will demonstrate how the combination of 
synthetic chemistry with genetic engineering can afford new tools for elucidating biological 
questions, and outline future directions that tethered photopharmacology could take. 
ix 
 
Chapters 
1  Introduction to Tethered Photopharmacology ............................... 1 
2  Optical Control of Receptor Tyrosine Kinases ............................ 11 
3  Optical Control of Potassium Channels ........................................ 48 
4  Tethered Photopharmacology of the AMPA Receptor ................ 99 
5  Tethered Photopharmacology of the μ-Opioid Receptor .......... 121 
6  Optical Control of the Smoothened Receptor ............................ 180 
7  Photoswitchable Receptor Tyrosine Kinase Inhibitors ............ 190 
8  Further Synthesis and Biology .................................................... 212 
9  Appendix ......................................................................................... 230 
  
x 
Table of contents 
1  Introduction to Tethered Photopharmacology ............................... 1 
2  Optical Control of Receptor Tyrosine Kinases ............................ 11 
2.1  Abstract ........................................................................................................................ 11 
2.2  Introduction .................................................................................................................. 11 
2.3  Results and Discussion ............................................................................................... 14 
2.3.1  Design ................................................................................................................... 14 
2.3.2  Activation of LiRTKs by L-Glutamate in Xenopus Oocytes ................................ 15 
2.3.3  Activation of LiRTKs by Light ............................................................................... 17 
2.3.4  Influence of the TMD of LihIR on Chimera Activation ........................................ 18 
2.3.5  Activation of LiRTKs by Light in Mammalian Cells ............................................. 19 
2.3.6  Control of Cell Adhesion in MDCK-II Cells Expressing LiEGFR ........................ 24 
2.4  Summary and Outlook ................................................................................................. 26 
2.5  Supporting Information ................................................................................................ 27 
2.5.1  Xenopus Laevis Oocytes ..................................................................................... 27 
2.5.2  Western Blotting ................................................................................................... 36 
2.5.3  Supplementary Western Blots (cropped) ............................................................ 37 
2.5.4  Supporting Contraction Timelapse Videos.......................................................... 39 
2.5.5  Plasmid Maps and DNA Sequences ................................................................... 41 
  LihIR ........................................................................................................................... 41 
  LiMet ......................................................................................................................... 43 
  LiEGFR ........................................................................................................................ 44 
  KTR‐Erk_mScarlet ...................................................................................................... 45 
2.5.6  Fluorescent Erk reporters .................................................................................... 46 
2.5.7  Compounds .......................................................................................................... 47 
3  Optical Control of Potassium Channels ........................................ 48 
3.1  Introduction .................................................................................................................. 48 
3.2  Results and Discussion ............................................................................................... 50 
xi 
 
3.2.1  Photochromic Blockers Based on Bupivacaine .................................................. 50 
3.2.2  Antibody-Photoswitch Conjugates (APCs) .......................................................... 58 
3.3  Summary and Outlook ................................................................................................. 66 
3.4  Supporting Information ................................................................................................ 67 
3.4.1  Synthesis .............................................................................................................. 67 
  (E)‐N‐(4‐((4‐Aminophenyl)diazenyl)phenyl)‐N‐ethylethane‐1,2‐diamine (3.1) ......... 67 
  N‐(Carboxymethyl)‐N,N,N‐triethylethanammonium chloride (3.3) .......................... 67 
  (E)‐N‐(2‐((4‐((4‐Aminophenyl)diazenyl)phenyl)(ethyl)amino)ethyl)‐1‐((1,3‐
dioxoisoindolin‐2‐yl)oxy)‐3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxanonatriacontan‐39‐
amide (3.2) ................................................................................................................................ 68 
  (E)‐2‐((4‐((4‐((1‐((1,3‐Dioxoisoindolin‐2‐yl)oxy)‐39‐oxo‐
3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxa‐40‐azadotetracontan‐42‐
yl)(ethyl)amino)phenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐oxoethan‐1‐ammonium 
formate (3.4) ............................................................................................................................. 68 
  (E)‐2‐((4‐((4‐((1‐(Amoxy)‐39‐oxo‐3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxa‐40‐
azadotetracontan‐42‐yl)(ethyl)amino)phenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐
oxoethan‐1‐amine diformate (3.5) ............................................................................................ 69 
  tert‐Butyl (3‐(1,3‐dioxoisoindolin‐2‐yl)propoxy)carbamate (3.13) ........................... 70 
  tert‐Butyl (3‐aminopropoxy)carbamate (3.14) .......................................................... 71 
  (E)‐2‐((4‐((4‐(2‐((tert‐Butoxycarbonyl)amino)acetamido)phenyl)diazenyl)phenyl) 
amino)‐N,N,N‐triethyl‐2‐oxoethan‐1‐ammonium formate (3.7) .............................................. 71 
  (E)‐1,4‐Dioxo‐1‐((4‐((4‐(2‐
triethylammonio)acetamido)phenyl)diazenyl)phenyl)amino)‐
7,10,13,16,19,22,25,28,31,34,37,40,43‐tridecaoxa‐3‐azahexatetracontan‐46‐oate (3.9) ....... 72 
  (E)‐2‐((4‐((4‐(50‐(Ammoniooxy)‐4,46‐dioxo‐
7,10,13,16,19,22,25,28,31,34,37,40,43‐tridecaoxa‐3,47‐
diazapentacontanamido)phenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐oxoethan‐1‐
ammonium bis‐(trifluroacetate) (3.8) ....................................................................................... 72 
  (E)‐1‐Butyl‐2‐((4‐((4‐(2,2‐dimethyl‐4,11,53‐trioxo‐3,6,14,17,20,23,26,29,32,35, 
38,41,44,47,50‐pentadecaoxa‐5,10,54‐triazahexapentacontan‐56‐amido)‐3,5‐
dimethylphenyl)diazenyl)phenyl)carbamoyl)piperidin‐1‐ium formate (3.10) .......................... 73 
  (E)‐N‐(4‐((4‐aminophenyl)diazenyl)phenyl)dodecanamide (3.15) ........................ 74 
  (E)‐2‐((4‐((4‐dodecanamidophenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐
oxoethan‐1‐ammonium formate (3.11) .................................................................................... 74 
  (E)‐1‐Butyl‐2‐((4‐((4‐(2‐dodecanamidoacetamido)phenyl)diazenyl) 
phenyl)carbamoyl)piperidin‐1‐ium formate (3.12) ................................................................... 75 
3.4.2  Antibody Modifications ......................................................................................... 76 
  Determining the detection limit of Antibody‐detection by SDS‐PAGE ..................... 76 
xii 
  Optimization of antibody modification procedure to the microgram scale ............. 76 
  Final conditions for all antibody modifications ......................................................... 77 
  Synthesis of keto‐anti‐Kv2.1‐IgG ................................................................................ 80 
  Synthesis of 3.8‐anti‐Kv2.1‐IgG conjugates ............................................................... 80 
3.4.3  Cell Culture and Electrophysiology ..................................................................... 81 
3.4.4  Brain Slice Preparation ........................................................................................ 82 
3.4.5  Supporting Figures ............................................................................................... 82 
3.4.6  Immunohistochemsitry ......................................................................................... 84 
3.4.7  Spectral Data ........................................................................................................ 86 
  (E)‐N‐(4‐((4‐Aminophenyl)diazenyl)phenyl)‐N‐ethylethane‐1,2‐diamine (3.1) ........ 86 
  N‐(Carboxymethyl)‐N,N,N‐triethylethanammonium chloride (3.3) .......................... 87 
  (E)‐N‐(2‐((4‐((4‐Aminophenyl)diazenyl)phenyl)(ethyl)amino)ethyl)‐1‐((1,3‐
dioxoisoindolin‐2‐yl)oxy)‐3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxanonatriacontan‐39‐
amide (3.2) ................................................................................................................................ 88 
  (E)‐2‐((4‐((4‐((1‐((1,3‐Dioxoisoindolin‐2‐yl)oxy)‐39‐oxo‐
3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxa‐40‐azadotetracontan‐42‐
yl)(ethyl)amino)phenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐oxoethan‐1‐ammonium 
formate (3.4) ............................................................................................................................. 89 
  tert‐Butyl (3‐(1,3‐dioxoisoindolin‐2‐yl)propoxy)carbamate (3.13) ........................... 90 
  tert‐Butyl (3‐aminopropoxy)carbamate (3.14) ......................................................... 91 
  (E)‐2‐((4‐((4‐(2‐((tert‐Butoxycarbonyl)amino)acetamido)phenyl)diazenyl)phenyl) 
amino)‐N,N,N‐triethyl‐2‐oxoethan‐1‐ammonium formate (3.7) .............................................. 92 
  (E)‐2‐((4‐((4‐(50‐(Ammoniooxy)‐4,46‐dioxo‐7,10,13,16,19,22,25,28,31,34,37,40,43‐
tridecaoxa‐3,47‐diazapentacontanamido)phenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐
oxoethan‐1‐ammonium bis‐(trifluroacetate) (3.8) ................................................................... 93 
  (E)‐N‐(4‐((4‐aminophenyl)diazenyl)phenyl)dodecanamide (3.15) ............................ 94 
  (E)‐2‐((4‐((4‐dodecanamidophenyl)diazenyl)phenyl)amino)‐N,N,N‐triethyl‐2‐
oxoethan‐1‐ammonium formate (3.11) .................................................................................... 96 
  (E)‐1‐Butyl‐2‐((4‐((4‐(2‐dodecanamidoacetamido)phenyl)diazenyl) 
phenyl)carbamoyl)piperidin‐1‐ium formate (3.12) ................................................................... 97 
4  Tethered Photopharmacology of the AMPA Receptor ................ 99 
4.1  Introduction .................................................................................................................. 99 
4.2  Results and Discussion ............................................................................................. 101 
4.3  Conclusion and Outlook ............................................................................................ 105 
4.4  Supporting Information .............................................................................................. 106 
xiii 
 
4.4.1  Synthesis ............................................................................................................ 106 
  Ethyl 4‐((5‐chloro‐2‐nitro‐4‐(trifluoromethyl)phenyl)amino)butanoate (4.2) ........ 106 
  tert‐Butyl 1‐phenylhydrazine‐1‐carboxylate (4.3) ................................................... 106 
  tert‐Butyl 2‐(5‐((4‐ethoxy‐4‐oxobutyl)amino)‐4‐nitro‐2‐(trifluoromethyl)phenyl)‐1‐
phenylhydrazine‐1‐carboxylate (4.4) ...................................................................................... 107 
  tert‐Butyl 2‐(4‐amino‐5‐((4‐ethoxy‐4‐oxobutyl)amino)‐2‐(trifluoromethyl)phenyl)‐1‐
phenylhydrazine‐1‐carboxylate (4.5) ...................................................................................... 108 
  tert‐Butyl 2‐(4‐(4‐ethoxy‐4‐oxobutyl)‐2,3‐dioxo‐7‐(trifluoromethyl)‐1,2,3,4‐
tetrahydroquinoxalin‐6‐yl)‐1‐phenylhydrazine‐1‐carboxylate (4.6) ....................................... 108 
  4‐(7‐(2‐(tert‐Butoxycarbonyl)‐2‐phenylhydrazineyl)‐2,3‐dioxo‐6‐(trifluoromethyl)‐
3,4‐dihydroquinoxalin‐1(2H)‐yl)butanoic acid (4.7) ................................................................ 109 
  tert‐Butyl 116‐(7‐(2‐(tert‐butoxycarbonyl)‐2‐phenylhydrazineyl)‐2,3‐dioxo‐6‐
(trifluoromethyl)‐3,4‐dihydroquinoxalin‐1(2H)‐yl)‐113‐oxo‐4,7,10,13,19,22,25,28,31, 
34,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82,85,88,91,94,97,100,103,106,109‐
pentatriacontaoxa‐112‐azahexadecahectanoate (4.8) ........................................................... 110 
  (E)‐116‐(2,3‐Dioxo‐7‐(phenyldiazenyl)‐6‐(trifluoromethyl)‐3,4‐dihydroquinoxalin‐
1(2H)‐yl)‐113‐oxo‐4,7,10,13,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67, 
70,73,76,79,82,85,88,91,94,97,100,103,106,109‐pentatriacontaoxa‐112‐
azahexadecahectanoic acid (4.9) ............................................................................................ 111 
  (E)‐N‐(2‐(2‐((6‐Chlorohexyl)oxy)ethoxy)ethyl)‐1‐(4‐(2,3‐dioxo‐7‐(phenyldiazenyl)‐6‐
(trifluoromethyl)‐3,4‐dihydroquinoxalin‐1(2H)‐yl)butanamido)‐
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,87,90,93,9
9,102,105,108‐pentatriacontaoxaundecahectan‐111‐amide (4.10) ....................................... 111 
4.4.2  Spectral Data ...................................................................................................... 113 
  Ethyl 4‐((5‐chloro‐2‐nitro‐4‐(trifluoromethyl)phenyl)amino)butanoate (4.2) ........ 113 
  tert‐Butyl 1‐phenylhydrazine‐1‐carboxylate (4.3) ................................................... 114 
  tert‐Butyl 2‐(5‐((4‐ethoxy‐4‐oxobutyl)amino)‐4‐nitro‐2‐(trifluoromethyl)phenyl)‐1‐
phenylhydrazine‐1‐carboxylate (4.4) ...................................................................................... 115 
  tert‐Butyl 2‐(4‐amino‐5‐((4‐ethoxy‐4‐oxobutyl)amino)‐2‐(trifluoromethyl)phenyl)‐1‐
phenylhydrazine‐1‐carboxylate (4.5) ...................................................................................... 116 
  tert‐butyl 2‐(4‐(4‐ethoxy‐4‐oxobutyl)‐2,3‐dioxo‐7‐(trifluoromethyl)‐1,2,3,4‐
tetrahydroquinoxalin‐6‐yl)‐1‐phenylhydrazine‐1‐carboxylate (4.6) ....................................... 117 
  4‐(7‐(2‐(tert‐butoxycarbonyl)‐2‐phenylhydrazineyl)‐2,3‐dioxo‐6‐(trifluoromethyl)‐
3,4‐dihydroquinoxalin‐1(2H)‐yl)butanoic acid (4.7) ................................................................ 119 
  (E)‐N‐(2‐(2‐((6‐chlorohexyl)oxy)ethoxy)ethyl)‐1‐(4‐(2,3‐dioxo‐7‐(phenyldiazenyl)‐6‐
(trifluoromethyl)‐3,4‐dihydroquinoxalin‐1(2H)‐yl)butanamido)‐
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,87,90,93,9
9,102,105,108‐pentatriacontaoxaundecahectan‐111‐amide (4.10) ....................................... 120 
5  Tethered Photopharmacology of the μ-Opioid Receptor .......... 121 
5.1  Introduction ................................................................................................................ 121 
xiv 
5.2  Results and Discussion ............................................................................................. 124 
5.2.1  Synthesis of the PCL Core ................................................................................ 124 
5.2.2  Synthesis of PORTLs ......................................................................................... 126 
5.2.3  Cis-stable Photoswitches ................................................................................... 127 
5.2.4  Further synthesis ................................................................................................ 130 
5.3  Summary and Outlook ............................................................................................... 131 
5.4  Supporting Information .............................................................................................. 132 
5.4.1  Synthesis ............................................................................................................ 132 
  tert‐Butyl (E)‐(2‐((4‐((4‐aminophenyl)diazenyl)phenyl)amino)‐2‐oxoethyl)carbamate 
(3.6, 5.10) ................................................................................................................................ 132 
  tert‐Butyl (E)‐(2‐oxo‐2‐((4‐((4‐((1‐phenethylpiperidin‐4‐yl)amino)phenyl)diazenyl) 
phenyl)amino)ethyl)carbamate (5.11) .................................................................................... 133 
  tert‐Butyl (E)‐(2‐oxo‐2‐((4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)carbamate (5.12) ............................. 134 
  (E)‐N‐(4‐((4‐(2‐Aminoacetamido)phenyl)diazenyl)phenyl)‐N‐(1‐phenethylpiperidin‐
4‐yl)propionamide (5.13) ........................................................................................................ 135 
  (E)‐1‐Azido‐N‐(2‐oxo‐2‐((4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)‐3,6,9,12,15,18,21,24,27,30,33,36‐
dodecaoxanonatriacontan‐39‐amide (5.28) ........................................................................... 135 
  BG‐DBCO .................................................................................................................. 136 
  (E)‐1‐(8‐(4‐((4‐(((2‐Amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)amino)‐4‐oxobutanoyl)‐
8,9‐dihydro‐1H‐dibenzo[b,f][1,2,3]triazolo[4,5‐d]azocin‐1‐yl)‐N‐(2‐oxo‐2‐((4‐((4‐(N‐(1‐
phenethylpiperidin‐4‐yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)‐
3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxanonatriacontan‐39‐amide (5.14) ..................... 137 
  tert‐Butyl (3‐(methyl(phenyl)amino)propyl)carbamate (5.3) ................................. 137 
  tert‐Butyl (E)‐(3‐(methyl(4‐((4‐nitrophenyl)diazenyl)phenyl)amino)propyl)carbamate 
(5.4)  138 
  tert‐Butyl (E)‐(3‐((4‐((4‐aminophenyl)diazenyl)phenyl)(methyl)amino)propyl) 
carbamate (5.5) ....................................................................................................................... 139 
  tert‐Butyl (E)‐(3‐(methyl(4‐((4‐((1‐phenethylpiperidin‐4‐
yl)amino)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.6) .......................................... 139 
  tert‐Butyl (E)‐(3‐(methyl(4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.7) ............................. 140 
  (E)‐N‐(4‐((4‐((3‐Aminopropyl)(methyl)amino)phenyl)diazenyl)phenyl)‐N‐(1‐
phenethylpiperidin‐4‐yl)propionamide dihydrochloride (5.8) ................................................ 141 
  (E)‐1‐Azido‐N‐(3‐(methyl(4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)‐3,6,9,12,15,18,21,24,27,30,33,36‐
dodecaoxanonatriacontan‐39‐amide (5.29) ........................................................................... 142 
xv 
 
  (E)‐1‐(8‐(4‐((4‐(((2‐Amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)amino)‐4‐
oxobutanoyl)‐8,9‐dihydro‐1H‐dibenzo[b,f][1,2,3]triazolo[4,5‐d]azocin‐1‐yl)‐N‐(3‐((4‐((4‐(N‐(1‐
phenethylpiperidin‐4‐yl)propionamido)phenyl)diazenyl)phenyl)‐λ2‐azaneyl)propyl)‐
3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxanonatriacontan‐39‐amide (5.15) ..................... 142 
  (E)‐1‐(4‐(3‐((4‐(((2‐Amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)amino)‐3‐oxopropyl)‐
1H‐1,2,3‐triazol‐1‐yl)‐N‐(3‐((4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)‐λ2‐azaneyl)propyl)‐
3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxanonatriacontan‐39‐amide (5.19) ..................... 143 
  (E)‐N1‐(4‐(((2‐Amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)‐N43‐(3‐(methyl(4‐((4‐(N‐(1‐
phenethylpiperidin‐4‐yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)‐
4,7,10,13,16,19,22,25,28,31,34,37,40‐tridecaoxatritetracontanediamide (5.17) .................. 144 
  (E)‐1,4‐Dioxo‐1‐((4‐((4‐(N‐(1‐phenethylpiperidin‐4‐yl)propionamido)phenyl) 
diazenyl)phenyl)amino)‐7,10,13,16,19,22,25,28,31,34,37,40,43‐tridecaoxa‐3‐
azahexatetracontan‐46‐oic acid (5.30) .................................................................................... 144 
  (E)‐N1‐(4‐(((2‐amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)‐N43‐(2‐oxo‐2‐((4‐((4‐(N‐(1‐
phenethylpiperidin‐4‐yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)‐
4,7,10,13,16,19,22,25,28,31,34,37,40‐tridecaoxatritetracontanediamide (5.16) .................. 145 
  (E)‐N1‐(4‐(((2‐Amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)‐N10‐(2‐oxo‐2‐((4‐((4‐(N‐(1‐
phenethylpiperidin‐4‐yl)propionamido)phenyl)diazenyl)phenyl) amino)ethyl)decanediamide 
(5.18)  146 
  2,2'‐(Ethane‐1,2‐diyl)bis(4‐bromoaniline) (5.21) ................................................. 146 
  (Z)‐2,9‐Dibromo‐11,12‐dihydrodibenzo[c,g][1,2]diazocine (5.22) ...................... 147 
  (Z)‐di‐tert‐Butyl‐(11,12‐dihydrodibenzo[c,g][1,2]diazocine‐2,9‐diyl)‐dicarbamate 
(5.23)  148 
  (Z)‐11,12‐Dihydrodibenzo[c,g][1,2]diazocine‐2,9‐diamine (5.24) ....................... 149 
  tert‐Butyl (Z)‐(2‐((9‐amino‐11,12‐dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)amino)‐2‐
oxoethyl)carbamate (5.25) ...................................................................................................... 149 
  tert‐Butyl (Z)‐(2‐oxo‐2‐((9‐((1‐phenethylpiperidin‐4‐yl)amino)‐11,12‐
dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)amino)ethyl)carbamate (5.26) ................................... 150 
  tert‐Butyl (Z)‐(2‐oxo‐2‐((9‐(N‐(1‐phenethylpiperidin‐4‐yl)propion‐amido)‐11,12‐
dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)amino)ethyl)carbamate (5.31) ................................... 151 
  (Z)‐N‐(9‐(2‐Aminoacetamido)‐11,12‐dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)‐N‐(1‐
phenethylpiperidin‐4‐yl)propionamide (5.27) ........................................................................ 152 
5.4.2  Crystallographic Data ......................................................................................... 153 
5.4.3  Plasmids, Cell Culture and Electrophysiology .................................................. 154 
5.4.4  Spectral Data ...................................................................................................... 158 
  tert‐Butyl (E)‐(2‐((4‐((4‐aminophenyl)diazenyl)phenyl)amino)‐2‐oxoethyl)carbamate 
(3.6)  158 
  tert‐Butyl (E)‐(2‐oxo‐2‐((4‐((4‐((1‐phenethylpiperidin‐4‐yl)amino)phenyl)diazenyl) 
phenyl)amino)ethyl)carbamate (5.11) .................................................................................... 159 
xvi 
  tert‐Butyl (E)‐(2‐oxo‐2‐((4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)carbamate (5.12) ............................. 160 
  (E)‐N‐(4‐((4‐(2‐Aminoacetamido)phenyl)diazenyl)phenyl)‐N‐(1‐phenethylpiperidin‐
4‐yl)propionamide (5.13) ........................................................................................................ 161 
  BG‐DBCO .................................................................................................................. 162 
  tert‐Butyl (3‐(methyl(phenyl)amino)propyl)carbamate (5.3) ................................. 163 
  tert‐Butyl (E)‐(3‐(methyl(4‐((4‐nitrophenyl)diazenyl)phenyl)amino)propyl)carbamate 
(5.4)  164 
  tert‐Butyl (E)‐(3‐((4‐((4‐aminophenyl)diazenyl)phenyl)(methyl)amino) 
propyl)carbamate (5.5) ........................................................................................................... 165 
  tert‐butyl (E)‐(3‐(methyl(4‐((4‐((1‐phenethylpiperidin‐4‐
yl)amino)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.6) .......................................... 166 
  tert‐butyl (E)‐(3‐(methyl(4‐((4‐(N‐(1‐phenethylpiperidin‐4‐
yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.7) ............................. 167 
  (E)‐N‐(4‐((4‐((3‐aminopropyl)(methyl)amino)phenyl)diazenyl)phenyl)‐N‐(1‐
phenethylpiperidin‐4‐yl)propionamide dihydrochloride (5.8) ................................................ 168 
  (E)‐1‐(8‐(4‐((4‐(((2‐amino‐9H‐purin‐6‐yl)oxy)methyl)benzyl)amino)‐4‐
oxobutanoyl)‐8,9‐dihydro‐1H‐dibenzo[b,f][1,2,3]triazolo[4,5‐d]azocin‐1‐yl)‐N‐(3‐((4‐((4‐(N‐(1‐
phenethylpiperidin‐4‐yl)propionamido)phenyl)diazenyl)phenyl)‐λ2‐azaneyl)propyl)‐
3,6,9,12,15,18,21,24,27,30,33,36‐dodecaoxanonatriacontan‐39‐amide (5.15) ..................... 171 
  2,2'‐(Ethane‐1,2‐diyl)bis(4‐bromoaniline) (5.21) ................................................ 172 
  (Z)‐2,9‐dibromo‐11,12‐dihydrodibenzo[c,g][1,2]diazocine (5.22) ...................... 173 
  (Z)‐di‐tert‐butyl‐(11,12‐dihydrodibenzo[c,g][1,2]diazocine‐2,9‐diyl)‐dicarbamate 
(5.23)  174 
  (Z)‐11,12‐dihydrodibenzo[c,g][1,2]diazocine‐2,9‐diamine (5.24) ....................... 175 
  tert‐butyl (Z)‐(2‐((9‐amino‐11,12‐dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)amino)‐2‐
oxoethyl)carbamate (5.25) ...................................................................................................... 176 
  tert‐Butyl (Z)‐(2‐oxo‐2‐((9‐((1‐phenethylpiperidin‐4‐yl)amino)‐11,12‐
dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)amino)ethyl)carbamate (5.26) ................................... 177 
  (Z)‐N‐(9‐(2‐aminoacetamido)‐11,12‐dihydrodibenzo[c,g][1,2]diazocin‐2‐yl)‐N‐(1‐
phenethylpiperidin‐4‐yl)propionamide (5.27) ........................................................................ 179 
6  Optical Control of the Smoothened Receptor ............................ 180 
6.1  Introduction ................................................................................................................ 180 
6.2  Results and Discussion ............................................................................................. 181 
6.3  Summary and Outlook ............................................................................................... 182 
6.4  Supporting Information .............................................................................................. 183 
6.4.1  Synthesis ............................................................................................................ 183 
xvii 
 
  1‐Chloro‐2‐iodo‐4‐nitrobenzene (6.2) ..................................................................... 183 
  (2‐Chloro‐5‐nitrophenyl)pyridine (6.3) .................................................................... 183 
  4‐Chloro‐3‐(pyridine‐2‐yl)aniline (6.4) .................................................................... 184 
  (E)‐2‐(2‐Chloro‐5‐((4‐(methylsulfonyl)phenyl)diazenyl)phenyl)pyridine (6.6) ........ 185 
6.4.2  Spectral Data ...................................................................................................... 186 
  1‐Chloro‐2‐iodo‐4‐nitrobenzene (6.2) ..................................................................... 186 
  2‐(2‐Chloro‐5‐nitrophenyl)pyridine (6.3) ................................................................ 187 
  4‐Chloro‐3‐(pyridine‐2‐yl)aniline (6.4) .................................................................... 188 
  (E)‐2‐(2‐Chloro‐5‐((4‐(methylsulfonyl)phenyl)diazenyl)phenyl)pyridine (6.6) ........ 189 
7  Photoswitchable Receptor Tyrosine Kinase Inhibitors ............ 190 
7.1  Introduction ................................................................................................................ 190 
7.2  Results and Discussion ............................................................................................. 191 
7.3  Summary and Outlook ............................................................................................... 194 
7.4  Supporting Information .............................................................................................. 195 
7.4.1  Synthesis ............................................................................................................ 195 
  2‐Mercapto‐N‐methylbenzamide (7.4) ................................................................... 195 
  6‐Bromo‐1H‐indazol‐3‐amine (7.2) ......................................................................... 196 
  (E)‐6‐Bromo‐3‐(pyridin‐2‐yldiazenyl)‐1H‐indazole (7.3) .......................................... 196 
  (E)‐N‐Methyl‐2‐((3‐(pyridin‐2‐yldiazenyl)‐1H‐indazol‐6‐yl)thio)benzamide (7.5) ... 197 
  2‐((4‐Cyano‐3‐fluorophenyl)thio)‐N‐methylbenzamide (7.6) ................................. 198 
  2‐((3‐Amino‐1H‐indazol‐6‐yl)thio)‐N‐methylbenzamide (7.7) ................................ 198 
  (E)‐N‐Methyl‐2‐((3‐(phenyldiazenyl)‐1H‐indazol‐6‐yl)thio)benzamide (7.8) .......... 199 
  (E)‐2‐((3‐((4‐(Diethylamino)phenyl)diazenyl)‐1H‐indazol‐6‐yl)thio)‐N‐
methylbenzamide (7.9) ........................................................................................................... 199 
7.4.2  Spectral Data ...................................................................................................... 201 
  2‐Mercapto‐N‐methylbenzamide (7.4) ................................................................... 201 
  6‐Bromo‐1H‐indazol‐3‐amine (7.2) ......................................................................... 202 
  (E)‐6‐Bromo‐3‐(pyridin‐2‐yldiazenyl)‐1H‐indazole (7.3) .......................................... 203 
  (E)‐N‐Methyl‐2‐((3‐(pyridin‐2‐yldiazenyl)‐1H‐indazol‐6‐yl)thio)benzamide (7.5) ... 204 
  2‐((4‐Cyano‐3‐fluorophenyl)thio)‐N‐methylbenzamide (7.6) ................................. 205 
  2‐((3‐Amino‐1H‐indazol‐6‐yl)thio)‐N‐methylbenzamide (7.7) ................................ 206 
  (E)‐N‐Methyl‐2‐((3‐(phenyldiazenyl)‐1H‐indazol‐6‐yl)thio)benzamide (7.8) .......... 207 
  (E)‐2‐((3‐((4‐(Diethylamino)phenyl)diazenyl)‐1H‐indazol‐6‐yl)thio)‐N‐
methylbenzamide (7.9) ........................................................................................................... 208 
xviii 
7.4.3  Crystallographic Data ......................................................................................... 209 
  2‐Mercapto‐N‐methylbenzamide (7.4) ................................................................... 209 
  4‐Bromo‐2‐fluoro‐benzonitrile (7.1) ....................................................................... 210 
  6‐Bromo‐1H‐indazol‐3‐amine (7.2) ......................................................................... 211 
  2‐((3‐Iodo‐1H‐indazol‐6‐yl)thio)‐N‐methylbenzamide ............................................ 212 
8  Further Synthesis and Biology .................................................... 212 
8.1  ExONatide .................................................................................................................. 212 
8.1.1  Supporting Information ....................................................................................... 213 
8.2  APCs for mGluR2 ...................................................................................................... 217 
8.2.1  Supporting Information ....................................................................................... 218 
8.3  Photocleavable dimerizers and oligomerizers .......................................................... 222 
8.3.1  Synthesis ............................................................................................................ 223 
  tert‐Butyl (3‐((4‐(Chloromethyl)‐2‐oxo‐2H‐chromen‐7‐yl)(methyl)amino)propyl) 
carbamate (8.1) ....................................................................................................................... 223 
  tert‐Butyl (2‐(methyl(4‐methyl‐2‐oxo‐2H‐chromen‐7‐yl)amino)ethyl)carbamate (8.2)
  223 
  tert‐Butyl (2‐((4‐(hydroxymethyl)‐2‐oxo‐2H‐chromen‐7‐yl)(methyl)amino)ethyl) 
carbamate (8.3) ....................................................................................................................... 224 
  (9H‐Fluoren‐9‐yl)methyl (2‐((4‐(hydroxymethyl)‐2‐oxo‐2H‐chromen‐7‐
yl)(methyl)amino)ethyl)carbamate (8.4)................................................................................. 225 
8.3.2  Spectral Data ...................................................................................................... 226 
  tert‐Butyl (3‐((4‐(Chloromethyl)‐2‐oxo‐2H‐chromen‐7‐yl)(methyl)amino)propyl) 
carbamate (8.1) ....................................................................................................................... 226 
  tert‐Butyl (2‐(methyl(4‐methyl‐2‐oxo‐2H‐chromen‐7‐yl)amino)ethyl)carbamate (8.2)
  227 
  tert‐Butyl (2‐((4‐(hydroxymethyl)‐2‐oxo‐2H‐chromen‐7‐yl)(methyl)amino)ethyl) 
carbamate (8.3) ....................................................................................................................... 228 
  (9H‐Fluoren‐9‐yl)methyl (2‐((4‐(hydroxymethyl)‐2‐oxo‐2H‐chromen‐7‐
yl)(methyl)amino)ethyl)carbamate (8.4)................................................................................. 229 
9  Appendix ......................................................................................... 230 
9.1  General Remarks Regarding Synthetic Procedures Including Spectroscopy and 
Spectrometry ......................................................................................................................... 230 
9.2  Abbreviations ............................................................................................................. 232 
9.3  References ................................................................................................................. 235 
 1 
 
1 Introduction to Tethered Photopharmacology 
Pharmacology is concerned with the use, effects and mode of action of drugs. Traditionally, 
many drugs are small molecules (SM) that interact with a target protein and elicit a desired 
effect (Figure 1a). Such a drug can be chemically functionalized with a photoswitch (Figure 1b) 
to render it light-sensitive (Figure 1c). Upon illumination, these so-called photochromic ligands 
(PCLs) change their efficacy and/or affinity towards their biological target, which is a protein in 
most cases. Consequently, depending on the nature of the drug, the protein target can be 
activated, inhibited or modulated in a light-dependent fashion; or in other words, the target can 
be turned ‘ON’ or ‘OFF’. Light is a powerful trigger since it offers unmatched spatiotemporal 
precision. This approach represents an extension of pharmacology and is appropriately termed 
Photopharmacology.1 PCLs operate on wild-type proteins and have been created for a wide 
range of diverse targets, including ligand-gated ion channels (such as AMPA,2,3 NMDA4), G 
protein-coupled receptors (GPCRs, such as μ-Opioid5), voltage-gated Na+ and K+ channels6,7 
and receptor-linked enzymes (such as the ANP receptor8).  
Commonly used photoswitches are azobenzenes (Figure 1b), as they isomerize upon 
illumination with light (~320–350 nm) from their thermodynamically-favored, elongated trans-
configuration to the bent cis-configuration. This isomerization is accompanied by a large 
change in geometry and in distance of the 4- and 4’-position (~13 Å to ~8 Å).9 In addition, there 
is a large increase in polarity. The cis-isomer can isomerize back to the trans-isomer under 
thermal conditions with a half-life of milliseconds to days. This feature, as well as the switching 
wavelength, can be readily tuned by choosing the substitution pattern of the azobenzene.10 For 
instance, azobenzene can also isomerize from trans- to cis- by illumination with light of longer 
wavelengths (~400–450 nm), when the electron density is increased by appropriate 
substitutions. Therefore, by using light of two different wavelengths, the switch can reversibly 
be toggled between its trans- and cis-configuration.  
Another strategy to render proteins light-sensitive is by using a photoswitchable tethered ligand 
(PTL, Figure 1d and Figure 2a). Here, a cysteine-mutation is introduced to the target protein 
and covalently conjugated to a PTL molecule that incorporates a maleimide handle. In PTLs, 
the tether and photoswitch are not necessarily part of the pharmacophore, i.e. do not 
necessarily interact with the protein, and the cis-trans isomerization serves to position the 
ligand in or out of its binding pocket. Consequently, the cysteine mutation has to be carefully 
screened to identify a suitable mutation site and the position on the protein of interest (POI) 
has a large impact on the PTLs activity. Indeed, the site of mutation might even dictate whether 
the PTL acts as an agonist or as an antagonist.11–13 The attachment site, along with length and 
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geometry of the tether between maleimide and photoswitch, therefore determines the 
biological effect. The PTL approach is the first example of Tethered Photopharmacology and 
has successfully been applied to a variety of proteins such as K+ channels (Kv,14 TREK-1,15 
HyLighter16), ionotropic glutamate receptor (kainate17 and NMDA12), metabotropic glutamate 
receptors,11 pentameric ligand-gated ion channels (nAChR18) and trimeric ligand-gated ion 
channels (P2X19). 
 
Figure 1. Photopharmacology: controlling biological function with light. a) A ligand 
(orange) interacts with a protein (grey), resulting in a biological effect. b) The photochromic 
ligand (PCL) concept. c) Photoisomerization of azobenzene upon illumination with different 
wavelengths of light (h1 and h2). d) The photoswitchable tethered ligand (PTL) concept.  
Because of their genetically-encoded specificity and high spatiotemporal control, PTLs have 
found several applications for the optical control of biological systems, ranging from in vitro to 
in vivo.20–22 In a notable example, PTLs could identify the role of Kolmer-Agduhr neurons in the 
spinal cord of freely moving zebrafish larvae.22 To this end, the light-gated ionotropic ligand 
channel LiGluR was expressed in these neurons via transgenic zebrafish lines and then 
labelled with the PTL ‘MAG1’. After stimulation by light, the larval fish showed ‘spontaneous 
swim behavior’, identifying a positive drive of Kolmer-Agduhr neurons to the underlying ‘central 
pattern generator’ neuronal network.  
Despite many reported studies, a major drawback of these early examples of tethered 
photopharmacology lies in their reliance on cysteine-maleimide bioconjugation. Prima facie, 
the introduction of a unique cysteine is a relatively small change to the protein and is unlikely 
to affect its expression, trafficking and function. Nevertheless, cysteines introduce a 
considerable amount of free energy to the protein and the free thiol or thiolate can undergo 
redox reactions, especially when surface exposed, and may disrupt the pattern of disulfide 
bonds required for proper protein folding.23 In addition, the requisite maleimide chemistry is 
less-than-ideal as maleimides undergo hydrolysis at physiological pH to form maleamic acid 
which in turn is unreactive towards sulfhydryls.24 Lastly, the design of PTLs is complicated by 
the required mutational cysteine-screen to identify suitable conjugation sites.25 As an 
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alternative to cysteine-mutation, Chin and coworkers introduced unnatural amino acids to the 
MAPK Kinase MEK1 by Amber codon suppression (Figure 2d).26 Here, the unnatural amino 
acid contains a strained alkene/alkyne in its side chain and is conjugated to a PTL termed 
photo-BOLT via bioorthogonal tetrazine click chemistry.27 While this approach is attractive and 
allowed for the optical control over the MAPK signaling cascade, Amber codon suppression is 
technically challenging and photo-BOLT has not yet been applied to receptors or ion channels. 
To overcome these limitations and to make tethered photopharmacology more applicable to in 
vivo experiments, we introduced photoswitchable orthogonal-remotely tethered ligands 
(PORTLs) for the metabotropic glutamate receptor 2 (mGluR2) in 2015.28 The PORTL is 
composed of three parts: (i) photoswitchable ligand, (ii) a long and flexible linker and (iii) a 
bioconjugation motif. For bioconjugation, PORTLs rely on self-labeling protein tags, such as 
the SNAP-tag. The SNAP-tag is a ~20 kDa mutant of the DNA-repair protein O6-alkylguanine-
DNA alkyltransferase that reacts specifically and rapidly (rate constant ~105 - 106 M-1 s-1)29 with 
O6-alkylated benzyl guanine (BG) derivatives in a single turn-over reaction (Figure 2b).30 The 
SNAP-tag is cloned to the POI, usually as an N- or C-terminal fusion protein; but, if required, a 
circularly permutated SNAP-tag can also be introduced into flexible loops. SNAP-fusions are 
well tolerated by many transmembrane proteins, are usually used for fluorophore labelling, and 
a wealth of SNAP-tagged receptors are commercially available, which can be readily 
repurposed for PORTLs.31 Benzyl guanines are essentially inert in aqueous buffers to regular 
cysteines or other nucleophiles that are present under physiological conditions. The SNAP-
receptor gains light-sensitivity only after covalent attachment of the PORTL (Figure 2c). Since 
the PORTL attachment site is remote, the self-labeling protein tag can also be attached to a 
protein in vicinity of the protein target. In the case of a transmembrane protein, the tag can be 
localized to the cell membrane by fusion with a membrane anchor and laterally act on the 
endogenously expressed target receptor. This was described very recently for the AMPA and 
muscarinic acetylcholine (mACh) receptors by Tadross and coworkers (Figure 2e) in an 
approach termed ‘drugs acutely-restricted by tethering’ (DART).32 The anchored self-labeling 
protein tag was labelled with a non-photoswitchable, tethered antagonist, which then acted 
remotely on wild-type AMPA receptors. Clearly, the same strategy readily applies to PORTLs. 
We term these molecules acting from a separate, close-by protein on an endogenous receptor 
‘para-PORTL’ (para from the Greek word for beside, next to, near; Figure 2f).  
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Figure 2. Tethered Photopharmacology: from photoswitchable tethered ligands to 
photoswitchable orthogonal remotely-tethered ligands. a) The photoswitchable tethered 
ligand (PTL) approach relies on a cysteine mutation which is conjugated to a photoswitch via 
cysteine-maleimide chemistry. b) In the photoswitchable orthogonal remotely-tethered ligand 
(PORTL) approach, a self-labeling protein tag (e.g. SNAP-tag) is employed as bioconjugation 
method. The SNAP-tag reacts specifically with benzyl guanine-functionalized payloads. 
Guanine is released in this reaction and the payload is covalently and permanently attached 
to the SNAP-tag. c) In the PORTL strategy, the SNAP-tag is genetically introduced as a fusion 
to the metabotropic glutamate receptor. The light-sensitivity is only gained after labelling with 
the PORTL and upon illumination with light of different wavelengths the receptor can be turned 
ON and OFF in a reversible fashion. d) The photo-BOLT system by Chin and coworkers.26 
Photo-BOLT relies on a photoswitchable inhibitor which is bolted the MAPK Kinase to MEK1 
via a bioorthogonal ‘Click’ reaction with an unnatural amino acid. e) The approach by Tadross 
and coworkers where a self-labeling Halo-tag fused to a membrane anchor was expressed 
and labelled it with a ‘drug-acutely restricted by tethering’ (DART).32 The DART then acts 
inhibitory and remotely on endogenous receptors present on the cell membrane. This approach 
was demonstrated for the ligand-ion channel AMPA and extended to the muscarinic 
acetylcholine receptor (mAChR). f) A combination of DART and PORTL gives rise to the para-
PORTL, allowing the PORTL approach to be extended to endogenous receptors. 
PORTL was pioneered on the mGlu receptors. These belong to the Class C subgroup of the 
GPCR superfamily and are widely, but not exclusively, expressed in neurons. mGluRs feature 
a large extracellular ligand binding domain (LBD) that binds the excitatory neurotransmitter 
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glutamate.33 Glutamate is sandwiched between two large lobes connected by a flexible hinge 
region. The binding event results in a large conformational change which resembles the 
movement of the venus flytrap plant Dionaea muscipula upon catching its prey. Consequently, 
the LBD is commonly referred to as a ‘Venus flytrap domain’. The conformational change is 
transmitted through a rigid, cysteine-rich domain (CRD) to the helical seven transmembrane- 
domain (7 TMD), which in turn couples to a G-protein. There are eight subtypes of mGluR with 
distinct biological functions that are hard to discriminate by traditional pharmacology. Tethered 
(photo)pharmacology can provide a solution, by encoding the SNAP-tag on mGluR subtypes, 
subtype-specific activation by light can be achieved after labeling with a PORTL molecule 
(BGAG12). Figure 3 serves as a model to visualize size and dimensions of the dimeric 
SNAP_mGluR2 fusion after labelling with BGAG12, for calibration a sphere with 5 nm diameter 
is shown (grey sphere).  
 
Figure 3. Model of a dimeric SNAP-mGluR2 labelled with the PORTL (BGAG12). Grey: 
mGluR2, green: SNAP-tag, orange: glutamate, multicolored: BGAG12. Abbreviations: LBD 
ligand binding domain, CRD cysteine-rich domain, 7 TMD seven-helix transmembrane domain. 
Please note that this model is modeled after the glutamate-unbound LBD crystal structure and 
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only serves to illustrate concept, relative size and dimensions of the labelled construct. (pdb: 
5kzq, 4or2, 5cni, 3kzy) 
The remoteness of the bioconjugation site has several consequences for the design of PORTL 
molecules: 
(i) A long, flexible, soluble and inert linker is required to span the distance between 
ligand binding site and bioconjugation handle. Polyethylene glycol (PEG) linkers 
fulfill these criteria; they are harmless, water soluble and do not adhere to protein 
surfaces. In addition, they are commercially available as monodisperse polymers 
of distinct lengths, facilitating syntheses of small libraries of PORTLs with 
increasing linker lengths. 
(ii) In contrast to the PTL approach, it is unlikely that photoswitching results in a 
significant change of length or pointing angle of the ligand headgroup due to the 
long overall length and flexibility of the linker. 
(iii) Similar to a PCL, the biological activity is caused by a change in efficacy or affinity 
upon photoswitching, and the photoswitch is necessarily a part of the 
pharmacophore. Therefore, photoswitching results in a change of affinity or efficacy 
of the PORTL. PORTLs can therefore be conceptualized as ‘PCLs on a leash’. 
(iv) The tethering ensures high local concentrations, since the tether is rarely in its fully 
extended conformation due to statistical sampling of the space. Even by low 
estimates, the effective molarity (Meff) of the headgroup is in the millimolar 
range.32,34  
(v) The high EM allows photoswitchable ligands to be employed with low or modest 
target affinities. It is important that the inactive form of the photoswitch has 
negligible affinity, otherwise the high Meff might result in background activity. 
(vi) The high EM can be advantageous in more complex experiments, e.g. application 
of PORTLs by intracranial injections, since it allows wash-free application at low-
doses that produce no effect in free solution.  
(vii) This is important since the PORTL molecule inherits its parent-drugs’ selectivity 
profile and gains its target specificity only after bioconjugation. The PORTL only 
produces an effect after capture by the self-labeling protein tag and the resulting 
increase in local concentration. 
(viii) Most bioconjugation reactions follow second-order rate constants and low doses of 
PORTL molecules require reactions with high rates. Only a handful of methods like 
self-labeling proteins and strain-promoted inverse electron-demand Diels-Alder 
cycloaddition fulfil this requirement. 
 7 
 
A PORTL can be thought of as a molecule with two or more separate functional parts 
connected by a linker (Figure 4). In the case of mGluR PORTLs, the molecules are made 
up of a photoswitchable pharmacophore that consists of an azobenzene (violet/blue) and 
a glutamate headgroup (orange) on one side and is fused via the long PEG linker (black) 
to a benzylguanine (BG, green) on the other side. The different parts can be interchanged 
and synthetically tailored to the specific need or application. The bioconjugation motif can 
be chosen as BG (for SNAP), benzylcytosine (BC, bright green, for CLIP) or chloroalkane 
(for Halo). The tether can be shortened or extended to adjust the EM or the tether can be 
branched to bear additional functionality, e.g. a second photoswitchable headgroup or a 
fluorophore. The substitution pattern of the azobenzene can be changed to tune the 
activation/deactivation wavelength, e.g. activation by violet (380 nm) or blue light (460 nm). 
mGluR PORTLs are denoted as follows: BXAGn,y B = benzyl; X = G (guanine) or C 
(cytosine); A = azobenzene; G = glutamate, n = number of PEG repeats; y = activation 
wavelength (no number equals 380 nm). In addition, ClAG n,y describes the Halo-tag 
reactive variant (Cl = Chloro). The combination of PORTLs with orthogonal reactivity 
(BG/BC) and activation wavelengths (380/460 nm) offers the opportunity to simultaneously 
control more than one receptor subtype in the same cell. We recently demonstrated this by 
expressing CLIP_mGluR2 and SNAP_mGluR7 in the same cell, labelling with 
BCAG12/BGAG12,460 and activating/deactivating both subtypes independently from each 
other.35  
 
Figure 4. Chemistry LEGO: PORTLs for the metabotropic glutamate receptors (mGluRs). The 
different functional parts are highlighted to show the high modularity and interchangeability of 
these multivalent molecules.36 
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Very recently, Berry et al. virally expressed SNAP_mGluR2 in retinal ganglion cells (RGCs) of 
blind rd1 mice and labelled it with BGAG12,460.37 One intravitreal injection at a concentration of 
500 nM was enough to produce a uniform OFF light response upon exposure of these rd1 
retinae to light that is similar to the OFF light response of wild-type mice retinae. Then, LiGluR 
(vide supra, PTL-conjugated light-gated ion channel) was additionally targeted to RGCs to 
restore ON light responses as previously described.21,38 Together, SNAP_mGluR2 and LiGluR 
could restore ON and OFF light responses. This restored visual acuity (i.e. clarity of vision) in 
living, blind rd1 mice. The mice could differentiate between parallel and perpendicular bars of 
light in behavioral light-avoidance experiments. When BGAG12,460 was employed together with 
the FDA-approved excipient additive β-cyclodextrine, compound release was slowed and light-
guided behavior of mice persisted for a remarkable duration of 6 weeks after one single 
intravitreal injection. This impressive and elegant work highlights the robustness and 
practicability of PORTL molecules and their potential for in vivo applications. The eye is an 
attractive organ for gene therapy due to its immune privilege which circumvents 
immunogenicity of the viral vector. In addition, viral particles can be delivered directly by 
subretinal injection. Due to these advantages, Luxturna®, a treatment to restore vision in 
patients with RPE65 mutation-associated retinal dystrophy, was the first gene therapy 
approved for human patients by the FDA in late 2017.39 Today, it seems plausible that the 
PORTL technology may find applications in human medicine, wherever gene therapy can 
deliver or alter the target protein. However, gene therapy is still in its infancy and 
immunogenicity of the exogenous gene and its mode of delivery is hard to predict.  
In principle, PORTL molecules don't necessitate tethering to the receptor itself or even a protein 
in its vicinity but could also be linked via strong binders that furnish target specificity (Figure 
5a). Such strong binders can be full-size antibodies, which can be synthetically modified with 
PORTLs (Figure 5b). Due to the advances with antibody-drug conjugates (ADCs), the 
chemistry of antibody-modification has been refined to a high level of sophistication40 and could 
be exploited for the synthesis of antibody-photoswitch conjugates (APCs). Nevertheless, 
smaller biologics that are more easily produced and modified might be more amenable to this 
approach. Recombinant single chain immunoglobulin (Ig) derivatives like nanobodies (Nb) as 
well as non-Ig antibody-mimetics such as monobodies, anticalins or affibodies41 can be 
expressed with high yields from bacteria and can straightforwardly be modified to carry a 
SNAP-tag or an unnatural amino acid for subsequent PORTL labelling.42 Very recently, 
Farrants et al. capitalized on this idea by cloning the SNAP-tag on a Nb.43 In this case, the Nb 
recognizes GFP,44 which is fused N-terminally with mGluR2. After conjugation of SNAP-Nb 
with BGAG12, robust photoactivation of GFP_mGluR2 was achieved. Up to now, this 
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represents the most remote attachment site of PORTL molecules. Genetic modification is still 
required to make the GFP-fusion but the outlined principles should apply to nanobodies that 
target the receptor itself. Allosteric nanobodies for the extracellular domain of mGluR2 have 
been developed as of now45 and they could be modified and loaded with BGAGs to ultimately 
photocontrol endogenous receptors without any genetic modification.  
Even more ambitiously, the biological binder could be replaced by a small molecule that binds 
allosterically in a subtype-selective manner. Subtype-selective agonists or antagonists for 
mGluRs have been challenging to develop due to the high similarity of the orthosteric glutamate 
binding pocket,33 but a variety of positive and negative allosteric modulators (PAMs and NAMs) 
exist.46 A bivalent molecule of an allosteric modulator tethered to a photoswitch could be 
synthesized; for mGluR2, the high-affinity PAM ‘BINA’ could be employed (Figure 5b). 
Exploiting the high-affinity of BINA for mGluR2, the low-affinity glutamate-photoswitch could be 
targeted to the allosteric site. This leads to an increase in Meff around the receptor and the 
photoswitch then acts on the orthosteric site through its long tether. These high-affinity PCLs 
would be fully synthetic and significantly smaller, which could aid their biodistribution and 
bioavailability. In addition, the high-affinity PCLs forego the need for biological binders, which 
could be hampered by immunogenicity. 
 
Figure 5. Strategies without genetic modification of the target receptor. a) PORTLs can 
be endowed with target specificity by fusion to a strong allosteric binder. b) This binder can be 
a full-size antibody, or smaller protein binders like nanobodies or affibodies. Even more, the 
binding can be assumed by allosteric modulators (BINA), to obtain fully-synthetic, high-affinity 
PORTLs (pdb: 1igt, 3g9a, 2kzi). The structures in b) are true to scale. 
In this thesis, I seize the opportunities outlined in this introduction. However, its main focus lies 
on an approach that employs PORTL molecules to render chimeric receptor tyrosine kinases 
light-sensitive (chapter 2). Next, I introduce an improved series of photoswitchable K+ channel 
blockers and elaborate on antibody-photoswitch conjugates that target K+ channels in chapter 
3. I will then describe the design of a para-PORTL for the AMPA receptor, and show its 
preliminary biological characterization in chapter 4. Approaches towards expanding the 
PORTL concept to the μ-opioid receptor are described in chapter 5. The synthesis of a PCL 
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for the smoothened receptor is presented in chapter 6. In chapter 7, the synthesis of 
photoswitchable kinase inhibitors is described. Lastly, chapter 8 summarizes miscellaneous 
work on various biological targets.  
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2 Optical Control of Receptor Tyrosine Kinases 
2.1 Abstract 
Understanding the complex orchestra between a signaling ligand, its target receptor and the 
signaling events followed by receptor activation is crucial to deciphering cell and animal 
behavior. Many ligands, their receptors and effector proteins are today understood to the 
molecular detail. However, the spatial and temporal precision of receptor activation and the 
dynamics of their interactions with intracellular signaling and effector proteins remain poorly 
understood. To date, central questions in cell signaling remain enigmatic: How are signals 
integrated along the signaling cascades? How are signaling patterns like oscillation or waves 
created, sensed and processed? What are the dynamics of signaling complexes that assemble 
upon receptor activation? What role does receptor internalization play? To elucidate these 
questions, a tool that allows for repeated, reversible, and adjustable activation of a cell 
signaling pathway is required. Here, I present the engineering and characterization of light-
activatable receptor tyrosine kinases by a fusion of synthetic chemistry with molecular biology. 
2.2 Introduction 
In mammals, three major classes of transmembrane receptors are involved in the transmission 
of extracellular input signals to the cytosol. (i) Ligand-gated ion channels transmit fast and 
short-lasting signals by changing the cell’s electrical potential. For instance, these receptors 
are involved in synaptic transmission in the brain. (ii) G protein-coupled receptors (GPCRs) 
are responsible for a myriad of functions ranging from sensing light over olfactory stimuli to 
regulating metabolism. (iii) Receptor linked enzymes (RLEs), of which the major class are 
receptor tyrosine kinases (RTKs), sense growth factors and hormones. RTKs are involved in 
the control of critical cellular processes like metabolism and cell cycle control, and constitute 
an important target for diabetes and cancer therapy.47 
58 RTKs have been described in humans. They consist of a large extracellular domain (ECD) 
connected to an intracellular kinase (TK) domain by a single-pass transmembrane (TM) α-helix 
(Figure 6a). According to the canonical picture of RTK activation, they mostly exist as 
monomers at the cell membrane and dimerize or oligomerize upon ligand binding, triggering 
activation of their intracellular TK domains. The insulin receptor (IR) is an exception, as it exists 
as preformed dimers in its inactive form (Figure 6b). Furthermore, in the inactive receptor, the 
TK domains are auto-inhibited and only have residual kinase activity. Upon ligand binding, the 
receptors undergo a conformational change, which results in juxtaposition and trans-
autophosphorylation of the inhibitory loop of the TK domains. In other words, the TK domains 
cross-phosphorylate each other triggering a large increase in kinase activity. Subsequently, 
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many of the receptor’s intracellular tyrosine residues are phosphorylated, which produces 
binding sites for adapter proteins. A host of receptor-specific and common adaptors assemble 
around the phosphorylated TK domain and various signaling pathways are activated. Among 
these are the AKT/PKB (protein kinase B) and the canonical Ras/MAP (mitogen-activated 
protein) kinase pathways, whose activations can be followed by the increase in 
phosphorylation of AKT and Erk1/2 (MAP Kinase), respectively.  
An unusual kind of an RTK was cloned in 2003 from the parasitic worm Schistosoma mansoni 
(SmVKR).48 As expected for an RTK, phylogenetic and structural analysis of SmVKR indicated 
a high similarity of the intracellular domain to that of the IR. Surprisingly, and in stark contrast 
to typical RTKs, the ligand binding domain showed a high sequence homology  with the venus 
flytrap domains (VFT) from Class C GPCRs, such as the GABAB or the mGlu receptors. 
Accordingly, this novel class of RTKs was named Venus Kinase Receptors (VKRs). 
Later, the amino acid L-arginine (L-arg) was identified as the ligand for SmVKR and it was 
shown that L-arg binding to the VFT functionally results in phosphorylation of its TKD.49 In the 
parasitic worm, SmVKR is involved in oogenesis (i.e. sexual reproduction), which occurs in the 
mammalian host. Therefore, inhibition of SmVKR is an attractive target in the hunt for new 
drugs for this hard-to-treat parasitic disease. Moreover, VKRs recently gained increased 
attention due to their discovery in other pathogen vectors such as the malaria-spreading 
mosquito Aedes aegypti.50 In later studies, genes encoding VKRs have been identified in in a 
large variety of invertebrates (and particularly in insects) and it is now evident that they form a 
special and distinct class of RTKs, which is absent in vertebrates.51 
 
Figure 6. Structure of receptor tyrosine kinases and Venus Kinase Receptors. a) RTKs 
are made up by a large extracellular domain connected to a tyrosine kinase domain via a 
single-pass α-helix. In VKRs, the large extracellular domain is replaced by a venus flytrap 
domain. Upon stimulation of RTKs or VKRs by their ligands, networks of signaling proteins are 
activated, among them are the AKT and the MAPK pathways. b) The insulin receptor dimer, 
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adapted from Goodsell.52 Its ECD adopts an inverted V-shape and binds insulin (red) on its 
outer edge.  
Early investigations of the biology of VKRs were carried out in oocytes from the frog Xenopus 
laevis (Figure 7). The immature, fully-grown oocyte (Dumont Stage 6) is in a G2-arrested state, 
in which it can remain for a long time. Only induction by external stimuli abolishes this arrest 
state, and the oocyte then maturates and is primed for fertilization. This maturation is 
accompanied by germinal vesicle breakdown (GVBD), which can be easily observed by the 
appearance of a white spot on the pigmented, brown animal pole of the oocyte. In the female 
frog, this maturation is triggered by the steroid hormone progesterone, which acts through an 
unknown receptor to activate intracellular kinase-dependent signaling pathways. These are 
amplified by positive feedback loops so that the stimulation is irreversible, i.e. the oocyte 
switches binary from an ‘OFF’ (immature) to an ‘ON’ (mature) state.53 GVBD can also be 
triggered by other molecules that induce downstream kinase activity, e.g. insulin, which likely 
binds to endogenously expressed insulin receptor-like growth factor (IGF) 1 receptor.54 
Oocytes are large in diameter (~1 mm) and are a robust assay for kinase activity. After injection 
of exogenous RNA encoding for VKRs, they can be used for highly-sensitive and qualitative 
tests for kinase-activity by simple observation of GVBD in response to potential ligands. In 
addition, the molecular components of the RTK-downstream signaling cascade are present in 
the oocyte, enabling the identification of VKR effectors and interaction partners. Taken 
together, these features make Xenopus oocytes an ideal model system to study RTKs. 
 
Figure 7. Xenopus laevis oocytes as assay system for kinase activity. The oocytes of 
female Xenopus laevis frogs (upper left) are large in diameter (~1 mm) and can be 
microinjected with mRNA (bottom left) for expression of proteins. Oocytes undergo germinal 
vesicle breakdown (GVBD) in response to outside stimuli that result in an increase of kinase 
activity. GVBD can be observed by the formation of a white spot on the brown animal pole of 
the oocyte (right). 
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Due to the successes of photopharmacology on receptors that contain a LBD with a venus 
flytrap motif, such as the glutamate-gated ion channels AMPA and NMDA, the ANP or mGlu 
and GABAb receptors, we became interested in the presence of these VFD in other membrane 
proteins. Indeed, it seems that this widespread motif originates from ancient periplasmic 
binding proteins (PBPs) found in prokaryotes and that their evolutionary fusion with 
transmembrane proteins gave rise to small-molecule binding receptors.55 Photopharmacology 
relies on small-molecule photoswitches. RTKs are not amenable to photopharmacology at first 
sight, since they sense large peptide molecules such as insulin (MW = 5.8 kDa), and it is 
unlikely that incorporation and photoswitching of a small-molecule changes the shape or 
geometry of such a large molecule enough to have a large impact on ligand binding. 
In this context, we came across the VKRs in 2008. Due to their late cloning and notable 
absence from classical animal models such as Drosophila melanogaster and C. elegans, the 
biological role of VKRs, their downstream signaling pathways, and their ligands were still 
largely unclear. Nevertheless, we envisioned that these VKRs could be repurposed and made 
light-sensitive by utilizing a photoswitch based on their small-molecule ligand. To this end, the 
VKR from the honeybee Apis mellifera (AmVKR) was chosen.56 Work on the AmVKR was 
initiated by Dr. Harald Janovjak and conducted together with Dr. Johannes Broichhagen during 
their time in the Trauner laboratory. This work was started in close collaboration with Dr. Colette 
Dissous and Dr. Jerome Vicogne, who discovered the VKRs in 2003. From the start, the work 
on AmVKR was hampered by three main issues in mammalian cells:  
(i) bad (surface-) expression, 
(ii) unclear downstream signaling and  
(iii) an incomplete picture of its ligands (supposedly including L-arginine).  
Despite extensive work on AmVKR, these hurdles could not be overcome (see PhD thesis Dr. 
Johannes Broichhagen). Consequently, it was decided to discontinue work on invertebrate 
VKRs but instead engineer chimeric receptors guided by the VKR structure but based on 
mammalian protein domains. 
2.3 Results and Discussion 
2.3.1 Design 
Chimeric receptors were constructed based on three RTKs, the (i) human insulin receptor 
(hIR), (ii) the epidermal growth factor receptor (EGFR) and (iii) the hepatocyte growth factor 
receptor (HGFR or Met). The extracellular domain (ECD) was completely removed after the 
transmembrane (TM) α-helix and fused to the rat mGluR2 domain, including its rigid cysteine-
rich domain (CRD). The mGluR2 domain additionally carries a SNAP-tag for bioconjugation on 
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its N-terminus and originates from the SNAP_mGluR2 construct which was already validated 
for photoswitching with PORTL molecules (BGAGs, see chapter 1).28 Between mGluR2-CRD 
and TM, an additional 2-3 amino acids were introduced to allow for some flexibility. In addition, 
the construct carries the non-cleavable signal peptide from mGluR5 on its N-terminus, to 
ensure trafficking to the cell-membrane, and an HA epitope for immunoprecipitation or 
immunodetection. These constructs were termed LihIR, LiEGFR and LiMet and are supposedly 
a) activated by glutamate and b) activatable by light after labelling with the photoswitch 
(BGAG). See Figure 8 for visualization of the molecular components and their approximate 
sizes.  
 
Figure 8. LiRTK model. Red: RTK domains, grey: mGluR2 domains, green: SNAP-tag, 
multicolor: BGAG PORTL; abbreviations: TKD tyrosine kinase domain, TM (transmembrane), 
LBD ligand binding domain. (pdb: 3kzy, 5kzq, 2mfr, 1irk) 
2.3.2 Activation of LiRTKs by L-Glutamate in Xenopus Oocytes 
Since the LiRTKs are engineered receptors, several questions have to be carefully 
investigated: 
(i) Are LiRTKs expressed? 
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(ii) Are they inactive in absence of L-glutamate or are they constitutively active? 
(iii) Do LiRTKs show an increase in kinase activity in response to addition of L-
glutamate? 
(iv) Does the glutamate-based photoswitch BGAG8 activate the receptor upon 
illumination with light of the appropriate wavelength? 
We produced mRNA coding for LihIR, LiMet and LiEGFR and expressed them in defollucillated 
Xenopus laevis oocytes by microinjection. It should to be noted that LiEGFR could not be 
expressed in oocytes, probably due to an intrinsic incompatibility of the EGFR TKD with the 
oocyte expression system.  
Then, L-glutamate (L-glu) was added (~4 h after  microinjection) and stimulation of kinase-
activity was qualitatively assayed on the next day (after ~18 h) by observing and counting the 
appearance of the white spot on the brown animal pole of the oocyte (more than 14 out of 20 
= GVBD; less than 6 = no GVBD; indicated by + or – on the bottom of Figure 9).  
Experiments where protein is detected, by Western Blotting (WB), had to be completed within 
5 h after microinjection, because cleavage and degradation of receptor proteins was observed 
at later time points. Accordingly, all treatments, e.g. addition of L-glu, were conducted ~4 h 
post-microinjection. After 5 h post-microinjection, the oocytes (n = 2 x 20 per condition/column 
on WB) were lysed and the lysate was divided into two equal parts. One part was used to 
directly detect cytosolic, high-abundance signaling proteins by WB, such as Akt and Erk. The 
other part was subjected to immunoprecipitation (IP) and then WB. Progesterone (PG) was 
included as a positive control, to confirm the health and correct development stage of the 
oocytes and rule out variances due the oocyte-donating animal. 
Several conclusions can be drawn from GVBD and immunoblotting assays with L-glu 
stimulated oocytes (Figure 9): 
(i) Expression of LihIR and LiMet was confirmed by detection of their HA epitope (top 
lane ‘HA’).  
(ii) LihIR and LiMET have no effect on GVBD or phosphorylation of Akt and Erk in 
absence of stimulation by L-glu.  
(iii) Oocytes expressing LihIR and LiMet undergo GVBD in response to L-glu. 
(iv) Oocytes expressing LihIR and LiMet are phosphorylated/activated on RTKs upon 
stimulation by L-glu (PY100 lane) 
(v) This results in phosphorylation of the two major signaling proteins Akt and Erk (pAkt 
and pErk lanes). 
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(vi) As negative control oocytes were injected with mRNA for dead kinase mutants of 
the LiRTKs (a single point mutation in the TKD which completely abolishes kinases 
activity). These do not show GVBD or phosphorylation under the stimulating 
condition, showing that L-glu acts through the LiRTK and that the effect is due to 
kinase activity.  
 
Figure 9. LihIR and LiMet are sensitive to L-glutamate. 20 oocytes each were used for each 
IP, WB and GVBD (in total 60 oocytes per vertical lane). DK= dead kinase, neg. ctrl.; PG = 
progesterone, pos. ctr.  
These experiments were performed at least in three separate, independent experiments using 
oocytes from different animals (see supporting information for additional and uncropped 
original blots) and indicates that we are able to convert the human receptors for insulin and for 
the hepatocyte growth factor into glutamate receptors by replacing their extracellular domain 
with the ligand binding domain from the metabotropic glutamate receptor. 
2.3.3 Activation of LiRTKs by Light 
Encouraged by these results, we next assayed if the photoswitch together with light stimulation 
can elicit the same effects as L-glu alone. Again, LihIR, LiMet and their dead kinase mutants 
were expressed in oocytes by microinjection of RNA. 3 h post-injection, the oocytes were 
placed into a labelling solution containing 100 μM BGAG8 (the PORTL molecule) in buffer. After 
1 h incubation at r.t., the oocytes were removed from the labelling solution and placed into 
fresh buffer. Then, light stimulation was performed from the top using a UV handheld lamp 
(power 12 W, excitation ~350 nm) as follows: 1 min illumination, 5 min dark, 5 cycles. As 
before, one set of oocytes (n = 20 eggs) was observed and counted for GVDB after ~18 h. The 
2. Optical Control of Receptor Tyrosine Kinases 
18 
second set (n = 20 eggs) was subjected to IP and WP for protein detection of chimeras. The 
third set (n = 20 eggs) was used for detection of cytosolic signaling proteins. 
Several observations and conclusions can be drawn from GVBD and immunoblotting assays 
with light-stimulated oocytes (Figure 10):  
(i) Oocytes expressing chimeras and labelled with BGAG8 are inactive in the dark. 
(ii) When illuminated with UV light, the oocytes undergo GVBD, and are 
phosphorylated both on receptor level and on downstream signaling level. 
(iii) AG8 is a negative labeling control and lacks the BG for bioconjugation. Oocytes 
treated with AG8 are not affected by illumination.  
(iv) No effect is observed with the dead kinase mutants. 
(v) Non-injected oocytes serve as another control to show that neither BGAG8 or AG8 
have an effect in absence of chimera. 
Taken together, this is conclusive evidence that we are able to convert the insulin and the 
hepatocyte growth factor receptor into light-activatable receptors.  
 
Figure 10. LihIR and LiMet labelled with BGAG8 can be activated by light. 20 oocytes each 
were used for each IP, WB and GVBD (in total 60 oocytes per vertical lane). DK = dead kinase, 
neg. ctrl.; PG = progesterone, pos. ctr.; BGAG8 = PORTL molecule; AG8 = PORTL without the 
bioconjugation motif, negative labeling control. 
2.3.4 Influence of the TMD of LihIR on Chimera Activation 
Due to their relevance to human medicine, RTKs have been the focus of extensive research 
efforts. Nevertheless, it still remains unclear how the information from ligand-binding to the 
ECD is relayed to the TKD, partly due to the challenges of expressing full-length RTKs for 
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biophysical and structural characterization by X-Ray crystallography or Cryo-EM.57,58 It is an 
astonishing feat that in receptors of over 1300 amino acids in size (only one monomer) this 
critical part of signal transduction is accomplished by a single transmembrane α-helix of only 
around 20-25 amino acids. The hIR TM helix has a repeat of three isoleucines at its N-terminal, 
membrane embedded part, and we reasoned that by adding or removing one isoleucine we 
could reposition the helix inside of the membrane (i.e. ‘push’ our ‘pull’ it out of the membrane) 
which should have a large impact on receptor activation. Accordingly, we cloned a ‘extended’ 
and a ‘truncated’ version of LihIR and investigated them in oocytes (Figure 11). Strikingly, the 
truncation by only one amino acid completely abolished kinase activity. On the other hand, the 
extension was not entirely deleterious but lowered LihIRs apparent affinity for glutamate. 1 mM 
L-glu is sufficient to induce full GVBD in oocytes for the ‘normal’ LihIR, while the extended 
variant only underwent full GVBD at 5 mM. In addition, the extended variant did activate the 
Erk and JNK pathways but not the AKT pathway. This confirms the crucial role of the TM helix 
in the LihIR construct and could be an interesting entry point for the generation of variants with 
reduced affinities or altered downstream signaling. 
 
Figure 11. Influence of a single amino acid insertion or deletion in the fusion region. 20 
oocytes each were used for each IP, WB and GVBD (in total 60 oocytes per vertical lane). DK 
= dead kinase, neg. ctrl.; PG = progesterone, pos. ctr 
2.3.5 Activation of LiRTKs by Light in Mammalian Cells 
LiRTKs would be an even more useful tool if they could be expressed in mammalian cells. To 
this end, LiRTKs were subcloned on a bicistronic vector (pIRES2-AcGFP1). By bicistronic 
expression, the expression levels of LiRTKs and GFP are linked, and it was anticipated that 
this would allow for selection of populations of cells with different expression levels by 
fluorescence-activated cell sorting (FACS). Cell lines were chosen with no or little expression 
of the parent wild-type RTK to avoid issues due to hetero-dimerization of wild-type RTKs with 
LiRTKs. Several cell lines were investigated for expression of the LiRTKs, including Hela, 
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HEK293T, MCF7, MDCK-II and PC12. Many experimental and technical issues were 
encountered. For instance, Hela and HEK293T cells had high background phosphorylation 
levels of AKT and Erk, making any further increases due to LiRTK activity difficult to observe. 
On the other hand, MCF7 did not respond well to transfection by electroporation and in general 
were extremely tedious to culture due to their tendency to form piles when growing on culture 
dishes. Lastly, PC12 partially underwent differentiation into neuronal precursor cells when 
expressing LiRTKs, which made the further culturing impossible. Due to these issues, it was 
later decided to focus on MDCK-II cells expressing LihIR and LiEGFR. 
MDCK-II cells were transfected with LihIR and LiEGFR (on pIRES2_AcGFP1) (and their dead 
kinase mutants) by electroporation. Then cells were selected by antibiotic resistance to 
Geneticin® and FACS-sorted for GFP expression. These cells were then employed for the 
subsequent experiments. 
Expression of LiRTKs in mammalian cells was technically challenging. In contrast to the 
experiments in Xenopus oocytes, a high level of background phosphorylation was observed, 
which could be due to several reasons: 
(i) L-glu is present in the growth medium used for mammalian cells, fetal calf serum 
(FCS) contains ~1 mM L-glu.59 Therefore, normal growth medium (10% FCS) 
contains ~100 μM L-glu stemming from serum alone. This is likely enough to fully 
activate the chimera, since the EC50 of L-glu for mGluR2 is in the two-digit 
micromolar range.60 
(ii) RTKs are never fully cis-autoinhibited since this would preclude the initial trans-
phosphorylation that is required for receptor activation. The TKD is therefore 
thought to ‘breathe’ between states of high or low kinase activity.47 In addition, 
overexpression of RTKs leads to constitutive activation in absence of ligand.61 
Therefore, the expression levels of the chimeras are very likely to have a crucial 
influence on their background activity and stimuli-responsiveness. 
(iii) The activated chimera activates downstream signaling pathways that promote cell 
survival and proliferation. Therefore, cells are selected during culturing that express 
activated chimera in absence of stimulation, i.e. highly expressing cells where an 
increase in activation can be hard to observe. 
These issues are also amplified by the biochemical assays used to detect RTK activation. 
Most commonly, RTK activation is observed by an increase in phosphorylation, detected 
by immunoblotting with phospho-specific anti-RTK antibodies. These antibodies usually 
detect low amounts of phospho-protein, and are in are visualized and amplified by a HRP-
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conjugated secondary antibody. Therefore, a low percentage of phospho-protein of an 
overexpressed RTK is enough to saturate the signal on the only semi-quantitative method 
of WB. In contrast, the detection of phosphorylated downstream proteins might be easier 
since these pathways can compensate for the high level of continuous activation during 
the cell culturing by downregulation, making them more responsive to an additional 
stimulation. 
First experiments were performed by L-glu addition to cells expressing LiRTKs, and in 
many cases, an increase in downstream Erk phosphorylation was observed. Nevertheless, 
reproducibility of these experiments was an issue, possibly due to unidentified interactions 
of L-glu with endogenous proteins, obscuring the results. Consequently, chimera activation 
was probed by light after labeling with the PORTL molecule BGAG8. This is the ‘cleaner’ 
experimental approach, limiting off-target effects, since BGAG8 is bioorthogonal and 
excess molecule is washed out after the labeling reaction. Light was applied using LED 
arrays as previously described and should not cause any phototoxic effects at the 
employed intensities and durations.62  
Accordingly, MDCK-II cells stably expressing LihIR were labelled with 10 μM BGAG8 in the 
dark and at 37°C for 45-60 min in reduced medium (0.5% FCS/OptiMEM/0.1% DMSO), 
which in addition serves to starve the cells and lower the background phosphorylation of 
Erk/Akt. Then, the labeling medium was removed, replaced with HBSS/HEPES and cells 
were constantly illuminated with an LED array equipped with 24 LEDs (380 nm or 505 nm) 
for the indicated time at 37°C. Two controls were included, one where cells were not 
starved, and the other to exclude unspecific effects of DMSO vehicle or light application. 
Directly after the indicated illumination time, cells were washed with ice-cold PBS, placed 
on ice, lysed and subjected to WB (Figure 12). While no increase in phosphorylation of 
LihIR was be observed, likely due to the reasons outlined above, a transient increase in 
phosphorylation of Erk was observed that peaked around 2 minutes and decreased to 
basal levels at 10 min. Longer illumination of 15 or 20 min did not lead to increased or 
sustained receptor activation. Control cells that were only treated with the vehicle (0.1% 
DMSO) did not show any effects upon illumination (‘neg’). Non-transfected (‘mock’) cells 
were treated exactly like the 20 min time point LihIR cells and did not show any increase 
on Erk level, ruling out non-specific effects by the illumination. 
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Figure 12. Activation of LihIR by light in MDCK-II cells. †Non-starved cells. ‡Negative 
control, cells treated exactly like 15 min time point, but only incubated with 0.1% DMSO 
(instead BGAG8). Mock control is non-transfected MDCK-II cells treated like the 20 min time 
point cell. 
Following the same protocol, MDCK-II cells expressing LiEGFR were assayed, but this time 
different light protocols were followed (Figure 13). It should to be noted, that after an initial bout 
of violet light (380 nm), which isomerizes the photoswitch to its cis-isomer, the LiRTK should, 
on these timescales, stay ‘ON’ due to its bistability. Only after illumination with green light (here: 
505 nm), the photoswitch isomerizes back to trans-, turning the LiRTK ‘OFF’. The experiment 
was conducted in a duplicate in presence of the EGFR-inhibitor Gefitinib (1 μM), as negative 
control. 
By comparison of the pErk level of illuminated conditions B-F to the dark pErk level in A, several 
conclusions can be made: 
(i) A: dark panel. 
(ii) B: Illumination with green light for 20 min leads to a small increase on pErk level, 
which is consistent with the fact that the PSS under green light contains a higher 
percentage of cis-isomer than the PSS in the dark. 
(iii) C: Illumination with violet light for 20 min leads to activation of the chimera with a 
~3-fold increase in Erk phosphorylation that is sustained over 20 min in the dark. 
(iv) D: Similar to C, Illumination with violet light for 30 min leads to activation of the 
chimera followed by 10 min in the dark leads to a ~3-fold increase in Erk 
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phosphorylation. This indicates that thermal relaxation in the dark from cis- to trans- 
is likely not occurring to a significant at these timescales. 
(v) E: The largest increase in Erk phosphorylation was observed in cells illuminated 
with green light for 20 min followed by activating violet light for 20 min. The increase 
in pErk is ~5-fold. 
(vi) F: Reversing the wavelengths of E, i.e. first violet and then green light, ceases the 
activation of the receptor, observed by the decrease in pErk to ‘green’ levels 
(compare to B). This decrease is unlikely due to downregulation of Erk itself 
(compare to C and D). Therefore, F serves as an indication that the photoswitching 
of the receptor is reversible, i.e. that the LiRTK can not only be switched ‘ON’ but 
also ‘OFF’. 
 
Figure 13. Activation of LiEGFR by light in MDCK-II cells. a) WB, b) Light-stimulation 
protocol (time in minutes). c) Bands were integrated with ImageJ and pErk divided by tErk, 
then normalized to pErk/tErk of condition A (=1). The absence of the tEGFR in the rightmost 
lane is an experimental artifact. 
In summary, both LihIR and LiEGFR could be activated by light after labelling with the 
photoswitch BGAG8. The downstream Erk activation via LihIR was only transient, while 
LiEGFR light-stimulation led to sustained Erk phosphorylation. This indicates that the LiRTK 
inherits their parent RTKs signaling features. Therefore, LiRTK can potentially be used for time- 
and spatially-resolved studies of the events following RTK activation. The reversibility of ON 
and OFF photoswitching could be illustrated by following different light protocols for LiEGFR 
stimulation. It should be noted that western blotting is not an appropriate method for observing 
signaling events in a time-resolved manner. Great care was taken not to introduce outside 
variances, cells were treated exactly in the same manner except the different light protocols. 
Nevertheless, WB is only a semi-quantitative method and integrates the signal over a 
population of a few hundred thousand cells. However, signaling pathways should be studied 
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on a single cell level since every cell is different and integrates outside stimulation. The bulk 
observation can be misleading and misrepresent the single-cell events. One textbook example 
of this is the maturation (GVBD) of Xenopus oocytes (vide supra).53,63 Despite these limitations, 
the experiments shown above are a strong indication that LiRTKs are indeed activated by light.  
Lastly, the astonishing events are highlighted here that have to happen on a molecular level to 
cause a light-induced effect on Erk phosphorylation: (i) a photoswitch is covalently attached to 
a protein, (ii) absorbs a photon of the appropriate energy and isomerizes to cis-, (iii) this 
induces ‘closure’ of the venus-flytrap, ligand-binding domain, (iv) which in turn is transmitted 
through the cell membrane to the intracellular tyrosine kinase domain, (v) ultimately resulting 
in kinase activation and initiation of downstream signaling events. 
2.3.6 Control of Cell Adhesion in MDCK-II Cells Expressing LiEGFR 
A431 cells overexpressing EGFR loose cell-to-cell adhesion upon addition of EGF 
(unpublished observations by Chiara Zambarda, Growth Factor Mechanobiology Group, MPI 
for Medical Research Heidelberg). To observe and analyze this, cells were seeded on 
micropatterned dishes, where cells can only attach and grow on circular islands. These dishes 
are produced by adapting published protocols,64,65 where a glass coverslip was PEGylated and 
this layer was removed by UV irradiation through a mask, i.e. photomasking. The A431 cells 
were seeded on these dishes to form round, confluent islets of cells and upon EGF addition, 
the cells seemed to ‘contract’, forming a pile in the islet’s middle. This can then be quantified 
by comparing the areas that are covered by cells before and after EGF addition.  
We asked if cells expressing LiEGFR upon L-glu addition exhibit the same behavior as the 
A431 upon EGF addition. To this end, MDCK-II cells expressing LiEGFR were seeded on the 
micropatterned dishes and a timelapse video with a 30 sec frame rate was recorded (Figure 
14). Before stimulation, the cells move around and completely fill out the round islets. Upon 
addition of L-glu (to a final conc. of 1 mM, 1/100 dilution from 100 mM stock) at t = 10 min, the 
cells lose cell-to-cell adhesion (see t = 11, 13, 18 min). In overall, the cell islets ‘contract’, a 
process that is immediate and rapid and can be followed on a minute timescale. The response 
is reversible, and the cells relax and re-expand to the previous state (t = 40 min). 
Importantly, the negative controls (MDCK-II ‘mock’, non-transfected) and MDCK-II/LiEGFR_dK 
(dead kinase mutant) do not contract after L-glu addition (see chapter 2.5.4). 
MDCK/LiEGFR_LBD cells that express a mutant with lower affinity for L-glu (R57A)66, exhibit 
the contraction but to a smaller extent, i.e. less cells contract and less pronounced. 
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Figure 14. Time-lapse of MDCK-II cells stably expressing LiEGFR. L-glu (1 mM) was added 
after t = 10 min. For clarity, the upper right islet is marked with a white circle, representing the 
area covered by cells at t = 0 min. 
The contraction of MDCK-II/LiEGFR is similar to the response of A431-EGFR upon EGF 
addition (unpublished results from Chiara Zambarda) but more heterogeneous. On a single 
cell level, it is obvious that some MDCK-II/LiEGFR cells show a strong response, but that other 
cells do not contract at all. This is most likely due to highly variable levels of receptor 
expression, which is a common issue of traditional stable expression from cDNA.67 
Experiments are underway to directly detect the LiEGFR receptor on cell-to-cell level by 
immunofluorescence. 
That RTKs such as EGFR can influence the mechanobiology of cells is an active and new field 
of research and the knowledge of the mechanisms underlying these observations and their 
significance is incomplete. In collaboration with the ‘Growth Factor Mechanobiology’ group we 
are actively working on identifying the molecular components underlying the signal 
transduction that must lie between binding of EGF/L-glu and the phenotypic response 
(‘contraction’). In addition, we are planning to adapt these experiments for labelling with the 
photoswitch ‘BGAG8’ and producing the same contraction with light. 
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2.4 Summary and Outlook 
Here, several Receptor Tyrosine Kinases (RTKs) were converted into glutamate receptors and 
then into photoreceptors. This was accomplished by engineering chimeric receptors in analogy 
to Venus Kinase Receptors (VKRs), a special class of RTKs only found in invertebrates. We 
cloned chimeras featuring the venus-flytrap, ligand-binding domain of the metabotropic 
glutamate receptor 2 and the intracellular domains from a selection of human RTKs. In addition, 
these chimeras carry a self-labeling protein tag (i.e. SNAP-tag) on its extracellular N-terminus. 
Experiments in a Xenopus laevis assay indicate that LiRTKs can be activated by the amino 
acid L-glutamate (L-glu). Moreover, after reaction of the SNAP-tag with a photoswitchable 
orthogonal remotely-tethered ligand (PORTL), the LiRTK gains light sensitivity. The labeled 
LiRTK can be activated by light in both the Xenopus laevis assay and in mammalian MDCK-II 
cells. We demonstrated that this approach is not only applicable to the insulin receptor but also 
to other RTKs, such as EGFR and Met. 
These LiRTKs can be expressed in mammalian cells, and enable optical control over the 
downstream MAPK signaling pathway. Moreover, they can control the mechanobiology of 
epithelial cells; in MDCK-II/LiEGFR cells stimulation by L-glu leads to a loss of cell-to-cell 
adhesion. 
While we could clearly demonstrate the LiRTK concept, all conclusions in mammalian cells are 
based on downstream observations, such as Erk activation or cell contraction. We are still in 
the process of observing the activation of the receptor by light or L-glu on the receptor level 
itself, i.e. the increase in RTK kinase activity. Investigations are ongoing to produce 
mammalian cells lines expressing LiRTKs on a more physiological level. In combination with 
microscopy-based readouts, these cell lines will allow perturbation of LiRTKs by light in a 
spatiotemporally defined manner, while observing the readout in real-time. 
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2.5 Supporting Information 
 
Supporting Figure 1. Elk1/SRF (from Qiagen) transcriptional dual luciferase readout of Erk 
activity in Hela cells transfected with LihIR and stimulated with L-glu. 
2.5.1 Xenopus Laevis Oocytes 
RNA was produced by mMESSAGE mMACHINE™ T7 Transcription Kit (Invitrogen #AM1344) 
according to the manufacturer’s instructions.  
mRNA preparation: 
DNA was linearized by digesting 5 μg of DNA (on pcDNA3.1 vector) by the FastDigest 
(ThermoScientific, #00151181) protocol with PmeI (MssI) (Thermo Scientific, #FD1344) for 1.5 
h at 37 °C. Afterwards, subsequent addition of 250 μL absolute EtOH, followed by 10 μL of 3 
M NaOAc was carried out before storing the solution at -20 °C overnight for precipitation of the 
linearized plasmid, which was then isolated by centrifugation for 20 minutes at 12,000 rpm at 
4 °C. After removal of the supernatant, DNA was dissolved in 15 μL dH2O and 1 μg was 
reverse-transcribed by using the mMessage mMachine T7 transcription kit (life technologies, 
#AM1344) according to the manufacturer’s instructions. Pure mRNA was taken up in nuclease-
free water, aliquoted and stored at -20 °C. 
Injection and treatment: 
Female frogs were anesthetized, oocytes were surgically harvested, washed and stored in 
ND96 buffer. Oocytes were defolliculated manually with forceps before injection with cRNA (60 
ng) coding for the construct. L-Glutamate was added to reach the appropriate final 
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concentration for stimulation (1 mM or 5 mM) 3 h after cRNA Injection. GVBD was observed 
after 15 h. 
For immunoprecipitation and western blotting, the oocytes were lysed 5 h after cRNA injection 
(i.e. before GVBD). 
For the light-stimulation experiments, oocytes were incubated at 19°C for 1 h with BGAG8 (1% 
DMSO in ND96 buffer), 3 h after cRNA injection was performed. The oocytes were transferred 
back to ND96 buffer and illuminated at 365 nm in cycles (12 W, 1 min UV, 5 min dark, 5 
repetitions). GVBD was observed after approximately after 15 h. 
 
Supporting Figure 2: GVBD scores and WB identifiers/layout. July 2017  
Original Blots (July 2017): 
GVBD 0/20 14/20 0/20 0/20 0/20 13/19 0/20 0/20 0/20 0/20 12/19.
IDENTIFIER # 3 1 2 5 9 7 8 12 14 15 16
conditions
mRNA IR IR IR IRDK MET MET MET METDK Ctrl Ctrl Ctrl
BGAG SPL15 SPL15 SPL14 SPL15 SPL15 SPL15 SPL14 SPL15 SPL15 SPL14 PG+DMSO
light UV UV UV UV UV UV UV UV UV
results
GVBD OK OK OK
total IR/MET OK OK OK OK OK OK OK OK
Phospho OK OK
P‐ERK OK OK OK
P‐Akt OK OK OK
BLOT1
GVBD 0/20 13/19 0/18 0/12 10/15. 0/12 14/20 SPL 15 = BGAG8
NUMERSO 18 4 6 11 10 13 17 SPL14 = AG8
IDENTIFIER #
mRNA IR IR IRDK MET MET MET‐DK Ctrl
treatment glut 1mM glut 1mM glut 1mM glut 1mM PG+DMSO
results
GVBD OK OK OK
total IR/MET OK OK OK OK OK OK
Phospho OK OK
P‐ERK OK OK OK
P‐Akt OK OK OK
BLOT2
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Original Blots (November 2014): 
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Original Blots (November 2016): 
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Cropped bots (spring 2016): 
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2.5.2 Western Blotting 
Western blotting protocol: 
• Cells were placed on ice, medium was removed and washed with cold PBS (2mL). 
• Cell lysis buffer was prepared: 0.5 vol% phosphatase inhibitor (Sigma, #P5726-5ML) and 
0.25 vol% protease (Sigma, #P8340) inhibitor were added to 100 μL cold RIPA-SDS buffer. 
• Cell lysis buffer was added to the wells and the cells were scrubbed off and transferred to a 
1.5 mL Eppendorf tube. The cell suspension was centrifuged (14000 rpm, 4 °C). The 
supernatant was transferred carefully to a new tube without disturbing the DNA pellet. 
• For determination of protein concentrations, a BCA assay was performed using a BCA kit 
(ThermoScientific, #23225) on a colorimetric platereader (Thermo Scientific, MultiscanEX) 
according to the the manufacturer’s instructions. 
• For each sample 20-30 μg of protein was added to 7.5 μL of NuPAGE blue LDS sample buffer 
(4X, life technologies, #NP0007) and 3 μL Redox buffer (10X) and filled up to a total volume of 
30 μL with ddH2O. Samples were heated to 70 °C for 10 min prior to loading on a SDS-PAGE 
gel (4-12% NuPAGE Bis-Tris Plus Gel, life technologies, #BG04120BOX or #WG1401BOX ). 
Electrophoresis was carried out at 80-180 V. 
• Protein was transferred on a PVDF membrane (1.5-2 h, 55-65 V) before blocking the 
membrane with caseine blocking buffer for 30 min at r.t., then the primary antibody (usual 
dilution 1/1000 in recommended primary antibody buffer) was added and incubated at 4 °C 
overnight under agitation. The membrane was washed 5 times 5-10 min each with PBS (0.05% 
Tween-20) before the secondary antibody was added (1/30000 dilution in blocking buffer) and 
incubated at r.t. for 30-45 min under agitation. The membrane was washed 2 times, 5-10 min 
each, with PBS (0.05% Tween-20) and one time with cold PBS. 
• After removal of washing buffer, the membrane was treated with chemiluminiscent substrate 
(Pico, Thermo Scientific, #34080 or Dura, Thermo Scientific, #34076F ) according to the 
manufacturer’s instructions. CL-XPosure X-ray film (Thermo Scientific, #OK196129) was 
exposed to luminiscence signal for a duration of 30 seconds to 20 minutes prior to 
development. Blots were scanned and processed with ImageJ for integration of signals. 
• For incubation with a different primary antibody, the membrane was stripped with stripping 
buffer (Gene Bio Application, #CST0100) and washed with 2 times with PBS (0.05% Tween-
20) before repeating the above steps. 
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2.5.3 Supplementary Western Blots (cropped) 
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2.5.4 Supporting Contraction Timelapse Videos 
 
Supporting figure: MDCK-II mock cells (non-transfected). L-Glu (1 mM) was added at t = 10 
min.  
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Supporting figure: MDCK-II/LiEGFR_LBD (low-affinity mutant). L-Glu (1 mM) was added at t = 
10 min.  
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Supporting figure: MDCK-II/LiEGFR_dk (dead-kinase mutant). L-Glu (1 mM) was added at t = 
10 min.  
2.5.5 Plasmid Maps and DNA Sequences 
 LihIR 
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 LiMet 
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 LiEGFR 
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 KTR-Erk_mScarlet 
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2.5.6 Fluorescent Erk reporters 
To take full advantage of the spatiotemporal precision that a light-activatable LiRTKs offer, the 
experimental setup has to be performed so that both light-stimulation as well as the 
downstream readout can be performed with a resolution of milliseconds to minutes. To this 
end, a downstream Erk readout could be employed, more specifically ‘kinase translocation 
reporters’ (KTRs).68,69 These consist of a fluorescent protein (FP) fused to a combined nuclear 
localization and nuclear export sequence (NLS and NES). The NLS/NES sequence is 
engineered to be a substrate for the Erk kinase, and is phosphorylated upon Erk activation in 
such a way that the KTR construct is exported from the nucleus into the cytosol. This enables 
real-time measurement of Erk activity by following the ratio of FP between the nucleus and the 
cytosol. The available, published KTR-Erk reporters are not compatible with the LiRTKs 
because they are fluorescent at wavelengths that are required for the activation/deactivation 
of the LiRTKs. Therefore, a KTR-Erk sensor was cloned utilizing the monomeric, bright FP 
‘mScarlet’ with maximum absorbance at 569 nm, which is red-shifted enough to allow for 
orthogonal ON/OFF photoswitching of the LiRTKs.70 
The advanced, fully-motorized DMi8 inverted wide field microscope (Leica) is an attractive 
platform for these experiments. It allows automatization of the protocols for light stimulation 
and readout, and at the same time allows the light to be applied only to a part of the dish, to 
demonstrated the spatial features of light activation. Complex, customized protocols can be 
easily programmed, e.g. light stimulation for N seconds on position XYZ is followed by a 
fluorescent readout at time M.  
To validate the KTR-Erk Sensor, it was transiently transfected in Hela cells and saturating 
insulin was added. Indeed, the translocation of KTR-Erk_mScarlet out of the nucleus could be 
followed in real-time peaking at 16 min, which normalized to baseline levels 30 minutes post-
stimulation (Figure 15). 
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Figure 15. Hela cells transfected with KTR-Erk_mScarlet and stimulated with insulin. 
Several time points are depicted (minutes). 
2.5.7 Compounds 
Detailed experimental procedures for the synthesis of all employed photoswitches are 
described in: 
Broichhagen, J., Damijonaitis, A., Levitz, J., Sokol, K.R., Leippe, P., Konrad, D., Isacoff, E.Y., 
Trauner, D., 2015. Orthogonal Optical Control of a G Protein-Coupled Receptor with a SNAP-
Tethered Photochromic Ligand. ACS Cent. Sci. 1, 383–393.  
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3 Optical Control of Potassium Channels 
3.1 Introduction 
Neurons are excitable cells that generate electrical signals, called action potentials. Upon 
receiving information, they propagate these signals along their cell body and transmit them to 
other neurons by synaptic transmission. 
Action potentials are primarily shaped by two components: a transient inward current of Na+ 
ions and a delayed outward current of K+ ions. When a neuron is depolarized from its resting 
potential (around -70 mV) to threshold potentials (around -50 mV) by a cationic 
neurotransmitter-gated channel (e.g. AMPA), voltage-gated Na+ (Nav) channels open (Figure 
16). This causes a rapid and transient inward flow of Na+ ions along their concentration 
gradient, resulting in a sudden further depolarization of the membrane. The depolarization 
induces a delayed opening of voltage-gated K+ (Kv) channels. K+ ions then flow outwards, since 
K+ ion concentration is higher inside than outside of the cell. The efflux of K+ repolarizes and 
resets the membrane potential to its resting value and primes the neuron for a new action 
potential.  
 
Figure 16. The first recorded action potential from Hodgkin and Huxley in 1939.71 The 
action potential was recorded between the in- and outside of a giant axon from squids. 
Action potentials are at the heart of neuronal signal transduction and the interplay between 
many neurons connected to networks and circuits in the brain is the foundation of animal 
behavior. To sculpt the circuitries’ responses to input signals, action potentials come in many 
shapes and frequencies. Contributing to that diversity in excitability, K+ channels exhibit a broad 
variety of gating properties. This is manifested in the large number of different K+ channel 
subtypes expressed in neurons. In total, four families encode a total of 78 K+ channel subtypes: 
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voltage-gated (Kv), two-pore domain (K2P), Ca2+-activated (KCa) and inwardly-rectifying (Kir). 
The largest family, Kv channels, counting 40 different genes in the human genome.72 K+ 
channels constitute important drug targets for a variety of diseases, not only in the CNS but 
also for metabolic or autoimmune disorders. Unfortunately, it has been difficult to target K+ 
channels in a subtype-selective manner with traditional pharmacology, since most K+ channel 
modulators interact with the pore region, a region with high sequence homology among 
subtypes. Due to this absence of selective openers or blockers, the target identification of K+ 
channels has largely been limited to information obtained from genetic diseases or rodent 
knockout models, greatly slowing down ion channel drug discovery.73 
The physiological action of K+ channels takes place on a millisecond timescale. Therefore, 
tools that allow perturbation of K+ channels on this timescale are highly useful, such as 
photoswitchable channel blockers. In 2004, Trauner, Kramer and Isacoff described such a 
photoswitchable blocker for the Shaker K+ channel.14 These blockers are based on 
tetraethylammonium (TEA), a quaternary ammonium (QA) and an unselective blocker of K+ 
channels. TEA was modified with a photoswitchable azobenzene and this enabled optical 
control over Shaker channel gating and allowed for remote control of neuronal firing by light in 
neurons. These compounds based on QAs, such as MAQ,14 AAQ74 and DENAQ75 have shown 
great promise in the field of vision restoration (Figure 18a). In particular, DENAQ confers light-
sensitivity to degenerated retinae from blind mice and is a potential treatment for eye diseases, 
e.g. retinitis pigmentosa and age-related macular degeneration.75 These compounds primarily 
act through intracellular block of the TEA binding site of K+ channels and are use-dependent, 
open-state blockers.6 Despite their potential, one drawback has been their low target affinity 
with effective concentrations in the high micromolar to single-digit millimolar range.6 This is 
presumably due to their permanent charge, which prevents these molecules from efficiently 
crossing the cell membrane to reach their site of action. While this issue is partly compensated 
for by uptake through pore channels such as P2X7, the comparatively low potency remains a 
challenging issue.76 In the first part of the chapter, this matter is overcome with the design, 
synthesis and electrophysiological characterization of an improved series of photoswitchable 
channel blockers based on the non-charged local anesthetic bupivacaine (Chapter 3.2.1). 
One way to furnish photoswitchable blockers with target specificity for a K+ channel subtype 
could lie in the fusion of small-molecule drugs with antibodies. The field of antibody-drug 
conjugates (ADCs) was mostly pioneered in cancer therapy. There, conjugation of cytotoxic 
drugs to antibodies that recognize specific markers on cancer cells allow drugs to be targeted 
to specific populations, without harming the healthy surrounding tissue. These advances 
culminated in FDA approvals for drugs like trastuzumab emtansine (Kadcycla®), which has 
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shown efficacy in HER2 positive breast cancer. Fueled by these successes, the requisite 
chemistry of antibody-drug conjugates (ADCs) has been refined to a satisfying degree of 
sophistication over the last decade.40 We envisioned that by attaching a photoswitchable K+ 
channel blocker to an antibody, we could photoswitch endogenous K+ channels with subtype 
specificity. Kv channels are mostly buried in the membrane with only the loop between 
transmembrane helices S1 and S2 accessible from the extracellular side (Figure 17a). In the 
second chapter, we describe the synthesis of antibody-photoswitch conjugates (APCs) 
targeting the S1-S2 loop of Kv1.1 and Kv2.1 and their electrophysiological characterization 
(Chapter 3.2.2). 
 
Figure 17. Concept of antibody-photoswitch conjugates a) left: Scheme based on the 
bacterial MthK, adapted from David Goodsell77 right: Shaker K+ structure b) A photochromic 
blocker is tethered to an antibody. The antibody binds to the exposed S1-S2-loop allowing the 
remotely attached photochromic blocker to light-gate the channel. 
3.2 Results and Discussion 
3.2.1 Photochromic Blockers Based on Bupivacaine 
One strategy to equip drugs with light-sensitivity is termed ‘azo-extension’.78 In this approach, 
furnishing drugs with a photoswitch is achieved by identifying positions in their chemical 
structure where modification changes the biological activity but where the modification is not 
completely deleterious. After functionalizing that position with a photoswitch, it is likely that 
photoisomerization leads to light-dependent change in biological activity. Accordingly, we 
envisioned to install an azobenzene in the para-position of the pipecolic amide of bupivacaine 
(Figure 18b). Isomerization of the azobenzene from its cis- to its trans-configuration by light 
should then change the PCLs efficacy and/or affinity to the K+ channel, enabling optical control 
over K+ currents (Figure 18c). It should be noted that bupivacaine contains an asymmetric 
carbon but is sold and used as a racemic mixture. Therefore, the synthesis was planned 
without stereoselectivity and in a modular fashion to yield a short series of three 
azobupivacaines AB1-3 bearing different substituents on the azobenzene to finetune switching 
wavelengths and photswitching kinetics. 
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Figure 18. Logic and design of photoswitchable azobupivacaines AB1-3. a) 
Photoswitchable blockers based on TEA. b) ‘Azo-extension’ strategy of azobupivacaines. c) 
Azobupivacaines AB1-3 block channels in one configuration while allow ion flow in the other. 
The synthesis of AB1-3 commenced with acyl chloride formation of pipecolic acid (1) followed 
by amide bond formation with 4-bromo-2,6-dimethylaniline to give pipecholyl xylidine 2. Direct 
treatment of 2 with n-butylbromide furnished tertiary amine 3 in fair overall yields (Scheme 1). 
Pd-catalyzed amination of 3 using LiHMDS as the nitrogen source, followed by direct 
deprotection of the silyl groups furnished aniline 4 as the common precursor for further 
derivatization. AB1 was then accessed by a Baeyer-Mills reaction of 4 with nitrosobenzene. 
Treatment of 4 with t-BuONO followed by trapping of the resultant diazonium ion with N,N-
dimethylaniline furnished AB3 in moderate yields. Aniline 6 was obtained from 4 after Baeyer-
Mills reaction with 4-nitronitrosobenzene followed by reduction of the nitro group using sodium 
sulfite. Amide bond formation of 6 with chloroacetyl chloride, followed by a Finkelstein reaction 
and careful substitution with ammonia furnished AB2 in good overall yields. 
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Scheme 1: Synthesis of AB1-3. 
Next, the photoswitching properties of AB1-3 were evaluated by means of UV/Vis 
spectroscopy. The optimal wavelengths for cis-to-trans isomerization were determined in a 
wavelength-screen by changing the illumination wavelength while looking at minimal/maximal 
extinction at the absorbance maximum near the π-π* transition, as described previously.79 
UV/Vis spectra of AB1-3 were then recorded under illumination of these optimal switching 
wavelengths (Figure 19, upper panels; AB1: cis = 360 nm (light gray), trans = 420 nm (violet); 
AB2: cis = 380 nm (dark gray), trans = 500 nm (green); AB3: cis = 460 nm (blue); no 
illumination is black in all cases. Both AB1 and AB2 exhibit bistable behavior, e.g. slow thermal 
relaxation back to the trans-isomer in the dark (Figure 19, lower panel). This is an 
advantageous property in photoswitches since it allows to switch using a short bout of light as 
opposed to constant illumination. AB3 is red-shifted and exhibits fast thermal relaxation in the 
dark. Red-shifting can be beneficial in applications such as vision restoration, where a quick 
turn-off in the dark is required. In addition, longer-wavelength light allows deeper tissue 
penetration. 
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Figure 19. Top: UV/Vis spectra of AB1-3 (15 μM in DMSO) in the dark (black) and illuminated 
at the indicated wavelengths. Bottom: Photoswitching is stable over many cycles. a) Black: 
dark-adapted, violet: 420 nm, light gray: 360 nm; b) Black: dark-adapted, green: 500 nm, dark 
gray: 380 nm and c) Black: dark-adapted, blue: 460 nm. 
To evaluate the effect of ABs on Kv channels, HEK293T cells were transiently transfected with 
the slowly-desensitizing, delayed-rectifier Kv2.1 channel. Prior to compound wash-in, a current-
voltage(IV) -curve was recorded for normalization to account for cell-to-cell variances like size, 
conductance or expression. In particular, K+ currents were evoked by depolarization from -80 
to +40 mV in whole-cell voltage-clamp mode. Then, ABs were washed in and illuminated with 
the appropriate wavelength to isomerize to the trans-configuration (i.e. violet/green or dark) 
while recording two IV-curves (Figure 20a). Maximum block was only achieved after the second 
IV (trans-) which is consistent with the mechanism of a use-dependent open channel blocker.80 
Next, two IV-curves were recorded under the appropriate switching wavelengths to the cis-
configuration (grey) to unblock the channel. The block was more pronounced at high voltages 
which indicates a channel block from the intracellular side (Figure 20b).80 We tested AB1-3 at 
different concentrations and determined AB2 as the most potent compound, showing the 
maximum photodependent block at 5 M (Figure 20c and Supporting Figure 3). As such, AB2 
blocks 70.1 ± 1.5% of K+ current under green light, of which 58.8 ± 4.7% can be relieved under 
UV-illumination (Figure 20b,c). Interestingly, the substitution at the para-position of the 
azobenzene impacts potency greatly since both AB1 and AB3 showed a decreased block 
(Figure 20c). At a high concentration of 100 M AB1 blocked under violet light with Imax = 0.22 
± 0.03 and unblocked under UV-light with Imax= 0.64 ± 0.03 (n = 4 cells). AB3 was only soluble 
up to 50 M in extracellular buffer and at this concentration blocked currents in the dark with 
Imax = 0.25 ± 0.06 while unblocking under blue illumination with Imax = 0.67 ± 0.07 (n = 4 cells). 
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To ultimately highlight the reversibility and rapid speed of block and unblock with AB2, we 
switched between UV/green illumination while holding the cell at +20 mV (Figure 20d). 
 
 
Figure 20. Light-gated Kv2.1 currents by AB1-3 in HEK293T cells transiently transfected 
with Kv2.1. a) After recording an initial IV-curve in 10 mV steps from -80 to +40 mV, AB2 (5 
M) was washed in, followed by illumination with green light (500 nm) to isomerize AB2 to its 
trans-configuration, leading to a block of K+ current. After isomerization to its cis-configuration 
by UV-light (380 nm), the blocking could be reversed. b) Representative single-cell IV-curve 
before wash-in, and in presence of AB2 under illumination with 380 or 500 nm. c) Maximum 
light-gated currents were normalized to the maximum current before wash-in in the dark. AB1 
(5 M) opened the channel under UV-light (360 nm) with Imax. = 0.86 ± 0.04, while blocking 
under violet light (420 nm) (Imax =0.60 ± 0.03). AB2 (5 M) showed currents of Imax = 0.89 ± 0.05 
under UV-light (380 nm) and Imax. = 0.30 ± 0.01 under green light (500 nm). AB3 showed no 
significant block at 5 M with Imax. (460 nm) = 0.95 ± 0.01 and Imax. (dark) = 0.89 ± 0.01. d) To 
demonstrate the reversibility and fast kinetics of block and unblock, the cell was held at -20 
mV while switching with UV/green light (380/500 nm) in presence of AB2 (5 M). 
TREK-1 is a two-pore domain K+ (K2p) channel which is widely expressed in the central nervous 
system (CNS) and exhibits unique physiological and pharmacological properties.81 Initially 
described as ‘background’ or ‘leak’ channel, this channel was cloned in 1996.82 It is described 
as an outward rectifier but has a comparatively high probability of opening at negatively 
membrane potentials. Therefore, TREK-1 opening sets the membrane potential closer to the 
potassium equilibrium potential. TREK-1 is activated by a variety of molecules, such as lipids 
and general anesthetics, but is also responsive to nociceptive stimuli like membrane stretch.83 
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TREK-1 is implicated in processes ranging from neuroprotection, anesthesia and pain, to mood 
disorders such as depression. It also constitutes a fairly novel drug target.84,85 TREK-1 is only 
weakly sensitive to quaternary ammoniums like TEA.86 Therefore, optical control of TREK-1 
blockade using the photoswitch MAQ could only be enabled at very high local concentrations 
by tethering MAQ to a genetically introduced cysteine at its pore region.15 While this elegant 
approach could unravel TREK-1 contributions to hippocampal GABAb signaling, it is limited by 
the requirement of genetic modification, and by the inherent drawbacks of cysteine-maleimide 
chemistry, such as reactivity towards glutathione or hydrolysis. We were intrigued by the first 
description of ‘leak’ channels in myelinated nerves in 1992, which identified bupivacaine as a 
leak channel blocker,87 and accordingly hypothesized that azobupivacaines could photoswitch 
this channel. First, the inability of permanently charged PCLs to block TREK-1 was 
reassessed. Indeed, after transfection of HEK293T cells with TREK-1, no block by AAQ in 
neither the cis- nor its trans- configuration was observed, even at 100 μM (Supporting Figure 
4). Then, AB1-3 (Figure 21a) were tested by looking at the IV-relationship from -80 to +40 mV. 
Again, one IV-curve for normalization was recorded before wash-in of compounds AB1-3. The 
cell was then illuminated with light of the appropriate wavelength for the trans-isomerization. 
(i.e. violet/green nm or dark). The channel was then unblocked by illumination with UV or blue 
light. Interestingly, and in contrast to the experiments with Kv2.1, AB1 emerged as the most 
efficacious compound for potentiating TREK-1 currents (Figure 18b and Supporting Figure 5). 
cis-AB1 potentiates TREK-1 at 100 M with a maximum normalized current of Imax, norm. = 1.20 
± 0.06 while trans-AB1 blocks the channel efficiently with Imax, norm. = 0.39 ± 0.07 (Figure 21c). 
Two aspects of TREK-1 blockade by AB1-3 were different in comparison to Kv2.1. First, TREK-
1 blocking and unblocking was fully apparent at the first recorded IV-step. Secondly, the 
percentage of block did not increase at positive potentials. Together, this points to a different 
mechanism of channel blockade on TREK-1 compared to Kv2.1. 
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Figure 21. Light-gated TREK-1 currents by AB1-3 in HEK293T cells transiently 
transfected with TREK-1. a) After recording an initial IV-curve in 10 mV steps from -80 to +40 
mV, AB1 (100 μM) was washed in, followed by illumination with violet light (420 nm) to 
isomerize to trans-AB1, leading to a block of K+ current. After isomerization to cis-AB1 by UV-
light (360 nm), the block was not only reversed but the channel was potentiated to larger 
currents than before wash-in. b) Representative single-cell IV-curve before wash-in, and in 
presence AB1 under illumination with UV-light (360 nm) and violet light (420 nm). c) Over 
multiple cells, maximum light-gated currents were normalized to the maximum current before 
wash-in in the dark. AB1 (100 μM) opened the channel under UV light (360 nm) with Imax. = 
1.29 ± 0.06, while blocking under violet light (420 nm, Imax =0.39 ± 0.07). AB2 (100 μM) showed 
currents of Imax = 1.01 ± 0.10 under UV light (380 nm) and Imax. = 0.44 ± 0.08 under green light 
(500 nm). AB3 (50 μM) blocked the current in in trans-configuration (Imax. = 0.50 ± 0.10) but 
could not be unblocked significantly under illumination with blue light (460 nm, Imax. = 0.63 ± 
0.07). d) To demonstrate the reversibility and fast kinetics of block and unblock, the cell was 
held at +20 mV while switching with UV/violet light (360/420 nm) in presence of AB1 (100 μM).  
Having set the stage in transfected cells, we tested AB2 for effects in coronal brain slices of 
the mouse hippocampus CA2 region, where Kv2.1 is highly expressed.88 Action potentials 
(APs) were evoked in whole-cell current-clamp mode by injection of an above-threshold 
current. In the dark, trans-AB2 allowed for AP firing by inhibiting potassium channels. Due to 
the bistable behavior of AB2, a short flash of UV-light (380 nm) was sufficient to silence AP 
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firing (Figure 22a). Silencing and unsilencing could be performed on a millisecond timescale 
(Figure 22b). Similar to HEK293T cells, transiently transfected with TREK-1, K+ currents were 
blocked rapidly by switching between UV/green light (380/500 nm) in brain slices (Figure 22c).  
 
Figure 22. Optical control of AP firing of hippocampal neurons in acute brain slices. a) 
A short flash of UV light (380 nm) was sufficient to silence AP firing. b) Switching between 
silenced and unsilenced mode proceeds in milliseconds c) K+ current was evoked by 
depolarization to +60 mV and potentiated by switching UV/green light (380/500 nm). 
In conclusion, we report three novel photoswitchable channel blockers which operate on Kv2.1 
at low concentrations. In addition, these compounds act as photochromic blockers on the K2p 
channel TREK-1. An opposing trend in efficacy in dependence on the azobenzene could be 
observed between the two channels. TREK-1 could not accommodate large substitutions on 
the azobenzene with the smallest photoswitch AB1 exhibiting the largest potentiation of K+ 
current. Furthermore, the cis-configuration could not only relieve the block, but showed an 
agonistic effect, potentiating the K+ currents towards larger values. On Kv2.1, the glycine-
substituted AB2 proved to be the most potent photoswitch.  
Potassium channels are implicated in processes ranging from cancer and metabolism to 
neurological and cardiovascular diseases. However, this huge therapeutic potential has 
remained largely untapped due to the lack of selective pharmacology, which additionally limited 
target validation to genetic knockout models.72 While photoswitchable blockers like 
azobupivacaine inherit their parent drugs’ unselectivity, the additional layer of control by 
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confining its activity in area and in time using light makes them a useful tool. The beauty of 
photopharmacology lies in its simplicity: it requires no genetic manipulation and can be applied 
as normal drugs while only requiring additional delivery of light, which is often already 
developed due to the abundance of fluorescence and microscopy techniques in life science 
research. Currently, we are actively working on equipping azobupivacaines and other 
photoswitchable blockers with additional functionality. By tethering these photoswitches to 
nanobodies, monobodies, toxins or other easily-modifiable, small protein-based strong binders 
that can take over the function of a full-sized antibody, we hope to combine the advantages of 
small-molecule photoswitches with the specificity of antibody binding (chapter 3.2.2).  
3.2.2 Antibody-Photoswitch Conjugates (APCs) 
The potential for using antibodies that target extracellular epitopes to deliver payloads subtype-
specifically to Kv channels was exemplified and highlighted by Sack et al. in 2013. There, the 
use of a singlet-oxygen generating, porphyrin-labelled anti-Kv4.2-IgG  was describe to 
selectively photoablate Kv4.2 channels.89 The photosensitizer porphyrin was attached by lysine 
labelling with activated NHS-esters. A photosensitizer has multiple turnovers and singlet-
oxygen has a long half-maximal reactive distance of approximately 40 Å.90 Therefore, the 
stoichiometry of porphyrin:antibody, as well as the exact location of conjugation, is unlikely to 
have a large influence on photoablation. Our approach of antibody-photoswitch conjugates 
(APCs) was aimed at linking photoswitchable blockers to antibodies and in this fashion equip 
them with subtype specificity. Since these blockers have to physically reach the external TEA 
blocking site rather than acting from a remote distance, a more controllable method than lysine 
labelling was necessary for antibody modification. More specifically, a method was required 
that labels residues at a defined stoichiometry and at a defined location on wild-type, 
commercially-available antibodies. The selected conjugation strategy is inspired by patent 
procedures from Novartis.91,92 These describe how the four interchain disulfides are mildly 
reduced by TCEP in presence of the doubly-alkylating agent 1,3-dichloroacetone. The 1,3-
dichloroacetone immediately and in situ rebridges the heavy and light chains of the antibody 
and inserts a ketone. The ketone is subsequently reacted with the aminooxy bioconjugation 
handle to irreversibly form an oxime and yield the APCs (Figure 23).  
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Figure 23. Strategy for antibody-photoswitch conjugation. Mild reduction by TCEP only 
occurs on the four interchain disulfide (black), which is not disrupting the IgG structure and is 
directly trapped by the double-alkylating agent 1,3-dichloroacetone. The rebridged keto-IgG is 
not susceptible to further reduction anymore and the inserted ketone serves as a 
bioconjugation handle. The photoswitchable blocker is attached to an aminooxy group via a 
long PEG-tether. The aminooxy group reacts in an irreversible, bioorthogonal reaction with the 
ketone to form an oxime, linking the antibody-photoswitch conjugate (APC). 
To span the distance between the antibody and the TEA binding site on the K+ channel, a long, 
flexible linker is required. As an estimation, a ‘molecular tape’ measure of maleimide-QA 
compounds with increasing linker lengths was described by Miller et al. in 2000. They 
concluded that the transmembrane-extracellular ends of the most distant S1 and S3 helices of 
the Shaker channel are only at a distance of around 30 Å away from the pore mouth. Therefore, 
we hoped that the monodisperse PEG12 linker, which has an approximate end-to-end distance 
of 46 Å according to the manufacturer (see SI for details), would be sufficient to span the gap 
of the antibody binding site on the closer S1-S2 loop to the external TEA blocking site, even 
when considering the additional bulk of the antibody. Even though most channel blockers 
(except MAQ) work from the intracellular side, we hoped to block the external TEA site by 
ensuring very high local concentrations around the channel by the antibody-binding. A careful 
survey of commercially available antibodies for Kv’s was conducted. The antibody had to fulfil 
several important criteria: (i) binding to extracellular epitopes, (ii) it must be monoclonal and (ii) 
it must have been validated in a few applications, such as immunohistology. In addition, the 
antibody had to target channels with an external TEA binding site. We found two antibodies 
from the UC Davis Neuromab facility targeting Kv1.1 (clone K36/15) and Kv2.1 (clone K39/25) 
that fulfilled these criteria and selected them for our APCs. 
Next, we moved to the synthesis of the photoswitch 3.5. It was accessed through a 4 step 
reaction sequence. 3.8 was prepared in a 4 step sequence from the commercial dye disperse 
red and then reacted with PhthNO-PEG12-NHS-ester. This was followed by amide coupling 
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with the betaine 3.3 and deprotection of the phthalimide using hydrazine hydrate to afford the 
final bioconjugation-ready aminooxy photoswitch 3.5. 
 
Scheme 2. Synthesis of the red-shifted 3.5. 
Next, the conditions of the aforementioned patent procedures were optimized to the microgram 
scale using a cheap, control-antibody MOPC-21 (mouse IgG1, kappa monoclonal isotype 
control, see chapters 3.4.2.1, 3.4.2.2 and 3.4.2.3). Then, Kv1.1- and Kv2.1-IgGs were 
conjugated with 3.5 and checked for intactness on SDS-PAGE (Figure 24a). The shift to higher 
molecular weight for the 3.5 (MW = 1042) conjugated Azo-Kv1.1- and Azo-Kv2.1-IgGs was 
easily observable. The antibody/azobenzene ratio was estimated from absorbance 
spectroscopy by nanodrop. Due to the high extinction coefficients of azobenzenes, the 
absorption of the photoswitch moiety can easily be observed at low concentrations (typical 
APC concentration 1-10 μM). The absorption at 280 nm was taken for estimation of antibody 
concentration and the absorption at 460 nm for determining the azobenzene concentration. 
Using the appropriate extinction coefficients for antibody and azobenzene, the approximate 
conjugation ratio was determined to be very close to the theoretical value of 4 azobenzenes 
per antibody (see chapter 3.4.2.5 for an example calculation). Next, to check for specific 
antibody-antigen binding, HEK293T cells were transfected with plasmids for Kv1.1 (rat) and 
Kv2.1 (rat), lysed, and analyzed by western blot. Both modified antibodies bound to Kv1.1 
(expected MW 57 kDa) and Kv2.1 (expected MW 105-125 kDa, Figure 24b) as expected. 
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Figure 24. Kv1.1-IgGs and Kv2.1-IgGs conjugated to 3.5. a) SDS-PAGE of the IgGs under 
non-reducing conditions. The rightmost lane is the molecular weight maker. b) HEK293T cells 
were transiently transfected either with Kv1.1 (rat) or Kv2.1 (rat) and YFP as transfection 
control. The lysate was immunoblotted and probed with the indicated wild-type, or conjugated 
IgG (1 μg/mL). Detection was performed using a PE conjugated fluorescent anti-mouse 
secondary AB (Biolegend #406708 or #407108). In between the sample lanes, lanes were 
charged with molecular weight marker, which fluoresces at 72 kDa.  
After having the modified antibodies in hand, functional characterization at the 
electrophysiology setup was performed. HEK293T cells were transfected with Kv1.1 or Kv2.1 
and multiple conditions were explored for the incubation with the Azo-Kv-IgGs: 
- Incubation at 2 μg/mL or 10 μg/mL Azo-Kv-IgG directly added to the extracellular bath 
solution, at r.t. for a duration of 15-60 min. 
- Application through a second “puffing” pipette (pressurized ejection of compound). The 
pipette was positioned in the near vicinity of the patched cell, ejection of up to 1 mg/mL 
of Azo-Kv-IgG. 
- Incubation at higher concentrations in the incubator, at 37 °C for 30 min (up to 20 
μg/mL) in reduced serum medium (OptiMEM).  
K+ currents were then evoked by ramps or IV-steps from -80 to +40 mV under illumination of 
either blue light (460 nm, cis-isomer) or in the dark (trans-isomer), while looking for light-
dependent blockade of the ion channel. Unfortunately, under none of the tested labelling 
conditions any effects of illumination could be observed and the data is therefore not shown 
here. 
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At this stage, we hypothesized that the lack of observed photoswitching could be due to the 
red-shifted nature of the photoswitch. In our hands, red-shifted azobenzenes require higher 
light intensities for the cis-isomerization with the photostationary state (PSS) showing a larger 
percentage of trans-isomer due to the fast thermal relaxation in aqueous environments. The 
block of the red-shifted 3.5 APCs is expected to occur by the trans-isomer, i.e. in the dark. 
Therefore, incubation with the APC in the absence of illumination should lead to a decrease in 
K+ current. Indeed, this could be observed in a few isolated cells but in the absence of clear 
photoswitching effects, i.e. unblock/opening of the channel by illumination to the cis-isomer, 
the effects of the APC on Kv channel gating were hard to decipher and inconclusive.  
In pursuit of a functional photoswitch, we opted to use an amide-substituted azobenzene which 
should exhibit bistable photoswitching behavior, i.e. slow thermal back-relaxation in the dark, 
allowing for a PSS with a higher percentage of cis-isomer. In addition, we simplified the 
synthesis, since the purification after final phthalimide deprotection of 3.5 was problematic due 
to the high reactivity of the aminooxy moiety, even with trace amounts of ketones. Therefore, 
the synthesis was redesigned such as to bear a Boc-group instead of the phthalimide to enable 
clean deprotection with neat TFA without a final chromatographical purification step. The 
synthesis yielded the bistable, aminooxy-photoswitch 3.8 (Scheme 3) in 4 steps starting from 
3.6. To streamline our efforts, it was decided to focus on the Kv2.1 channel from this point on. 
 
Scheme 3. Synthesis of bistable 3.8. 
The 3.8-conjugated Kv2.1-IgG antibody was again evaluated for quality by SDS-PAGE and 
western blot. We performed the SDS-PAGE under non-reducing as well as reducing conditions 
(by DTT+β-ME heated to 70°C for 10 min, Figure 25a). While wild-type, unmodified, IgGs are 
reduced to heavy and light chains, the ketone- or azo-inserted IgGs are not susceptible to 
further reduction. There is a distinct shift in mobility after attachment of the azobenzene. 
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UV/Vis-spectroscopy confirmed a conjugation ratio close to 4. Specificity of the modified 
antibodies was confirmed by immunblot (Figure 25b). 
 
Figure 25. Kv2.1-IgGs conjugated to 3.8. a) SDS-PAGE of the IgGs under non-reducing (left) 
or reducing conditions (right). b) HEK293T cells were transfected with Kv2.1 and YFP, mock 
transfection with YFP alone served as negative control. The lysate was immunoblotted and 
probed with the indicated conjugated IgG (1 μg/mL). was performed using a PE conjugated 
anti-mouse secondary AB (Biolegend #407108). 
In addition, the 3.8-Kv2.1-IgG conjugate was evaluated in fixed cells by confocal imaging with 
the hope of observing antibody-antigen binding in a setting more transferable to the 
electrophysiological patch-clamp setup (in contrast to western blots). Therefore, HEK293T 
cells transiently transfected with GFP_Kv2.1 (C-terminal fusion protein) were incubated for 6 h 
at 37°C degrees with 3.8-Kv2.1-IgG (10 μg/mL) and secondary Alexa-647 conjugated antibody 
(10 μg/mL). Confocal images confirmed colocalization of the green GFP_Kv2.1 and the Alexa 
647 signal, although some unspecific binding of the secondary antibody was observed in the 
Alexa 647 channel (Figure 26). 
The patch-clamp experiments were repeated using the same aforementioned antibody 
incubation methods 3.8-Kv2.1-IgG. IV-steps and ramps were recorded under either UV-light 
(380 nm, cis-isomer) or green light (500 nm, trans-isomer). After an exhaustive set of 
experiments, mostly varying antibody incubation conditions (i.e. concentrations, additives, 
buffers, incubation time and temperature; data not shown), no light-dependent effects on Kv2.1 
gating could be observed. 
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Figure 26. HEK293T cells were transfected with Kv2.1_GFP, fixed and incubated with Azo-
Kv2.1-IgG (3.8 conjugate). Secondary antibody conjugation was performed using an Alexa 
Fluor 647 goat anti-mouse antibody (ThermoFisher Scientific #A-21241). 
Altogether, we successfully synthesized and characterized a set of APCs for Kv1.1 and Kv2.1. 
The binding of APCs to the Kv1.1 and Kv2.1 channel was confirmed both by western blot and 
live-cell imaging. Discouragingly, none of the APCs showed any light-dependent effects in 
patch-clamp experiments. Taken together, we hypothesized that the linker between the 
photoswitch and the bioconjugation handle (aminooxy group) must be the issue. The linker 
could be preventing the photoswitch from reaching its site of action, either by its nature 
(hydrophilic vs hydrophobic), length (too short), or by its placement on the photoswitch. To 
investigate this, we returned to Kv2.1 experiments with freely diffusible photoswitche-linker 
comibnations. The PEGylated compounds 3.9 and bupivacaine-based 3.10 were tested. In 
addition, we prepared two compounds with a hydrophobic chain fused to the azobenzene, 3.11 
and 3.12 (Scheme 4). The compounds were tested at either 50 μM or 100 μM, depending on 
solubility (n = 3 cells each). In short, none of the compounds showed any light-dependent block 
of Kv2.1. 
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Scheme 4. Further compounds tested in patch clamp experiments on Kv2.1. 
In conclusion, basic parameters of the structure-activity relationship of photoswitchable 
blockers are still unclear. Since the basic structure of these blocker allow a wide variety of 
substitutions in para-position to the azobenzene,6 our intuition initially guided us to attach the 
long chain necessary for this APC approach on this position. It now seems clear that 
attachment of a linker on this position is deleterious to channel block and that further work must 
be directed at identifying novel linker-photoswitch combinations. 
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3.3 Summary and Outlook 
A short series of novel photoswitches based on the general anesthetic bupivacaine, termed 
azobupicacaines AB1-3, was presented. AB1-3 are non-permanently charged and enable 
optical control over the voltage-gated K+ channel Kv2.1 at one to two orders of magnitude lower 
concentrations than the previously described, quaternary-ammonium (QA) ion based 
photoswitches. In addition, AB1-3 light-gate the two-pore domain K+ channel TREK-1 by 
exploiting a mode of action different from QA block and without use-dependence. An opposing 
trend in efficacy was observed for the effects on Kv2.1 and TREK-1 varying with the 
azobenzenes substituents, which could serve as the entry point for an improved, more-
selective generation of azobupivacaines. AB1-3 efficiently control the hyperpolarization of 
hippocampal neurons in acute mouse brain slices and using light as the trigger, AB1-3 could 
efficiently silence and unsilence action potential firing in a reversible manner.  
In addition, the synthesis and characterization of antibody-photoswitch conjugates (APCs) 
based on the combination of small-molecule photochromic blockers with subtype-specific K+ 
channel antibodies is described. While the preparation of APCs in a very defined manner 
without interfering with the antibody-antigen binding could be exemplified, APCs targeting 
extracellular epitopes of Kv1.1 and Kv2.1 did not exhibit any functional effects. More 
specifically, the APCs did not show opening or blockage of Kv1.1 or Kv2.1 channels after 
incubation and upon illumination. Therefore, the influence of the tether between the antibody 
and photoswitchable head group was reevaluated. It now seems clear that the placement of 
the tether is a crucial determinant of the Kv channel blockade. Future work should be directed 
at deciphering the structure-activity relationship of the small-molecule photochromic blockers. 
In addition, future APCs should be based on bivalent photoswitch-fluorophore combinations to 
confirm the antibody binding during the electrophysiological experiments in situ.  
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3.4 Supporting Information 
3.4.1 Synthesis 
Synthesis of AzoBupivacaines (ABs) 1-3 was performed by Dr. Nils Winter and are described 
in his thesis. 
 (E)-N-(4-((4-Aminophenyl)diazenyl)phenyl)-N-ethylethane-1,2-diamine (3.1) 
N
N
N
H2N
NH2
 
3.1 was synthesized as previously described in 4 steps from the commercially available dye 
Disperse Red 1.93 
TLC (NEt3/MeOH/CH2Cl2 = 0.1/1/9) = 0.30. 
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.70 (m, 4H), 6.86 – 6.71 (m, 4H), 4.08 – 3.92 (m, 2H), 
3.49 (dq, J = 11.4, 6.9 Hz, 3H), 2.99 (t, J = 6.8 Hz, 2H), 1.68 (s, 3H), 1.24 (q, J = 7.1 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 149.6, 148.1, 146.1, 143.6, 124.4, 124.1, 114.84, 111.4, 53.4, 
45.6, 39.9, 12.2. 
HRMS (ESI): m/z calc. C16H22N5+ (M+H)+: 284.1870, found: 284.1871. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 4.04 (cis), 4.13 min 
(trans). 
UV/Vis (LCMS): max1 = 420 nm, max2 = 446 nm. 
 N-(Carboxymethyl)-N,N,N-triethylethanammonium chloride (3.3) 
HO
O
N
Cl  
In a round-bottomed flask, triethylamine (2.00 g, 19.8 mmol) and methyl bromoacetate (3.02 g, 
19.7 mmol) were combined. A magnetic stirring bar was added and the reaction mixture was 
stirred at room temperature. Within 1 h, the reaction mixture had solidified. After 4 h, 37% HCl 
(10 mL) was added and the reaction mixture was heated at 100 °C with stirring for 4 h. The 
reaction mixture was concentrated under reduced pressure, providing a white solid that was 
washed with diethyl ether. The crude product was dissolved in a minimal amount of water and 
then precipitated with acetone. The white solid was collected by filtration and dried under 
vacuum to yield the desired product (1.54 g, 39%). 
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1H NMR (400 MHz, D2O) δ 3.97 (s, 2H), 3.52 (q, J = 7.3 Hz, 6H), 1.26 (t, J = 7.3 Hz, 9H). 
 (E)-N-(2-((4-((4-Aminophenyl)diazenyl)phenyl)(ethyl)amino)ethyl)-1-((1,3-
dioxoisoindolin-2-yl)oxy)-3,6,9,12,15,18,21,24,27,30,33,36-
dodecaoxanonatriacontan-39-amide (3.2) 
OON
O
O
12
O
NH
N
N N
NH2  
In a small vial with a magnetic stirring bar, Phth-NO-dPEG(12)-NHS (Iris Biotech #PEG4630, 
20.0 mg, 23.2 μmol, 1.0 equiv.) was dissolved in 1mL of anhydrous CH3CN, and to this solution 
were added 3.1 (13.2 mg, 46.6 μmol, 2.0 equiv.) and DIPEA (6 μL, 46.5 μmol, 2.0 equiv.). The 
orange reaction mixture was stirred at r.t. overnight. The reaction mixture was concentrated 
under reduced pressure and the crude product was dissolved in 0.1% aq. formic acid. The 
crude material was purified by reverse-phase chromatography on a 5 g SepPak C8 SPE 
cartridge (0%-30% CH3CN/H2O + 0.1% FA). The product containing fractions were lyophilized 
to provide 3.2 as a glassy orange solid (22.8 mg, 95%).  
TLC (NEt3/MeOH/CH2Cl2 = 0.1/1/9) = 0.67. 
1H NMR (400 MHz, CD3CN) δ 7.81 (s, 4H), 7.69 (d, J = 8.9 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H), 
6.85 (d, J = 8.9 Hz, 2H), 6.80 – 6.66 (m, 3H), 4.60 (s, 2H), 4.31 – 4.24 (m, 2H), 3.79 – 3.72 (m, 
2H), 3.63 (t, J = 6.1 Hz, 2H), 3.59 – 3.41 (m, 48H), 3.36 (q, J = 6.4 Hz, 2H), 2.33 (t, J = 6.0 Hz, 
2H), 1.16 (t, J = 7.0 Hz, 3H). 
HRMS (ESI): m/z calc. for C51H76N6O16+ (M+H)+: 1029.5391, found 1029.5424; m/z calc. for 
C51H77N6O16 (M+2H)+: 515.2732, found: 515.2739. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.44 min. 
UV/Vis (LCMS): max1 = 452 nm. 
 (E)-2-((4-((4-((1-((1,3-Dioxoisoindolin-2-yl)oxy)-39-oxo-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-
yl)(ethyl)amino)phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-
ammonium formate (3.4) 
OON
O
O
12
O
NH
N
N N
NH
O
N
HCOO-  
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In a small vial with a magnetic stirring bar, 3.3 (22.8 mg, 22.2 μmol, 1.0 equiv) was dissolved 
in 2 mL of dry CH3CN, and to this solution were added 3.2 (21.7 mg, 110.9 μmol, 5.0 equiv.) 
and pyridine (88 μL, 1.11 mmol, 50 equiv.). T3P (50% wt in EtOAc, 706 μL, 1.11 mmol, 50 
equiv.) was added to the reaction mixture, which was stirred r.t. overnight. The next day, the 
reaction mixture was concentrated under reduced pressure and the crude product was 
dissolved in 0.1% aqueous formic acid.  The crude was purified by reverse phase 
chromatography on a 5g SepPak C8 SPE cartridge (0%-20% CH3CN/H2O + 0.1% FA). The 
product-containing fractions were lyophilized to provide 3.4 as an orange solid (17.4 mg, 65%).  
1H NMR (400 MHz, CD3CN) δ 12.79 (br s, 1H), 8.60 (s, 1H), 7.79 (d, J = 9.7 Hz, 10H), 6.85 
(dd, J = 20.3, 7.4 Hz, 3H), 4.54 (br s, 2H), 4.31 – 4.23 (m, 2H), 3.75 (t, J = 4.2 Hz, 2H), 3.63 (t, 
J = 6.1 Hz, 2H), 3.56 – 3.46 (m, 48H), 3.37 (q, J = 6.4 Hz, 3H), 2.65 (br s, 6H), 2.34 (t, J = 6.1 
Hz, 2H), 1.32 (br s, 9H), 1.17 (t, J = 7.0 Hz, 3H). 
HRMS (ESI): m/z calc. for C59H93N7O17+ (M+): 1170.6544, found 1170.6599; m/z calc. for 
C59H93N7O17 (M++H+): 585.8309, found 585.8320. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.20 min. 
UV/Vis (LCMS): max1 = 451 nm. 
 (E)-2-((4-((4-((1-(Amoxy)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-
azadotetracontan-42-yl)(ethyl)amino)phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-
oxoethan-1-amine diformate (3.5) 
OOH3N 12
O
NH
N
N N
NH
O
N
HCOO-
HCOOH
 
In a small vial with a magnetic stirring bar, 3.4 (10.8 mg, 8.9 μmol) was dissolved in 2 mL of 
anhydrous CH2Cl2, and to this solution was added hydrazine hydrate (89 μL, 1.8 mmol). A 
white precipitate formed almost immediately and the reaction mixture was stirred at r.t. 
overnight. After 0.5 h, an aliquot of the reaction mixture was diluted in acetonitrile (1 mL) 
containing a few drops of methyl ethyl ketone (MEK) for LCMS analysis— the major peak 
observed has m/z values consistent with the expected oxime condensation product (m/z = 
+365.5 and +547,8 for M+2H and M+H, respectively). The solvent was evaporated under a 
stream of nitrogen and the crude product was dissolved in 0.1% aq. formic acid. The crude 
material was purified by reverse phase chromatography on a 5g SepPak C8 SPE cartridge 
(0%-20% CH3CN/H2O + 0.1% FA). Two major orange-colored bands were collected and 
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aliquots were analyzed by LCMS after diluting in acetonitrile containing MEK. The earlier 
eluting orange band has m/z values consistent with the expected MEK oxime condensation 
product. The later eluting orange band has m/z values consistent with the formaldehyde oxime 
condensation product (+351,5, +526,7 for M+2H and M+H, respectively). The desired product-
containing fractions were lyophilized to provide 3.5 as an orange solid (1.2 mg 10%). The 
formaldehyde oxime condensation product was discarded. The aminoxy compound was 
dissolved in water to provide a 5 mM stock solution and stored at –20°C when not being used. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.20 min. 
LRMS (ESI): m/z calc. for C55H97N7O152+ (M++MEK+H+) 547.7. 
UV/Vis (LCMS): max1 = 454 nm. 
HRMS (ESI): m/z calc. for C51H91N7O152+ (M++CH2O+ H+): 520.8281, found 520.8291. 
Note: The aminooxy compound was highly reactive and requires careful handling to avoid any 
sources of ketones or aldehydes. In fact, it was observed that extra-pure formic acid which is 
routinely used in LCMS and HRMS systems has sufficient amounts of formaldehyde 
contamination to react aminoxy compounds fully to the condensed product. Due to the low 
isolated amounts and high reactivity, no NMR spectra were recorded. 
 tert-Butyl (3-(1,3-dioxoisoindolin-2-yl)propoxy)carbamate (3.13) 
N O
H
N
O
O
O
O  
N-(3-Bromopropyl)phthalimide (2.45 mg, 9.10 mmol, 1.0 equiv.), N-hydroxycarbamate (1.33 g, 
10.00 mmol, 1.1 equiv.) were mixed in dry toluene (20 mL) under a nitrogen atmosphere before 
addition of DBU (1.50 mL, 10.00 mmol, 1.1 equiv.). The reaction mixture was heated to 110 °C 
for several hours while stirring vigorously. An orange-brow oil separated from the solution. The 
reaction mixture was extracted with DCM (200 mL) against citrate solution (10% wt to pH = 5.5 
with HCl, 200 mL). The organic layer was washed with citrate solution (10% wt to pH = 5.5 with 
HCl, 3x200 mL) and then dried over MgSO4 before concentration in vacuo. The crude material 
was purified by flash column chromatography (DCM/EtOAc = 9/1) to yield 1.85 g of the desired 
product as a white solid (0.42 mmol, 63%). 
TLC (DCM/EtOAc= 9/1) = 0.67, stain: ninhydrin. 
1H NMR (400 MHz, Methanol-d4) δ 7.89 – 7.83 (m, 2H), 7.83 – 7.76 (m, 2H), 3.84 (t, J = 6.3 
Hz, 2H), 3.78 (t, J = 7.1 Hz, 2H), 1.97 (p, J = 6.6 Hz, 2H), 1.46 (s, 9H). 
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 tert-Butyl (3-aminopropoxy)carbamate (3.14) 
H2N O
H
N
O
O
 
3.13 was dissolved in MeOH (9.3 mL) and hydrazine hydrate (5.8 mL) was added. The reaction 
mixture was stirred at r.t. overnight before concentration to dryness in vacuo. The residue was 
triturated, suspended in CHCl3 and filtered. The solid was washed with a copious of CHCl3 
before the filtrate was concentrated to yield a yellowish oil. After purification by flash column 
chromatography (MeOH/DCM/aq. NH3 = 20/80/1), 3.14 was obtained as colorless solid (606 
mg, 3.18 mmol, 55%)  
1H NMR (400 MHz, CDCl3) δ 3.93 (t, J = 6.0 Hz, 2H), 2.84 (t, J = 6.6 Hz, 2H), 1.76 (p, J = 6.3 
Hz, 2H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 157.0, 81.6, 74.9, 39.2, 31.5, 28.2. 
HRMS (ESI): m/z calc. for C8H19O3N2+ (M+H+): 191.1390, found 191.1390. 
 (E)-2-((4-((4-(2-((tert-Butoxycarbonyl)amino)acetamido)phenyl)diazenyl)phenyl) 
amino)-N,N,N-triethyl-2-oxoethan-1-ammonium formate (3.7) 
N
N
H
N
N
H
O
N HCOO
-
O
BocHN
 
tert-Butyl (E)-(2-((4-((4-aminophenyl)diazenyl)phenyl)amino)-2-oxoethyl)carbamate 3.6 (55 
mg, 0.15 mmol, 1.0 equiv.), 3.3 (45 mg, 0.23 mmol, 1.5 equiv.), HBTU (68 mg, 0.18 mmol, 1.2 
equiv.) were combined in DMF (1 mL) and DIPEA (52 μL, 0.30 mmol, 2.0 equiv.) was added. 
Reaction progress was monitored by LCMS and judged to be complete after ca. 30 min. The 
reaction mixture was acidified using a few drops of formic acid and purified on a 2 g SepPak 
C18 SPE cartridge (0%-30% CH3CN/H2O + 0.1% FA). Product containing fractions were 
identified by LCMS, combined and concentrated in vacuo to dryness to yield the desired 
product as a yellow-orange glaze (34 mg, 61 μmol, 41%). 
1H NMR (400 MHz, Methanol-d4) δ 7.89 (t, J = 8.4 Hz, 4H), 7.78 (t, J = 8.5 Hz, 4H), 4.19 (d, J 
= 4.7 Hz, 2H), 3.90 (s, 2H), 3.67 (q, J = 7.2 Hz, 6H), 1.48 (s, 9H), 1.39 (t, J = 7.2 Hz, 9H). 
13C NMR (400 MHz, Methanol-d4) δ 169.4, 161.8, 157.2, 149.4, 148.7, 141.1, 139.8, 126.5, 
123.3, 123.2, 120.1, 119.7, 79.4, 56.2, 54.4, 43.7, 27.3, 6.6. 
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HRMS (ESI): m/z calc. for C27H39O4N6+ (M+H+):511.3027, found 511.3024. 
 (E)-1,4-Dioxo-1-((4-((4-(2-triethylammonio)acetamido)phenyl)diazenyl)phenyl)amino)-
7,10,13,16,19,22,25,28,31,34,37,40,43-tridecaoxa-3-azahexatetracontan-46-oate 
(3.9) 
N
N
N
H
H
N
O
N
O
N
H
O
O
13
O
O
 
3.7 (34 mg, 62 μmol, 1.0 equiv.) was deprotected at r.t. for 10 min using 1 mL neat TFA. TFA 
was removed in a gentle stream of nitrogen before the residue was dried under HV. The residue 
was dissolved in DMF, before sequential addition of PEG13-diacid (polypure #37137-1295, 51 
mg, 74 μmol, 1.2 equiv.), HBTU (25 mg, 66 μmol, 1.05 equiv.) and DIPEA (53 μL, 0.30 mmol, 
5.0 equiv.). The reaction mixture was stirred for 1 h at r.t. when LCMS analysis indicated full 
conversion. The reaction mixture was acidified using a few drops of FA and purified on a 5 g 
SepPak C18 SPE cartridge (0%-25% CH3CN/H2O + 0.1% FA). Product containing fractions 
were identified by LCMS, combined and dried in vacuo to yield the desired product as an 
orange glaze (38 mg, 35 μmol, 56%). 
HRMS (ESI): m/z calc. for C52H85O18N6- (M-H)-: 1081.5926, found:1081.5922. 
 (E)-2-((4-((4-(50-(Ammoniooxy)-4,46-dioxo-
7,10,13,16,19,22,25,28,31,34,37,40,43-tridecaoxa-3,47-
diazapentacontanamido)phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-
ammonium bis-(trifluroacetate) (3.8) 
N
N
N
H
H
N
O
N
O
N
H
O
O
13
N
H
O
O
NH3
2 F3CCOO
-
 
3.9 (100 μL of 0.1M in DMF, 10 μmol, 1.0 equiv.) and 3.14 (24 μL of 0.5M in DMF, 12 μmol, 
1.2 equiv.) were combined and HBTU (5.0 mg, 12 μmol, 1.2 equiv.) and DIPEA (4.2 μL, 24 
μmol, 2.0 equiv.) were added. The reaction was stirred at r.t. overnight before LCMS analysis 
indicated incomplete conversion. Therefore, the same amounts of all reagents except 3.9 were 
added to the reaction mixture again. After an additional hour of stirring, the reaction mixture 
was acidified using a few drops of FA and purified on a 5 g SepPak C18 SPE cartridge (0%-
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30% CH3CN/H2O + 0.1% FA). Product containing fractions were identified by LCMS and dried 
in vacuo to yield the desired product as an orange glaze (5.8 mg, 4.5 μmol, 45%). 
HRMS (ESI): m/z calc. for C60H102O20N8- (M-H)-: 1254.7210, found: 1254.7197 
For deprotection, neat TFA (0.2 mL) was added and allowed to stand at r.t. for 10 min before 
removal of all volatiles in a gentle stream of nitrogen. The residue was dried under HV. 
Quantitative yield was assumed. A small quantity of the product was tested for reactivity and 
purity by addition of a drop of acetone. LCMS analysis showed one clean peak with an m/z (+) 
of 1195, consistent with the expected m/z of the acetone condensation product.  
1H NMR (400 MHz, DMSO-d6) δ 11.05 (s, 1H), 10.65 (s, 4H), 10.36 (s, 1H), 8.30 (t, J = 5.6 
Hz, 1H), 7.91 (td, J = 12.0, 7.2 Hz, 5H), 7.81 (dd, J = 9.1, 2.8 Hz, 4H), 4.24 (d, J = 4.3 Hz, 
2H), 4.03 – 3.90 (m, 5H), 3.51 (s, 65H), 3.11 (q, J = 6.6 Hz, 2H), 2.44 (t, J = 6.5 Hz, 2H), 2.31 
(t, J = 6.4 Hz, 3H), 1.71 (t, J = 6.7 Hz, 2H), 1.28 (q, J = 7.2 Hz, 10H). 
13C NMR (101 MHz, DMSO) δ 171.1, 170.6, 168.8, 162.8, 158.8, 158.5, 158.1, 148.9, 148.0, 
142.3, 140.6, 124.1, 123.9, 120.6, 119.8, 72.6, 70.2, 70.1, 70.0, 70.0, 67.2, 67.2, 56.8, 55.4, 
54.5, 43.3, 36.6, 36.3, 35.5, 28.0, 7.9.  
HRMS (ESI): m/z calc. for C58H97N8O18- (M+acetone-2H)-: 1193.6926, found: 1193.6928; m/z 
calc. for C58H99N8O18+ (M+acetone)+: 1195.7077, found:1195.7086. 
 (E)-1-Butyl-2-((4-((4-(2,2-dimethyl-4,11,53-trioxo-3,6,14,17,20,23,26,29,32,35, 
38,41,44,47,50-pentadecaoxa-5,10,54-triazahexapentacontan-56-amido)-3,5-
dimethylphenyl)diazenyl)phenyl)carbamoyl)piperidin-1-ium formate (3.10) 
N
N
H
N
O
H
N
O H
N
O
O
13 O
H
N O
N
H
O
O
HCOO-
N
H  
(E)-N-(4-((4-(2-aminoacetamido)phenyl)diazenyl)-2,6-dimethylphenyl)-1-butylpiperidine-2-
carboxamide (27 mg, 59 μmol, 1.0 equiv.), PEG13-diacid (polypure #37137-1295, 49 mg, 71 
μmol, 1.2 equiv.), DIPEA (51 μL, 0.30 mmol, 5 equiv.) and HBTU (24 mg, 62 μmol, 1.05 equiv.) 
were added to DMF (0.5 Ml). The reaction mixture was stirred for 1 h at r.t., when LCMS 
analysis indicated full conversion of the starting azobenzene. The reaction mixture was 
acidified with a few drops of FA and purified on a 5 g SepPak C18 SPE cartridge (0%-40% 
CH3CN/H2O + 0.1% FA). Product containing fractions were identified by LCMS, combined and 
dried in vacuo to obtain the desired product as a yellow solid (32 mg, 28 μmol, 48%). 
HRMS (ESI): m/z calc. for C56H91N6O18- (M-H)-: 1135.6395, found:1135.6394. 
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The entire product of the previous step was dissolved in DMF (0.7 mL) and 3.14 (6.5 mg, 34 
μmol, 1.2 equiv.), HBTU (13 mg, 34 μmol, 1.2 equiv.) and DIPEA (10 μL, 56 μmol, 2.0 equiv.) 
were added. The reaction mixture was stirred overnight at r.t., when LCMS analysis indicated 
full conversion of the starting azobenzene. The reaction mixture was acidified with a few drops 
of FA and purified on a 5g SepPak C18 SPE cartridge (0%-40% CH3CN/H2O + 0.1% FA). 
Product containing fractions were identified by LCMS, combined and dried in vacuo to obtain 
the desired product as a yellow solid (18 mg, 13 μmol, 22% over 2 steps). 
HRMS (ESI): m/z calc. for C64H107N8O20- (M-H)-: 1307.7607, found: 1307.7606. 
 (E)-N-(4-((4-aminophenyl)diazenyl)phenyl)dodecanamide (3.15) 
N
N
H
N
H2N
O
4,4‘-diazoniline (212 mg, 1 mmol, 2.0 equiv.), dodecanoic acid (100 mg, 0.5 mmol, 1.0 equiv.), 
HBTU (209 mg, 0.55 mmol, 1.1 equiv.) and DIPEA (0.17 mL, 1 mmol, 2.0 equiv.) were 
combined in DMF (2 mL). The reaction was stirred at r.t. overnight. The product was extracted 
against aq. 10% LiCl, water (2x) and brine. The organic layer was dried over MgSO4 and 
concentrated in vacuo to yield the desired product as a yellow solid (134 mg, 0.34 mmol, 68%). 
1H NMR (400 MHz, CDCl3) δ 7.74 (dd, J = 21.7, 8.6 Hz, 4H), 7.58 (d, J = 8.5 Hz, 2H), 7.22 (s, 
1H), 6.67 (d, J = 8.5 Hz, 2H), 3.96 (s, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.67 (p, J = 7.5 Hz, 2H), 
1.37 – 1.10 (m, 16H), 0.81 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.4, 149.4, 149.3, 145.6, 139.4, 124.9, 123.4, 119.7, 114.7, 
38.0, 31.9, 29.6, 29.6, 29.5, 29.4, 29.4, 29.3, 25.6, 22.7, 14.2. 
HRMS (ESI): m/z calc. for C24H35N4O+ (M+H)+: 395.2805, found: 395.2808. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 7.16 min. 
UV/Vis (LCMS): max = 394 nm. 
  (E)-2-((4-((4-dodecanamidophenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-
oxoethan-1-ammonium formate (3.11) 
N
N
H
N
N
H
O
O
N
HCOO-  
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3.15 (40 mg, 0.10 mmol, 1.0 equiv), 3.3 (22 mg, 0.11 mmol, 1.1 equiv.), HBTU (42 mg, 0.11 
mmol, 1.1 equiv) and DIPEA (35 μL, 0.20 mmol, 2.0 equiv.) were combined in DMF (1 Ml). 
After 3.5 h, the reaction mixture was acidified with a few drops of FA and purified on a 5g 
SepPak C8 SPE cartridge (0%-45% CH3CN/H2O + 0.1% FA). Product containing fractions 
were identified by LCMS, combined and dried in vacuo to obtain the desired product as a yellow 
foam (15 mg, 28 μmol, 28%). 
1H NMR (400 MHz, DMSO-d6) δ 12.20 (br s, 1H), 10.31 (s, 1H), 8.50 (s, 1H), 7.93 – 7.74 (m, 
8H), 4.45 (s, 2H), 3.55 (q, J = 8.4, 7.5 Hz, 6H), 2.35 (t, J = 7.4 Hz, 2H), 1.27 (dd, J = 16.1, 8.6 
Hz, 26H), 1.64 – 1.55 (m, 2H), 0.84 (t, J = 6.5 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 172.3, 163.2, 148.7, 147.8, 142.7, 141.2, 123.9, 123.8, 120.6, 
119.6, 56.9, 54.5, 37.0, 31.8, 29.5, 29.5, 29.4, 29.3, 29.2, 29.1, 25.5, 22.6, 14.4, 7.9. 
HRMS (ESI): m/z calc. for C32H50N5O2+ (M)+: 536.3959, found: 536.3965. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.18 min. 
UV/Vis (LCMS): max = 368 nm. 
 (E)-1-Butyl-2-((4-((4-(2-dodecanamidoacetamido)phenyl)diazenyl) 
phenyl)carbamoyl)piperidin-1-ium formate (3.12) 
N
N
H
N
N
H
O
NH
O
N
H
O
HCOO
 
(E)-N-(4-((4-(2-Amminoacetamido)phenyl)diazenyl)-2,6-dimethylphenyl)-1-butylpiperidine-2-
carboxamide (23 mg, 43 μmol, 1.0 equiv.), dodecanoic acid (8.6 mg, 43 μmol, 1.0 equiv.), 
HBTU (18 mg, 47 μmoL, 1.1 equiv.) and DIPEA (38 μL, 0.22 mmol, 5.0 equiv.) were combined 
in DMF (1 mL) and stirred for 45 min at r.t. when LCMS analysis indicated full conversion. The 
reaction mixture was acidified with a few drops of FA and purified on a 5 g SepPak C18 SPE 
cartridge (0%-50% CH3CN/H2O + 0.1% FA). Product containing fractions were identified by 
LCMS, combined and dried in vacuo to obtain the desired product as a yellow foam (25 mg, 
39 μmol, 91%). 
1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 9.44 (s, 1H), 8.20 (t, J = 5.9 Hz, 1H), 8.15 (s, 
1H), 7.87 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 7.59 (s, 2H), 3.91 (d, J = 5.8 Hz, 2H), 
3.22 – 3.12 (m, 1H), 3.10 – 2.98 (m, 1H), 2.78 – 2.64 (m, 1H), 2.35 (s, 1H), 2.24 (s, 6H), 2.16 
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(t, J = 7.4 Hz, 2H), 1.92 (d, J = 11.6 Hz, 1H), 1.73 (d, J = 10.1 Hz, 2H), 1.53 (dt, J = 14.8, 6.5 
Hz, 5H), 1.25 (d, J = 6.8 Hz, 17H), 0.87 (dt, J = 17.7, 7.1 Hz, 6H). 
13C NMR (101 MHz, DMSO-d6) δ 173.3, 168.9, 163.6, 150.6, 148.0, 142.4, 138.0, 137.0, 124.1, 
122.1, 119.7, 67.4, 56.2, 51.5, 43.3, 35.6, 31.8, 30.3, 29.5, 29.4, 29.3, 29.2, 29.1, 28.1, 25.7, 
24.8, 23.2, 22.6, 20.6, 19.3, 18.8, 14.4, 14.4. 
HRMS (ESI): m/z calc. for C38H59N6O3+ (M)+: 647.4643, found: 647.4652. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) 4.70 min. 
UV/Vis (LCMS): max = 356 nm. 
3.4.2 Antibody Modifications 
 Determining the detection limit of Antibody-detection by SDS-PAGE 
To determine the limit of detection for full size IgGs as well as well as evaluate reduction 
conditions of IgGs to heavy and light chains on SDS-PAGE gels (NuPAGE 4-12% Bis-Tris, 12 
well) in combination with InstantBlue Coomassie (Expedeon) protein stain, a dilution series 
was performed.  
Lanes were loaded with MOPC-21-IgG as follows: 
Per lane: total volume 30 μL, TCEP 0 (non-reducing) or 0.017 M (reducing) 
Lanes: 1: 0.025 μg, 2: 0.025 +TCEP, 3: 0.375 μg, 4: 0.375 μg + TCEP, 5: 0.75 μg, 6: 0.75 μg 
+ TCEP, 7: 1.5 μg, 8: 1.5 μg + TCEP 
Gel was run for 75 min at 200 V in the ThermoScientific Mini Gel Tank. Gel was removed from 
its casing and stained overnight with InstantBlue Coomassie (Expedeon). 
As little as 0.325 μg of MOPC-21-IgG could be detected using these conditions. Reducing 
conditions showed no full-size antibody but two bands migrating further on the gel, indicative 
of quantitative reduction of IgG to heavy and light chains. 
 Optimization of antibody modification procedure to the microgram scale 
The ketone insertion reaction procedure was adapted for microgram scale reactions from 
procedures described in US patents #US2015032126 and #US20150150998. 
Optimization of IgG reduction by TCEP: 
20 pmol of MOPC-21 IgG (3 μg) were reduced using increasing amounts of TCEP (0 nmol, 0.8 
nmol, 1.2 nmol, 1.6 nmol, 2.0 nmol, 2.4 nmol, 2.8 nmol, 3.2 nmol, 3.6 nmol, 500 nmol) were 
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incubated at 4 °C for 30 min. Then, the samples were analyzed per SDS-PAGE and with 
InstantBlue Coomassie (Expedeon) staining. 
Observations:  
An increasing trend with higher TCEP equivalents towards reduction was observed. Only with 
500 nmol TCEP, full reduction was observed. Possibly, in absence of the alkylating agent DCA 
the antibody is reoxidized to the full-size IgG when using only a small amount of TCEP. 
Optimization of Ketone insertion: 
IgG reacted with DCA and TCEP under different stochiometries. The reaction was allowed to 
proceed in 0.25 M TRIS Ph 7.3 (total volume 30 μL) at 4 °C overnight followed SDS-PAGE and 
InstantBlue Coomassie (Expedeon) staining. If antibody is reduced by TCEP and DCA is 
inserted, it is expected that only one clean band at the full-size IgG is present. The modified 
antibody with the inserted ketone can’t be reduced by the reducing gel conditions. 
Lanes were loaded as followed: 
Tube /lane 1 2 3 4 5 6 7 
IgG (μg) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
pmol IgG 20 20 20 20 20 20 20 
TCEP (equiv.) 120 120 180 180 240 240 300 
DCA (equiv.) 4000 4000 4000 4000 4000 4000 4000 
Reducing gel? N Y N Y N Y N 
 
Observations:  
Cleanest bands were for lane 6 and 7. Therefore, it was concluded that 240-300 equiv TCEP 
in presence of 4000 equiv. is the optimal stoichiometry for ketone insertion. 
 
 Final conditions for all antibody modifications 
General procedure for the synthesis of keto-IgGs (procedure is shown with keto-MOPC-
21 IgG) 
 Stock solutions:  
A 0.1 mg/mL stock solution of MOPC-21 (BioXCell, catalog # BE0083) was prepared by diluting 
7.4 μL of 6.75 mg/mL stock with 493 μL of 0.25 M pH 7.3 TRIS buffer. A 20 mg/mL stock 
solution of 1,3-dichloroacetone (DCA) was prepared by dissolving 26.2 mg of DCA in 1.31 mL 
DMSO. A 4 mM stock solution of TCEP x HCl was prepared by diluting 10 μL of 0.5 M TCEP 
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x HCl with 1.25 mL milliQ water. The 0.5 M stock solution of TCEP x HCl was prepared by 
dissolving 69.7 mg of TCEP x HCl in 0.486 mL milliQ water.  
Reaction:  
In a microcentrifuge tube at room temperature, 6.8 μL of 20 mg/mL DCA was combined with 
400 μL of 0.1 mg/mL MOPC-21 (4000:1 DCA:IgG). The tube was vortexed and cooled to 4 °C. 
In a separate microcentrifuge tube, 20 μL of 4 mM freshly prepared TCEP x HCl was added 
and cooled to 4 °C. Using a pipette, the entire volume of the MOPC-21/DCA solution was 
added to the TCEP x HCl solution and the resulting solution was mixed thoroughly by repeated 
pipetting (300:1 TCEP:IgG). The reaction mixture allowed to stand at 4 °C overnight. The 
antibody was purified the next morning by membrane filtration using an Amicon centrifugal filter 
with 10 kDa MWCO (10 min, 14000 rcf). After concentration, the retentate was diluted to ~500 
μL with PBS pH 7.4 and concentration was repeated. In total, seven concentration steps were 
performed, using PBS pH 7.4 as diluent each time. The final retentate was collected via 
centrifugation according to the manufacturer’s instructions into a tared tube and then weighed 
to determine the retentate volume (60.5 mg = 60.5 μL, assuming d = 1 mg/μL). The 
concentration of keto-MOPC-21 was determined by absorbance spectroscopy: A280 = 0.628, 
corresponding to 0.46 mg/mL using ε280 of 1.36 mL·mg-1·cm-1. Recovery of keto-MOPC-21 was 
70% (28 μg).   
The following samples were analyzed by SDS-PAGE on a NuPage 4-12% Bis-Tris gel with 
MES running buffer at 200V for 25 min: 
 Keto-MOPC-21 (0.69 μg) diluted with PBS and NuPage LDS sample buffer 
 Keto-MOPC-21 (0.69 μg) diluted with PBS and reduced with 1 μL 1M TCEP x HCl for 
15 min at 37 °C, then diluted with NuPage LDS sample buffer 
 MOPC-21 (1 μg) diluted with 0.25 M pH 7.3 Tris and NuPage LDS sample buffer 
 MOPC-21 (1 μg) diluted with 0.25 M pH 7.3 Tris and reduced with 1 μL 1 M TCEP x 
HCl for 15 min at 37°C, then diluted with NuPage LDS sample buffer 
 Blue-Elf Protein MW Markers (Jena Bioscience) 
The gel was removed from its plastic casing and stained using InstantBlue Coomassie 
(Expedeon). Keto-MOPC-21 and MOPC-21 were observed to migrate near the 165 kDa MW 
marker, consistent with an intact IgG (~150 kDa). The reduced MOPC-21 migrated as two 
bands near the 24 kDa and 57 kDa MW markers, consistent with complete reduction of the 
interchain disulfide bonds yielding separate HC (~50 kDa) and LC (~25 kDa). The reduced 
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keto-MOPC-21 migrated near the 165 kDa MW marker, consistent with successful crosslinking 
with DCA, where reduction-insensitive thioether bonds have replaced disulfides. 
General procedure for the synthesis of oxime-IgGs (procedure is shown for CF488DI-anti-
Kv2.1-IgG) 
Stock solutions: 
A 1 M stock solution of 3,5-diaminobenzoic acid (DABA) was freshly prepared by dissolving 
49.6 mg DABA in 326 μL DMSO. 
A 5 mg/mL stock solution of CF488DI aminooxy (Biotium, catalog #92177) was prepared by 
dissolving 1 mg CF488DI aminooxy in 200 μL DMSO. 
Reaction: 
Keto-Kv2.1-IgG was prepared from 10 μg anti-Kv2.1 IgG (Antibodies Incorporated, catalog 
#75-159) following the general procedure for keto-IgG synthesis. To purified keto-Kv2.1-IgG in 
PBS pH 7.4 at room temperature in a microcentrifuge tube was added PBS pH 7.4 (26.3 μL), 
DMSO (17.4 μL), 1M DABA (10 μL), and 5mg/mL CF488DI aminooxy (2.6 μL, 300 eq). The 
keto-Kv2.1-IgG target concentration was 0.1mg/mL, the DMSO target concentration was 30% 
vol/vol, and the DABA target concentration was 0.1 M. The reaction mixture was stored at r.t., 
protected from light, overnight. The next morning the reaction was diluted to ~500 μL by 
addition of PBS pH 7.4 and the antibody was purified by membrane filtration using an Amicon 
centrifugal filter with 10 kDa MWCO (10 min, 14000 rcf) using the same procedure as described 
for keto-IgG purification. The final retentate was collected via centrifugation according to the 
manufacturer’s instructions into a tared tube and then weighed to determine the retentate 
volume (41.8 mg = 41.8 μL, assuming d = 1 mg/μL). The concentration of CF488DI-oxime-
Kv2.1-IgG was determined by absorbance spectroscopy: A280 = 0.12, corresponding to 88 
μg/mL using ε280 of 1.36mL·mg-1 ·cm-1. An absorbance peak at 466 nm was observed, 
indicative of successful conjugation: A466 = 0.16. Recovery of CF488DI-oxime-Kv2.1-IgG was 
37% (3.7 μg) over two steps. 
The following samples were analyzed by SDS-PAGE on a NuPage 4-12% Bis-Tris gel with 
MES running buffer at 200V for 25min: 
 Keto-Kv2.1-IgG (0.31 μg) diluted with PBS and NuPage LDS sample buffer 
 CF488DI-oxime-Kv2.1-IgG (0.18 μg) diluted with PBS and NuPage LDS sample buffer 
 MOPC-21 (0.25, 0.5, 1, and 2 μg) diluted with PBS and NuPage LDS sample buffer 
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 Blue-Elf Protein MW Markers (Jena Bioscience) 
The gel was removed from its plastic casing and imaged with a Bio-Rad fluorescent imager 
using settings for Alexa Fluor 488.  After fluorescent imaging, the gel was stained using 
InstantBlue Coomassie (Expedeon).  In the Coomassie-stained gel, CF488DI-oxime-Kv2.1-
IgG migrated at a position very similar to keto-Kv2.1-IgG, MOPC-21, and the 165 kDa MW 
marker. The band intensity was slightly less than the 0.25 μg MOPC-21 band, consistent with 
the CF488DI-oxime-Kv2.1-IgG stock concentration being ~100 μg/mL. The band migrating 
near the 165kDa MW marker for CF488DI-oxime-Kv2.1-IgG fluoresced intensely, indicating 
successful conjugation. The presence of multiple weakly-fluorescing, faster-migrating bands 
was also noted for this sample (these bands were not apparent in the Coomassie-stained gel). 
Notes: DMSO was added to improve solubility of CF488DI aminooxy in the reaction mixture. 
 Synthesis of keto-anti-Kv2.1-IgG 
Procedure as described for MOPC-21 IgG. 
Amounts:  
- 100 μL anti-Kv2.1-IgG (1.07 mg/mL, 107 ng), 900 μL 0.25 M TRIS pH 7.3 
- 17 μL DCA (20 mg/mL)  
- 50 μL freshly prepared 4 mM TCEP x HCl 
Weight of retentate after Amicon filtration: 51.8 mg = 51.8 μL, assuming d = 1 mg/μL. The 
concentration of keto-anti-Kv2.1-IgG was determined by absorbance spectroscopy: A280 = 
2.162, corresponding to 1.59 mg/mL using ε280 of 1.36 mL·mg-1·cm-1. Recovery of keto-anti-
Kv2.1-IgG was 77% (82.4 ng).  
 Synthesis of 3.8-anti-Kv2.1-IgG conjugates 
Procedure as described for CF488DI-anti-Kv2.1-IgG. 
Amounts: 
- 31.4 μL keto-anti-Kv2.1-IgG (1.59 mg/mL, 50 μg) 
- 6 μL DABA (1 M in DMSO) 
- 96 nmol 3.8 (9.6 μL of 10 mM stock) 
- PBS pH 7.4 (13 μL) 
Weight of retentate after Amicon filtration: 44.6 μg = 44.6 μL, assuming d = 1 mg/μL. 
The concentration of keto-anti-Kv2.1-IgG was determined by absorbance spectroscopy: A280 = 
1.468, corresponding to 1.08 mg/mL using ε280 of 1.36 mL·mg-1·cm-1. Recovery of keto-anti-
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Kv2.1-IgG was 96% (1.08 mg/mL * 44.6 μL = 48.2 μg). Using ma (IgG) = 156 kDa, this amounts 
to 309 pmol (48.2 μg / (156,000 g/mol)). A second absorption peak at 367 nm was indicative 
of successful conjugation with azobenzene: A367 = 0.638. This corresponds to a concentration 
of 26.4 μM of azobenzene 3.8 using ε280 of 20000 mL·mol-1·cm-1 (which is an averaged 
absorption of a bis-amide sustituted azobenzene) which amounts to 1.18 nmol (26.4 μM * 44.6 
μL). This accounts to a conjugation ratio of 3.82 molecules of 3.8 per anti-Kv2.1-IgG antibody 
(1.18 nmol / 309 pmol). 
3.4.3 Cell Culture and Electrophysiology 
Plasmids 
Kv1.1, Kv2.1 and GFP_ Kv2.1 on pcDNA3.1 were a kind gift from James Trimmer (UC Davis). 
TREK-1 and TREK-2 on pcDNA3.1 were a kind gift from Joshua Levitz (Cornell). 
Cell Culture and whole-cell electrophysiology. HEK293T (obtained from Leibniz-Institute 
DSMZ: #305) cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (Biochrom, Merk Millipore, Germany) in a 10% CO2 
atmosphere at 37 °C and were split at 80-90% confluency. Medium was removed and the cells 
were washed with PBS before cell detachment with trypsin. Cells were taken up in fresh 
medium and counted. 40-60,000 cells were plated on acid-etched glass coverslips in 500 μL 
full medium. DNA (per coverslip: TREK1 (50 ng) and YFP (50 ng) or GFP_ Kv2.1 (50 ng)) was 
diluted in jetPRIME® buffer (per coverslip: 50 μL) and jetPRIME® transfection reagent (per 
coverslip: 0.5 μL) was added. After mixing and 10 min incubation, the DNA-jetPRIME® mixture 
was added to the cells. Medium was exchanged after 4-5 hours. Electrophysiology was 
performed 16-36 h post-transfection. Electrophysiology was performed using a standard 
electrophysiology setup equipped with a HEKA Patch Clamp EPC10 USB amplifier and 
PatchMaster software (HEKA Electronic). Micropipettes were generated from “Science 
Products GB200-F-8P with filament” pipettes using a Narishige PC-10 or PC-100 vertical 
puller. The patch pipette resistance varied between 5-9 M. The bath solution contained (in 
mM): NaCl (137), KCl (4), MgCl2 (1), CaCl2 (1.8), HEPES (10), D-glucose (10), pH to 7.4 with 
NaOH. The pipette solution contained (in mM): KCl (12), K-gluconate (140), HEPES (10), 
MgATP (4), Na2GTP (0.4), NaCl (4), pH to 7.4 with KOH. All analyzed cells were first visualized 
to contain YFP or GFP_Kv2.1 by irradiation at 480 nm using a Polychrome V (Till Photonics) 
monochromator. All patch clamp experiments were performed at room temperature. For 
photoswitching, light was applied using the epifluorescence coupling equipped with a 
Polychrome V (Till Photonics) monochromator.  
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3.4.4 Brain Slice Preparation 
Hippocampal brain slices were prepared from mice strain C57Bl6JRj (postnatal day 10-14) as 
described previously.2 Briefly, mice were euthanized, the skull was quickly removed and the 
brain placed in ice cold saline solution saturated with carbogen (95/5 = O2/CO2). The saline 
solution contained (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 NaHCO3, 0.5 CaCl2, 7 MgCl2, 
25 D-glucose, 75 sucrose. Coronal brain slices of 250 mM thickness were prepared using 
Campden vibrating microtome 7000smz-2. Prior to recording, the brain slice was placed in 
artificial cerebrospinal fluid and saturated carbogen (95/5 = O2/CO2). The artificial 
cerebrospinal fluid contained (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, 26 
NaHCO3, and 20 D-glucose. Experiments were performed in continuous flow of aCSF in 
presence of AB2 (50 M). 
3.4.5 Supporting Figures 
 
Supporting Figure 3. Light-dependent dose response of AB2 block of Kv2.1. 
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Supporting Figure 4. The permanently-charged photoswitchable blocker AAQ has no 
effect on TREK-1 upon isomerization. 
 
Supporting Figure 5. Light-dependent dose response of AB1 block of TREK-1. 
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3.4.6 Immunohistochemsitry 
Expression of Kv1.1 and Kv2.1 in HEK293T cells with transient transfection: 
Day 1 
seed HEK293T cells on a LabTek (coated with Fibronectin) or on an ibidi slide. 
• Prepare Fibronectin-solution (50 μL Fibronectin stock solution (1 mg/mL) + 4.95 mL 1x PBS 
+ Mg, Ca). Transfer 400 μL of Fibronectin solution into LabTek wells (LabTeks II #1.5). 
Incubate LabTek at 37°C, 10% CO2 for 45 min. Then, remove Fibronectine solution.  
• Plate HEK293T cells (1.4 104 cells / 400 μL cell culture medium (DMEM/10% FCS) per 
well) into LabTek chambers. Incubate HEK293T cells at 37°C, 10% CO2 for approximately 
24 h. 
Day 2 
Transfection of the HEK293T cells. 
• On the next day, inspect HEK293T cells whether they grew sufficiently. 
• Prepare transfection mix in the following order (Transfection mix per well of LabTek II #1.5) 
- Add Opti-MEM (40 μL Opti-MEM - x μL (DNA) into a new reaction tube. 
- Add appropriate volume of DNA (usually x μL of a 100 ng/μL dilution). 
- Add 0.6 μL TurboFect to each reaction mix, mix thoroughly, incubate transfection 
mixtures for 20 min at room temperature. 
- Meanwhile remove half of the cell culture medium (200 μL) from LabTeks harbouring cells. 
• After incubation of transfection mixtures, add transfection mixtures to cells drop by drop. 
After adding the transfection mixtures, rock LabTeks gently back and forth to dispense 
transfection mixture. Incubate cells at 37 °C, 10 % CO2 for 4 h - 6 h. 
• After incubation, remove the transfection mixture from plated cells and add 400 μL of 
DMEM/10 % FCS in each well. Incubate cells at 37°C, 10 % CO2 overnight. 
Day 3 
On the next day, inspect HEK293T cells and check for florescence using the UV lamp and 
appropriate filters on the microscope (cell culture). 
Labelling with one Antibody in HEK293T cells (with fixation but not with permeabilisation). 
• wash with 2 x 200 μL DPBS 
• fix the cells with 1 x 200 μL PFA (4%) in PEM, 20 min 21 °C, fixation 
• wash with 2 x 200 μL DPBS 
• block with 1 x 200 μL DPBS + 1% BSA, 45 min 21 °C, blocking 
• stain with 1 x 200 μL antibody (1 μg/mL) in DPBS + 1 % BSA, 18 h 4 °C 
• wash with 3 x 200 μL DPBS 
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At this point cells can be imaged by fluorescence microscopy. 
Labelling with two Antibodies in HEK293T cells (with fixation but not with permeabilisation). 
• wash with 2 x 200 μL DPBS 
• fix the cells with 1 x 200 μL PFA (4%) in PEM, 20 min 21 °C, fixation 
• wash with 2 x 200 μL DPBS 
• block with 1 x 200 μL DPBS + 1% BSA, 45 min 21 °C, blocking 
• stain with 1 x 200 μL antibody 1 (2, 4 or 8 μg/mL) in DPBS + 1 % BSA, 18 h 4 °C 
Day 4 
• wash with 2 x 200 μL DPBS 
• stain with 1 x 200 μL antibody 2 (1 μg/mL) in DPBS + 1% BSA, 10 h 4 or 21 °C 
• wash with 3 x 200 μL DPBS 
At this point cells can be imaged by fluorescence microscopy 
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3.4.7 Spectral Data 
 (E)-N-(4-((4-Aminophenyl)diazenyl)phenyl)-N-ethylethane-1,2-diamine (3.1) 
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 N-(Carboxymethyl)-N,N,N-triethylethanammonium chloride (3.3) 
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  (E)-N-(2-((4-((4-Aminophenyl)diazenyl)phenyl)(ethyl)amino)ethyl)-1-((1,3-
dioxoisoindolin-2-yl)oxy)-3,6,9,12,15,18,21,24,27,30,33,36-
dodecaoxanonatriacontan-39-amide (3.2) 
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 (E)-2-((4-((4-((1-((1,3-Dioxoisoindolin-2-yl)oxy)-39-oxo-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-
yl)(ethyl)amino)phenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-oxoethan-1-
ammonium formate (3.4) 
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 tert-Butyl (3-(1,3-dioxoisoindolin-2-yl)propoxy)carbamate (3.13) 
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 tert-Butyl (3-aminopropoxy)carbamate (3.14) 
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 (E)-2-((4-((4-(2-((tert-Butoxycarbonyl)amino)acetamido)phenyl)diazenyl)phenyl) 
amino)-N,N,N-triethyl-2-oxoethan-1-ammonium formate (3.7) 
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 (E)-2-((4-((4-(50-(Ammoniooxy)-4,46-dioxo-7,10,13,16,19,22,25,28,31,34,37,40,43-
tridecaoxa-3,47-diazapentacontanamido)phenyl)diazenyl)phenyl)amino)-N,N,N-
triethyl-2-oxoethan-1-ammonium bis-(trifluroacetate) (3.8) 
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 (E)-N-(4-((4-aminophenyl)diazenyl)phenyl)dodecanamide (3.15) 
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 (E)-2-((4-((4-dodecanamidophenyl)diazenyl)phenyl)amino)-N,N,N-triethyl-2-
oxoethan-1-ammonium formate (3.11) 
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 (E)-1-Butyl-2-((4-((4-(2-dodecanamidoacetamido)phenyl)diazenyl) 
phenyl)carbamoyl)piperidin-1-ium formate (3.12) 
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4 Tethered Photopharmacology of the AMPA Receptor 
4.1 Introduction 
Ionotropic glutamate receptors (iGluRs) are the major mediators of excitatory synaptic 
transmission. Upon arrival of an action potential in the axon-terminal of the presynaptic neuron, 
glutamate is released into the synaptic cleft. This spike in glutamate concentration opens 
postsynaptically expressed iGluRs, triggering an efflux of K+ and an influx of Na+ and/or Ca2+ 
ions, resulting in a depolarization of the cell membrane and an excitatory postsynaptic potential 
(EPSP). Above-threshold EPSPs can in turn trigger voltage-gated Na+ channels and hence 
generate an action potential. To date, 18 iGluR subunits have been identified which are 
classified according to their sensitivity to agonists (AMPA, kainate, and NMDA). Among these, 
AMPA receptors carry the bulk of the fast excitatory current, producing fast-rising, quickly-
desensitizing and high-amplitude EPSPs with a time to peak of around 1 ms.94 AMPA receptors 
are tetramers composed of four closely relates subtypes (GluA1-4) which predominantly form 
a symmetric ‘dimer of dimers’ of GluA2 with either GluA1, GluA3 or GluA4.95 While traditional 
pharmacology has been crucial to identify the different iGluR classes and untangle their 
contributions to synaptic transmission, its utility is limited not only by their imperfect selectivity 
profile but also by the ubiquity and abundance of iGluR expression, which at the same time is 
highly regulated and varied. For instance, AMPA receptors are not only defined by their subunit 
composition but are also subject to alternative splicing or editing, giving rise to a huge number 
of possible subunit combinations.95 Adding another layer of complexity, their precise function 
is influenced by expression level, location or trafficking and is modulated by auxiliary and 
regulatory proteins.95–97 Even more so, when moving from this molecular level to a circuitry of 
neurons it is easy to see how a systemic application of drugs with limited subtype-selectivity is 
a tool far too crude to study events of glutamergic synaptic transmission in detail.  
One possibility of studying proteins in one population of cells over another is by genetic 
targeting. For instance, membrane-tethered toxins can be expressed in specific cell 
populations and block endogenous ion channels.98 One drawback of this method compared to 
pharmacology is the lack of acute onset which could cause complications such as 
compensatory gene expression. Shields et al. described an alternative strategy termed ‘drugs 
acutely restricted by tethering’ (DART) to combine the cell-type specificity and endogenous-
protein specificity of genetic methods with the acute onset of pharmacology (Figure 27a).32 
Therein, the AMPAR antagonist YM90K is synthetically modified with bioconjugation motif 
(Halo-tag ligand), separated by a long PEG36 chain as tether. The Halo-tag is a self-labelling 
protein tag (size: ~34 kDa) derived from the a bacterial haloalkane dehalogenase.99 It reacts 
with chloroalkanes (Halo-tag ligand) with high speed and specificity. The Halo-tag is fused to 
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a membrane anchor, and by expressing it in AMPAR-positive cells and subsequent labelling 
with the tethered antagonist, endogenous AMPARs can be antagonized. The large advantages 
of this approach over other genetically encoded approaches lie in the inactivity of the Halo-tag 
prior to application of the tethered antagonist and that it does not require modification of the 
receptor itself. We envisioned that we could equip this tethered DART antagonist with another 
layer of control by incorporation of the photoswitch ShuBQX-3 (Figure 27b). ShuBQX-3 is a 
photoswitchable antagonist of the AMPAR and was introduced by the Trauner group in 2017.79 
It is derived from quinoxaline-2,3-dione antagonists such as DNQX or zonampanel/YM90K 
which allow for a variety of substitutions in the 6-position of their core structure. Applied as a 
freely diffusible photoswitch, it is an antagonist in its trans-form, blocking glutamate-induced 
AMPAR currents entirely. Upon illumination and isomerization to the cis-configuration, about 
50% of the block is relieved (in presence of 300 μM L-glu). The envisioned hybrid molecule of 
ShuBXQ-3 and YM90K-DART that is termed ‘para-PORTL’ (Figure 27c). It represents a 
refinement of the photoswitchable orthogonal remotely-tethered ligands (PORTL) 
demonstrated in 2015 for the SNAP-tagged metabotropic glutamate receptors (mGluRs; see 
chapter 1 for more details on PORTL).28 While the SNAP-tag in the PORTL concept resides 
on the receptor of interest, the tag in para-PORTL is even further removed to a protein its near 
vicinity, e.g. a membrane anchor or a membrane-bound auxiliary or regulatory protein (para 
from the Greek word for beside, next to, near). 
 
Figure 27. para-PORTL concept and design. a) Drugs acutely restricted by tethering (DART) 
by Shields et al.32 b) By incorporating a photoswitch in the DART molecule, optical control can 
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be achieved by the obtained para-PORTL. (ATD: amino terminal domain, LBD: ligand binding 
domain, TMD: transmembrane domain, EPSP: excitatory postsynaptic potential). 
4.2 Results and Discussion 
The synthesis of para-PORTL 4.10 was started by a nucleophilic aromatic substitution of 
electron-poor, commercially available starting material 4.1 with the ethyl ester of 4-
aminobutanoic acid (Scheme 5). The reaction was carried out with a limiting two equivalents 
of cesium carbonate in DMSO to avoid ester hydrolysis. 4.2 was then coupled to 1-Boc-1-
phenylhydrazine 4.3 in a Buchwald-Hartwig cross-coupling reaction employing palladium 
diacetate as catalyst and t-Bu3P as ligand. 4.4 was subsequently reduced by palladium on 
carbon and hydrogen gas to afford aniline 4.5. A condensation reaction with oxalyl chloride 
furnished quinoxaline-2,3-dione 4.6. The ester was saponified by sodium hydroxide in a 
mixture of MeOH and THF, providing the free acid 4.7. A PEG36 tether was then installed by 
amide coupling to H2N-PEG36-COOtBu. By addition of neat TFA, the molecule was deprotected 
globally to obtain the azobenzene moiety and the free acid handle. Finally, amide coupling to 
Halo-Tag ligand afforded the para-PORTL 4.10 over a total of 8 linear synthetic steps.  
 
Scheme 5. Synthesis of para-PORTL 4.10. 
The para-PORTL 4.10 was then evaluated in an in vitro labelling experiment. To this end, 
purified Halo-tag protein (MW ~34 kDa) was incubated with a fourfold excess of 4.10 and then 
directly loaded on a SDS-PAGE precast gel (Figure 28). The clean shift to higher molecular 
weight is indicative of successful labeling with 4.10. As positive control, Halo-tag protein was 
labelled with the fluorescent Halo-TMR, which is 6-carboxytetramethylrhodamine amide 
coupled to Halo-tag ligand (Lane 3 in a) and b). To determine if 4.10 labels the Halo-tag protein 
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to completion, it was labelled in a first reaction with 4.10 and afterwards in a second reaction 
with Halo-TMR. The absence of TMR fluorescence is indicative of full labelling in the first 
reaction with 4.10 (lane 4 in b). 
 
Figure 28. In vitro labelling of purified Halo-tag protein with para-PORTL 4.10. a) Protein 
was labelled as indicated and total protein amount was detected by UV-induced fluorescence 
(Bio-Rad Mini-Protean stain-free™ precast gels). Overlay with near-infrared fluorescent ladder. 
The Halo-tag protein shows a clear shift in molecular weight upon reaction with the ca. 2.3 kDa 
para-PORTL (lane 1 and 2). TMR-labelled Halo-tag shows bleed-through into the protein 
detection channel (lane 3). The Halo-tag is labelled to completion by the para-PORTL, a later 
incubation with Halo-TMR leads to no TMR-labelling (lane 4). b) Same as a) but TMR-
fluorescence channel. 
As of now, the electrophysiological evaluation of 4.10 is only in its very early stages. In 
preliminary experiments, 4.10 was tested by Dr. Prashant Donthamsetti (Isacoff lab, UC 
Berkeley) in patch-clamp recordings (Figure 37). The AMPAR (GluA1, non-desensitizing 
mutant) was opened by application of L-glu (1 mM). 4.10 was then able to photoblock 11.9 ± 
2.3% of the inward current (n = 9 cells) after photoisomerization to cis (380 nm, grey). Under 
blue light (460 nm), no effect was observed. The small block observed with orange light (600 
nm) is likely an effect of the light’s first harmonic oscillation (300 nm), which is isomerizing a 
fraction of 4.10 to cis. Therefore, 4.10 is inactive in its trans-configuration while the cis-isomer 
acts as a competitive antagonist. 
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Figure 29. Photoblock of AMPAR by para-PORTL 4.10. Blue: 460 nm, grey: 360 nm, orange: 
600 nm.  
That the cis-isomer of 4.10 is the active configuration is unexpected and in stark contrast to 
the initial expectations (compare to Figure 27). The freely diffusible photoswitch ShuBQX-3 
was active in its trans-isomer.3 In addition to being trans-active, ShuBQX-3 exhibited a strong 
bathochromic shift in switching wavelengths. More specifically, in DMSO or in aqueous Ringer-
Buffer, ShuBQX-3 behaved like a normal azobenzene in UV/Vis experiments, with optimal 
switching wavelengths of 380 nm (trans to cis) and 460 nm (cis to trans). However, when 
ShuBQX-3 was applied to HEK293T cells expressing AMPAR, the optimal wavelength for 
trans- to cis-isomerization in patch-clamp experiments was 460 nm. In an attempt to explain 
this bathochromic shift, the authors consulted the X-ray structure of MPXQ bound to the 
AMPAR.100 In this structure, the guanidinium moiety of an arginine (R-485) is positioned near 
the quinoxaline-2,3,-dione core of the antagonist MPQX. Consequently, the authors ascribed 
the observed bathochromic shift to similar interactions of this arginine with the quinoxaline-2,3-
dione core of ShuBQX-3. This was corroborated by UV/Vis-experiments in which a DMSO 
solution of ShuBQX-3 was spiked with L-arginine or guanidine (20 equiv.). In both cases, a 
bathochromic shift was observed that was comparable to the one observed in the patch-clamp 
experiments. In conclusion, trans-ShuBQX-3 binds competitively (with L-glu) to AMPAR, the 
interaction with arginine results in the bathochromic shift, and the receptor-bound trans-
ShuBQX-3 is isomerized to cis by illumination with blue light (460 nm). This triggers the release 
of ShuBQX-3 from the binding pocket. 
In 4.10, the installation of the PEG chain likely restrains the positioning of the quinoxaline-2,3-
dione core in the AMPAR binding pocket. Therefore, trans-4.10 cannot be accommodated 
anymore while the ‘smaller’ cis-isomer still fits into the binding pocket, antagonizing the 
4. Tethered Photopharmacology of the AMPA Receptor 
104 
receptor. Unfortunately, the amplitude of photoblock under physiological concentrations of L-
glu (1 mM) is likely too low to efficiently block AMPAR-mediated synaptic transmission in 
neurons, which is the primary goal. 
In the PORTL concept, the use of low-affinity ligands can be advantageous (see chapter 1). 
Improvements of photoblock will therefore not be aimed at improving the affinity but rather at 
increasing the effective concentration of tethered 4.10 around the AMPAR. This will be tackled 
by two strategies, i) cloning of Halo-membrane anchors that position 4.10 more efficaciously 
and ii) by introducing multivalent, dendritic ligands that have multiple photoswitches attached 
to one bioconjugation motif. 
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4.3 Conclusion and Outlook 
A novel approach, termed para-PORTL, is illustrated on the AMPA receptor which represents 
an improvement and a refinement of the PORTL concept. In para-PORTL, the bioconjugation 
tag is removed from the receptor itself to a protein in its near vicinity, e.g. an auxiliary or a 
scaffold protein. Since no modification of the receptor is required, the para-PORTL concept 
better reflects the underlying receptor biology. The biological investigation is currently 
underway in collaboration with the Isacoff laboratory and first experiments were promising, 
showing a light-dependent block of AMPAR (GluA1-L497Y, non-desensitizing point mutant). 
Due to their central role in synaptic transmission, dysregulation or dysfunction of AMPA 
receptors often result in neurological diseases with massive human cost such as epilepsy or 
Alzheimer’s.101,102 para-PORTLs permit perturbation of endogenous AMPA receptors with light 
and could be an useful tool to study physiological and pathophysiological processes with 
AMPAR contribution. For instance, the subunit composition governs the ratio of Ca2+ 
impermeable (CI) and permeable (CP) AMPA receptors, which is a major determinant of 
excitotoxicity and is linked to diseases like amyotrophic lateral sclerosis.103 The ratio of CP/CI-
AMPARs is also influenced by their association with auxiliary subunits of which a large variety 
has been identified, such as transmembrane AMPA receptor regulatory proteins (γ2-8 TARPs), 
cornichons, Shisas and GSG1L.104 By fusing a Halo-tag to the different auxiliary subunits and 
labelling with a para-PORTL molecule, associated populations of AMPARs may be blocked 
and unblocked using light. This could help to break down contributions of subunit-AMPAR 
complexes to disease states. 
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4.4 Supporting Information 
4.4.1 Synthesis 
LCMS was performed on a Shimadzu MS2020 connected to a Nexerra UHPLC system 
equipped with a Waters ACQUITY UPLC BEH C18 1.7 μm 2.1x50 mm column. Buffer A: 0.05% 
HCOOH in H2O Buffer B: 0.05% HCOOH in acetonitrile. Analytical gradient was from 10% to 
90% B within 4.0 min with 1 mL/min flow.  
 Ethyl 4-((5-chloro-2-nitro-4-(trifluoromethyl)phenyl)amino)butanoate (4.2) 
NO2
H
NCl
F3C
O
O
 
1,5-Dichloro-2-nitro-4-(trifluoromethyl)benzene (2.01 g, 7.73 mmol, 1.04 equiv.) and ethyl 4-
aminobutanoate (1.25 g, 7.46 mmol, 1.0 equiv.), cesium carbonate (6.00 g, 15.35 mmol, 2.96 
equiv.) and DMSO (30 mL) were heated to 80 °C overnight. The reaction mixture was diluted 
with water (600 mL) and extracted with EtOAc (4 x 400 mL). The combined organic layers were 
washed against water (400 mL), 10% aq. LiCl solution (400 mL) and brine (400 mL), and dried 
over MgSO4 before concentration in vacuo. The residue was purified by flash column 
chromatography (EtOAc/hexanes = 1/5) to yield the desired product as a citron-yellow, waxy 
solid (1.37 g,3.86 mmol, 52%). 
TLC (EtOAc/hexanes = 1/5): 0.30 (UV + yellow color). 
1H NMR (400 MHz, CDCl3) δ 8.52 (d, J = 0.7 Hz, 1H), 8.40 – 8.18 (m, 1H), 7.04 (s, 1H), 4.18 
(q, J = 7.1 Hz, 2H), 3.42 (td, J = 7.2, 5.5 Hz, 2H), 2.47 (t, J = 6.9 Hz, 2H), 2.19 – 1.99 (m, 2H), 
1.28 (t, J = 7.2 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 172.53, 146.68, 139.76, 129.38, 127.24 (q, J = 5.7 Hz), 122.34 
(q, J = 271.6 Hz), 116.04, 115.42 (q, J = 33.4 Hz), 60.88, 42.58, 31.20, 23.79, 14.21. 
Note: Purity ca. 95%. Ca. 5% contamination with the free acid. The impurity had no impact on 
subsequent reactions. 
HRMS (ESI): m/z calc. for C13H15ClF3N2O4+ (M+H)+: 355.0667, found: 355.0667. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 4min) = 1.90 min. 
 tert-Butyl 1-phenylhydrazine-1-carboxylate (4.3) 
N
Boc
NH2
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4.3 was prepared according to a published procedure.105 Analytical data matched those 
reported. 
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.41 (m, 2H), 7.42 – 7.27 (m, 2H), 7.13 (ddt, J = 8.6, 7.0, 
1.2 Hz, 1H), 4.23 (s, 3H), 1.52 (s, 9H). 
 tert-Butyl 2-(5-((4-ethoxy-4-oxobutyl)amino)-4-nitro-2-(trifluoromethyl)phenyl)-1-
phenylhydrazine-1-carboxylate (4.4) 
NO2
H
NHN
F3C
O
ON
Boc
 
4.2 (1.06 g, 3.00 mmol, 1.0 equiv.), tert-butyl 1-phenylhydrazine-1-carboxylate (750 mg, 3.60 
mmol, 1.2 equiv.), cesium carbonate (1.37 g, 4.20 mmol, 1.4 equiv.), tBu3PHBF4 (174 mg, 0.60 
mmol, 0.2 equiv.), Pd(OAc)2 (67.4 mg, 0.30 mmol, 0.1 equiv.) and toluene (50 mL) were 
combined in a pressure flask, purged with Argon, sealed and heated to 110 °C for 24 h. The 
reaction mixture was allowed to cool to r.t., filtered over celite, washing with a copious of EtOAc. 
The filtrate was concentrated in vacuo and purified by flash column chromatography 100% 
DCM) to yield the product as a yellow gum (754 mg, 1.43 mmol, 48%).  
TLC (100% DCM): 0.27 (UV+yellow color); SM: 0.49 (UV+yellow color). 
1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 0.9 Hz, 1H), 8.35 – 8.27 (m, 1H), 7.51 – 7.45 (m, 2H), 
7.32 – 7.26 (m, 2H), 7.14 – 7.08 (m, 2H), 6.07 (s, 1H), 4.05 (q, J = 7.1 Hz, 2H), 3.13 (td, J = 
7.0, 5.5 Hz, 2H), 2.27 (t, J = 7.2 Hz, 2H), 1.83 (p, J = 7.1 Hz, 2H), 1.38 (s, 9H), 1.18 (t, J = 7.1 
Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 172.5, 152.9, 150.4, 148.6, 141.2, 129.1, 128.2 (q, J = 5.5 Hz), 
125.6, 125.3, 121.5, 103.6 (d, J = 33.0 Hz), 93.6, 83.6, 60.8, 42.4, 31.5, 28.2, 23.8, 14.4. 
Note: CF3 carbon not observed. 
HRMS (ESI): m/z calc. for C24H30F3N4O6+ (M+H)+: 527.2112, found: 527.2117. 
tR (LCMS) = 3.96 min. 
UV/Vis (LCMS): max1 = 239 nm, max2 = 351 nm (broad). 
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 tert-Butyl 2-(4-amino-5-((4-ethoxy-4-oxobutyl)amino)-2-(trifluoromethyl)phenyl)-1-
phenylhydrazine-1-carboxylate (4.5) 
NH2
H
NHN
F3C
O
ON
Boc
 
4.4 (486 mg, 0.92 mmol, 1.0 equiv.) was dissolved in MeOH (10 mL) and Pd/C (10 wt % Pd, 
195 mg, 0.18 mmol, 0.2 equiv.) was added. The reaction flask was flushed with hydrogen (3x). 
The resulting mixture was stirred at r.t. overnight. The reaction mixture was filtered over celite, 
washing with EtOAc. The filtrate was concentrated and purified by flash column 
chromatography (2% MeOH/DCM) to give the product as a brownish, viscous oil (133 mg, 0.27 
mmol, 29%) 
TLC (5% MeOH/DCM): 0.38 (UV+ninhydrin). 
1H NMR (400 MHz, CDCl3) δ = 7.54 (dt, J = 8.1, 1.1 Hz, 2H), 7.30 – 7.20 (m, 2H), 7.08 – 6.99 
(m, 1H), 6.93 – 6.66 (m, 2H), 6.04 (s, 1H), 4.05 (q, J = 7.2 Hz, 2H), 2.96 (s, 3H), 2.32 (t, J = 
7.3 Hz, 2H), 1.83 (p, J = 7.0 Hz, 2H), 1.33 (s, 9H), 1.17 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ = 173.8, 153.7, 143.8, 142.5, 128.6, 128.6, 124.9, 124.5, 121.4, 
116.9, 95.1, 82.4, 60.7, 42.9, 32.1, 28.0, 24.2, 14.2. 
Note: CF3 carbon not observed, C-F couplings not observed. 
HRMS (ESI): m/z calc. for C24H32F3N4O4+ (M+H)+: 497.2370, found: 497.2371. 
tR (LCMS) = 2.85 min. 
UV/Vis (LCMS): max1 = 198 nm, max2 = 233 nm, max3 = 269 nm. 
 tert-Butyl 2-(4-(4-ethoxy-4-oxobutyl)-2,3-dioxo-7-(trifluoromethyl)-1,2,3,4-
tetrahydroquinoxalin-6-yl)-1-phenylhydrazine-1-carboxylate (4.6) 
N
H
NHN
F3C
O
N
Boc
O
O
O
 
4.5 (133 mg, 0.27 mmol, 1.0 equiv.) was dissolved in DCM (2.7 mL). Triethylamine (82 μL, 
0.59 mmol, 2.2 equiv.) and oxalyl chloride (2 M in DCM, 160 μL, 0.32 mmol, 1.2 equiv.) were 
sequentially added. The reaction mixture was stirred at r.t. for 30 min, quenched by addition of 
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a drop of MeOH and directly purified by flash column chromatography (5% MeOH/DCM). The 
product was obtained as a brown oil (43.5 mg, 79 μmol, 29%).  
TLC (5% MeOH/DCM): 0.19 (UV). 
1H NMR (400 MHz, CDCl3) δ = 7.69 – 7.61 (m, 2H), 7.51 (d, J = 5.7 Hz, 1H), 7.39 – 7.28 (m, 
2H), 7.19 – 7.10 (m, 1H), 7.05 (d, J = 1.8 Hz, 1H), 6.92 (s, 1H), 4.19 – 4.05 (m, 4H), 2.34 (t, J 
= 7.0 Hz, 2H), 1.85 (p, J = 7.1 Hz, 2H), 1.44 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H). 
Note: NH proton of the quinoxaline-2,3-dione is not observed. 
13C NMR (101 MHz, CDCl3): δ = 172.2, 155.3, 154.3, 153.3, 143.0, 141.6, 130.4, 128.8, 125.2, 
121.6, 123.7 (d, J = 272.2 Hz), 117.4, 115.6 (d, J = 5.8 Hz), 110.7 (d, J = 32.5 Hz), 99.4, 83.3, 
60.7, 42.8, 31.1, 28.0, 21.8, 14.2. 
HRMS (ESI): m/z calc. for C26H30F3N4O6+ (M+H)+: 551.2112, found: 551.2115. 
tR (LCMS) = 3.23 min. 
UV/Vis (LCMS): max1 = 224 nm, max2 = 337 nm. 
 4-(7-(2-(tert-Butoxycarbonyl)-2-phenylhydrazineyl)-2,3-dioxo-6-(trifluoromethyl)-3,4-
dihydroquinoxalin-1(2H)-yl)butanoic acid (4.7) 
N
H
NHN
F3C
O
N
Boc
O
OH
O
 
4.6 (43.5 mg, 79 μmol, 1.0 equiv.) was dissolved in THF/MeOH (1 mL/0.5 mL) and aq. NaOH 
(1 M, 0.16 mL, 0.16 mmol, 2.0 equiv.) was added. The reaction was stirred at r.t. for 1 h, then 
acidified by addition of 50 μL AcOH. The reaction mixture was concentrated in vacuo to 
dryness. The residue was taken up in 900 μL DMSO and 100 μL water and centrifuged (14,000 
rcf, 2 min). The supernatant was purified by HPLC. Product containing fractions were combined 
and freeze-dried. The desired product was obtained in 44% yield (18.1 mg, 35 μmol). 
1H NMR (400 MHz, DMSO-d6) δ = 11.85 (s, 1H), 8.64 (s, 1H), 7.73 – 7.46 (m, 2H), 7.46 – 7.25 
(m, 3H), 7.23 – 7.04 (m, 1H), 6.64 (s, 1H), 3.95 (t, J = 7.3 Hz, 2H), 2.29 (t, J = 7.3 Hz, 2H), 
1.72 (t, J = 7.3 Hz, 2H), 1.38 (s, 9H). 
Note: NH proton of the quinoxaline-2,3-dione is not observed. 
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13C NMR (101 MHz, CDCl3): δ = 174.0, 156.1, 153.6, 153.1, 142.7, 141.7, 131.1, 128.8, 124.5 
(d, J = 272.5 Hz), 125.5, 123.5, 118.5, 114.2 (q, J = 5.2 Hz), 107.2 (q, J = 31.7 Hz), 98.3, 81.8, 
42.3, 31.4, 28.2, 22.1. 
HRMS (ESI): m/z calc. for C24H26F3N4O6+ (M+H)+: 523.1799, found: 523.1801. 
tR (LCMS) = 2.78 min. 
UV/Vis (LCMS): max1 = 198 nm, max2 = 224 nm, max3 = 337 nm.. 
 tert-Butyl 116-(7-(2-(tert-butoxycarbonyl)-2-phenylhydrazineyl)-2,3-dioxo-6-
(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl)-113-oxo-4,7,10,13,19,22,25,28,31, 
34,37,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82,85,88,91,94,97,100,103,106,10
9-pentatriacontaoxa-112-azahexadecahectanoate (4.8) 
N
H
NHN
F3C
O
N
Boc
O
N
H
O
O OtBu
O
36
 
4.7 (13.1 mg, 25 μmol, 1.0 equiv.) was dissolved in DMSO (0.8 mL) and DIPEA (9.2 μL, 53 
μmol, 2.1 equiv.) and TSTU (9.0 mg, 30 μmol, 1.2 equiv.) were added. The reaction mixture 
was stirred at r.t. for 30 min, before additional DIPEA (18.5 μL, 106 μmol, 4.2 equiv.) and NH2-
PEG36-COOtBu (Iris Biotech #PEG3710, 52.0 mg, 30 μmol 1.2 equiv.) were added. The 
reaction mixture was stirred at r.t. overnight before it was acidified by addition of 40 μL of 
AcOH. The reaction mixture was centrifuged (14,000 rcf, 2 min) and the supernatant was 
subjected to HPLC purification. The product was obtained after freeze-drying of product 
containing fractions in 57% yield (32.0 mg, 14 μmol). 
HRMS (ESI): m/z calc. for C103H184F3N5O432+ (M+2H)2+: 1118.6170, found: 1118.6170. 
tR (LCMS) = 3.29 min. 
UV/Vis (LCMS): max1 = 198 nm, max2 = 225 nm, max3 = 337 nm. 
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 (E)-116-(2,3-Dioxo-7-(phenyldiazenyl)-6-(trifluoromethyl)-3,4-dihydroquinoxalin-
1(2H)-yl)-113-oxo-4,7,10,13,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67, 
70,73,76,79,82,85,88,91,94,97,100,103,106,109-pentatriacontaoxa-112-
azahexadecahectanoic acid (4.9) 
N
H
NN
F3C
O
N
O
N
H
O
O OH
O
36
 
Precooled TFA (0.5 mL) was added to 4.7 (32.0 mg, 14 μmol, 1.0 equiv.) on ice. The reaction 
mixture quickly turned to an orange color and as allowed to stand on ice for 10 min and 
analyzed by LCMS. Then, the reaction mixture was allowed to warm to r.t. and allowed to stand 
for an additional 30 min and again analyzed by LCMS. TFA was removed by a gentle stream 
of nitrogen. The residue was taken up in 900 μL DMSO and 100 μL water, centrifuged (14,000 
rcf, 2 min) and the supernatant was subjected to HPLC purification. The product was obtained 
as an orange, viscous oil (3.9 mg, 1.9 μmol, 13%) 
Note: Due to wrong mass assignments in the LCMS analysis, the reaction progress was 
incorrectly judged to be incomplete after 10 min on ice. Degradation of the product was 
observed upon warming to r.t.. If this reaction was repeated, longer reaction times on ice and 
addition of a cation scavenger (e.g. a drop of water or anisole) are recommended. 
LRMS (ESI): m/z calc. C94H167F3N5O413+for (M+3H)3+: 692.4, found: 693.4 
HRMS (ESI): m/z calc. C94H166F3N5O413+for (M+2H)2+: 1039.5516 found: 1039.5524. 
tR (LCMS) = 2.94 min. 
UV/Vis (LCMS): max1 = 220 nm, max2 = 263 nm, max3 = 291, max4 = 360 nm. 
 (E)-N-(2-(2-((6-Chlorohexyl)oxy)ethoxy)ethyl)-1-(4-(2,3-dioxo-7-(phenyldiazenyl)-6-
(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl)butanamido)-
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,8
7,90,93,99,102,105,108-pentatriacontaoxaundecahectan-111-amide (4.10) 
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4.9 (3.9 mg, 1.9 μmol, 1.0 equiv.), DIPEA (2 μL, 11.5 μmol, 6.0 equiv.) and TSTU (0.7 mg, 2.4 
μmol, 1.3 equiv.) were combined in DMSO (200 μL) and stirred at r.t. for 30 min. 2-(2-((6-
Chlorohexyl)oxy)ethoxy)ethan-1-amine (HaloTag-ligand, 1.2 mg, 3.8 μmol, 2.0 equiv.) was 
prepared in a 4 mL dram vial and the solution of the activated acid was added in one portion. 
The reaction mixture was stirred at r.t. overnight. The reaction mixture was acidified by a drop 
of AcOH, centrifuged (14,000 rcf, 2 min) and the supernatant was subjected to HPLC 
purification. The product was obtained as an orange, viscous oil (1.8 μmol, 95%) 
1H NMR (400 MHz, CDCl3) δ 8.08 – 8.01 (m, 2H, trans), 8.00 (s, 1H, trans), 7.70 (s, 1H, trans), 
7.65 – 7.56 (m, 3H, trans), 7.34 (t, J = 7.8 Hz, 1H, cis), 7.24 – 7.16 (m, 0H, cis), 7.00 – 6.92 
(m, 1H, cis), 6.48 (s, 0H, cis), 4.39 – 4.29 (m, 2H), 3.92 – 3.85 (m, 1H), 3.84 – 3.77 (m, 1H), 
3.73 (t, J = 6.2 Hz, 3H), 3.66 – 3.56 (m, 191H), 2.46 (t, J = 6.2 Hz, 3H), 2.40 (t, J = 7.0 Hz, 2H), 
2.11 (q, J = 7.1 Hz, 3H), 1.83 – 1.71 (m, 3H), 1.60 (p, J = 6.8 Hz, 3H), 1.52 – 1.31 (m, 5H). 
Note: Mixture of cis- and trans-isomers. To assign cis- and trans- peaks, the NMR tube was 
illuminated by a UV-handheld lamp for a few minutes and directly measured by NMR (see 
chapter 4.4.2.7). 
HRMS (ESI): m/z calc. for C104H187ClF3N6O423+ (M+3H)3+: 761.7446, found: 761.7451. 
tR (LCMS) = 3.30 min. 
UV/Vis (LCMS): max1 = 219 nm, max2 = 263 nm, max3 = 291, max4 = 360 nm. 
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4.4.2 Spectral Data 
 Ethyl 4-((5-chloro-2-nitro-4-(trifluoromethyl)phenyl)amino)butanoate (4.2) 
 
4. Tethered Photopharmacology of the AMPA Receptor 
114 
 tert-Butyl 1-phenylhydrazine-1-carboxylate (4.3) 
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 tert-Butyl 2-(5-((4-ethoxy-4-oxobutyl)amino)-4-nitro-2-(trifluoromethyl)phenyl)-1-
phenylhydrazine-1-carboxylate (4.4) 
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 tert-Butyl 2-(4-amino-5-((4-ethoxy-4-oxobutyl)amino)-2-(trifluoromethyl)phenyl)-1-
phenylhydrazine-1-carboxylate (4.5) 
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 tert-butyl 2-(4-(4-ethoxy-4-oxobutyl)-2,3-dioxo-7-(trifluoromethyl)-1,2,3,4-
tetrahydroquinoxalin-6-yl)-1-phenylhydrazine-1-carboxylate (4.6) 
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 4-(7-(2-(tert-butoxycarbonyl)-2-phenylhydrazineyl)-2,3-dioxo-6-(trifluoromethyl)-3,4-
dihydroquinoxalin-1(2H)-yl)butanoic acid (4.7) 
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 (E)-N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-1-(4-(2,3-dioxo-7-(phenyldiazenyl)-6-
(trifluoromethyl)-3,4-dihydroquinoxalin-1(2H)-yl)butanamido)-
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75,78,81,84,8
7,90,93,99,102,105,108-pentatriacontaoxaundecahectan-111-amide (4.10) 
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5 Tethered Photopharmacology of the μ-Opioid Receptor 
5.1 Introduction 
Since antiquity, morphine and related opiates have widely been used for pain relief. As opiates 
also induce euphoria, they also have been abused recreationally for hundreds of years. The 
mechanistic target of opiates is the μ-opioid receptor (MOR), which is a class A GPCR. In 
contrast to Class B or C GPCRs, it features no large extracellular domain and consists of 7 
transmembrane helices (Figure 30a). Its third intracellular loop is coupled to an inhibitory Gi/o 
protein (colored red in Figure 30a). Upon receptor stimulation, the trimeric Gi/o protein binds 
GTP and dissociates into α- and βγ-subunits. The α-subunit inhibits adenylyl cyclase, resulting 
in decreased cAMP levels, while the βγ-subunit opens G protein-coupled inwardly-rectifying 
potassium (GIRK) channels. In addition, MOR, like other GPCRs, can signal in G protein-
independent fashion, e.g. through β-arrestin or activation of downstream kinases. 
The MOR is also the target of non-opiate opioids such as fentanyl and tramadol (Figure 30b). 
Fentanyl is a highly-addictive and extremely potent agonist with an EC50 around 1 nM106 and 
is used as analgesic in the clinic, together with many structural analogs. In recent years, 
fentanyl abuse has increased dramatically, especially in the US. It now is the major cause for 
lethal opioid overdoses with deaths peaking at roughly 64,000 in 2017, and still rising. At these 
numbers, opioid overdoses cause more deaths in the US than gun violence or car accidents.107 
Especially fentanyl is dangerous because it produces respiratory depression to a larger extent 
than other opioids.108  
 
Figure 30. Structure and Pharmacology of the μ-opioid receptor. a) Structure of the active-
state MOR bound to the synthetic agonist BU72. The intracellular loop that binds to the G 
protein is highlighted in red. (pdp 5C1M) b) The MOR has an extensive pharmacology and a 
few examples of MOR agonists are shown (top). Photofentanyl-I (PF-I) and Photofentanyl-II 
(PF-II) according to Schönberger et al.5 PF-II exhibited light-dependent agonism on MOR, 
while PF-I was inactive.  
To develop novel therapies and fight drug addiction it is important to understand the molecular 
processes underlying tolerance and addiction. In the last decades, considerable effort has 
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been directed into the mechanisms of acute MOR signaling, receptor regulation and tolerance 
and their implications on drug tolerance and addiction.109 Novel tools that permit the 
perturbation of MOR with the high spatiotemporal precision that light offers could be highly 
useful to decipher the relationship of receptor activation and regulation to drug tolerance.  
In line with this, we wanted to extend the PORTL concept (see chapter 1) to the MOR. Our 
group published a freely-diffusible photochromic agonist (PCL) for the MOR in 2014.5 There, 
fentanyl was furnished with an azobenzene in two different positions to give access to 
Photofentanyl-I (PF-I) and Photofentanyl-II (PF-II, Figure 30b). While PF-I was inactive, PF-II 
was an agonist in its trans-isomer, i.e. in the dark, activating MOR while its cis-isomer was 
inactive. This was observed by reading out the opening of GIRK channels by voltage-clamp 
electrophysiology.  
A suitable point of attachment of the flexible PEG-linker needed to be identified. The PEG-
chain is required as a tether between the photoswitchable agonist and the bioconjugation motif. 
To this end, we turned to Nil Patel and Seva Katrich (USC) for molecular docking studies. 
Based on the active-state MOR structure (pdb 5C1M), PF-II with PEG chains in different 
positions was docked computationally. Initially, intuition guided us to propose a structure with 
the PEG chain attached to the para-position of the azobenzene. Our reasoning was such that 
this position already tolerated the introduction of the azobenzene, making it likely that 
increasing the bulk there by attaching the PEG chain could be accommodated by the receptor. 
PF-II adopts a similar binding mode as fentanyl itself (Figure 31a) with the azobenzene sticking 
out in direction of the extracellular space. The PEGylated PF-II binds comparably, albeit with 
reduced scores due to steric constraints around the linker. It should be noted that the N-
terminus of MOR in the crystal structure is modified and that its correct conformation is hard to 
predict precisely. 
We also considered to attach the PEG linker on the propionic amide residue (Figure 31b) but 
the linker clearly clashes with the protein, with no exit tunnel remaining.  
In a last design, we proposed to attach an acrylic acid moiety on the phenethyl residue. This 
was inspired by a recent report that described synthetic modification of fentanyl in that 
fashion.106 Subsequently, the acrylic acid was used to attach a PEG chain via amide coupling 
and this did not disrupt the fentanyl’s analgesic properties. Accordingly, we hypothesized that 
the acrylic acid and the PEG chain might be tolerated at the same position on PF-II. The 
docking study revealed that the PEGylated fentanyl can flip in the binding pocket, and therefore 
allow exit of the PEG chain. Unfortunately, this flip was not possible in the PF-II derivative due 
to the presence of the azobenzene.  
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Figure 31. Docking studies with various linker attachment points on PF-II. a) Overlay of 
docked structures for fentanyl (orange sticks), PF-II (green sticks) and tethered PF-II (yellow 
sticks). b) Overlay of docked structures for fentanyl (orange) and tethered PF-II (turquoise). c) 
Overlay of fentanyl orange sticks) and a PEGylated acrylic acid derivative of fentanyl from 
Averick and coworkers106 (beige sticks). The PEGylated acrylic acid derivative of PF-II could 
not be accommodated by the MOR receptor. Computational models are based on active-state 
MOR structure (pdb 5C1M) and were performed by Nil Patel and Seva Katritch (USC). 
According to the docking studies, we proposed the design of fentanyl-based PORTLs 
according to design A. PF-II was to be modified in para-position on the azobenzene, including 
a long PEG chain as tether, linking the photoswitch to a benzylguanine (BG) for SNAP-tag 
labelling (Figure 32). 
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Figure 32. Design of fentanyl-based PORTL molecules. 
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5.2 Results and Discussion 
5.2.1 Synthesis of the PCL Core 
Early syntheses aimed at installing a protected amine in para-position to the azobenzene for 
further derivatization. It quickly became apparent that the acylation with propionyl chloride was 
problematic. With electron-withdrawing substituents on the azobenzene, the acylation reaction 
with propionyl chloride only gave very low conversions and upon heating gave the doubly 
reacted Michael-addition product. Therefore, it was attempted to use the N,N-diallyl-derivative 
as electron-rich protecting group for in a para-position of the azobenzene. While the acylation 
proceeded with high yield, deprotection of the N,N-diallyl amine failed under all conditions 
tested, i.e. basic (KOtBu) or catalytic (Ruthenium catalysts). To circumvent this issue, the 
electron-rich, red-shifted fentanyl PORTL was synthesized first. The synthesis was 
commenced by reductive amination of N-methylaniline with N-Boc-3-aminopropanal to give 5.3 
(Scheme 6). Azobenzene 5.4 was obtained by Azo-coupling with the tetrafluoroborate salt of 
the 4-nitrobenzenediazonium electrophile. The aniline 5.5 was obtained after reduction by 
sodium sulfide in a THF/water mixture and reductively aminated with N-phenethylpiperidin-4-
one to afford 5.6. The final red-shifted photoswitch 5.8 was then obtained after acylation with 
propionyl chloride and Boc-deprotection by EtOAc saturated with gaseous HCl. 
 
Scheme 6. Synthesis of red-shifted photopharmacophore 5.8: 
Since Photofentanyl-II is a cis-active photoswitch, it was anticipated that a bis-amide 
substituted photoswitch might prove more suitable since it can be isomerized to cis more 
efficiently than red-shifted azobenzenes. Therefore, the synthesis of the photoswitch with 
bistable photostationary states was started by amide coupling of Boc-glycine with an excess 
of 4,4’-azodianiline to yield 5.10 (Scheme 7). The final photoswitch 5.13 was then obtained in 
the same manner as for the red-shifted photoswitch by the sequence of reductive amination, 
acylation and deprotection.  
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Scheme 7 Synthesis of photopharmacophore 5.13. 
To investigate if the substitutions on the azobenzene are tolerated by the μ-Opioid receptor 
(MOR), 5.8 and 5.13 were tested by electrophysiology. The μ-Opioid receptor is coupled to a 
Gi/o protein, of which the activated βγ subunit couples to inwardly-rectifying K+ channels 
(GIRKs). Therefore, activation of MOR can be read-out indirectly by measuring the K+ flux over 
the cell membrane via patch-clamp at appropriate K+ concentrations/holding potentials. The 
GIRK read-out very closely reflects both the conformational changes underlying receptor 
activation as well as the downstream activation of effectors. Therefore, HEK293 cells stably 
expressing GIRK1/2 were transiently transfected with N-terminally SNAP-tagged MOR. Two 
variants of SNAP-MOR were used that differed in species (rat or mouse), in signal peptide and 
in linker sequences between the domain. One construct was cloned by Helen Farrants 
(Johnsson group, MPIMF Heidelberg) and the other was a kind gift of J. T. Williams (OHSU). 
Both were validated for expression and surface fluorophore labelling by the respective 
research groups, for details maps see supporting information.  
HEK293 cells stably expressing GIRK1/2 (HEK-GIRK, kind gift from Sonja Kleinlogel)110 were 
transfected with the SNAP_MOR constructs and tested for functional activation by wash-in of 
peptide agonist Leu-Enkephalin (LE) at a saturating concentration. In later experiments, 
DAMGO was used as positive control instead, since it is more stable towards hydrolysis 
(Supporting Figure 6). Both constructs were functional as confirmed by wash-in currents of LE 
or DAMGO.  
Then, the photoswitches 5.8 and 5.13 were tested. After establishing a patch in whole-cell 
mode, the compound was washed in and photoswitching was attempted (Figure 33). Both 
compounds were active in their trans-configuration and could be switched ON and OFF with 
illumination at the respective wavelength. 
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Figure 33. Patch-clamp data of the freely diffusible photoswitches. HEK-GIRK cells were 
transiently transfected with SNAP_MOR. Then, photoswitch was washed in and 
photoswitching was performed at the indicated wavelengths. 
5.2.2 Synthesis of PORTLs 
After establishing that the feely-diffusible, photoswitchable cores enable optical control over 
the SNAP_MOR constructs, the final PORTL molecules 5.14 and 5.15 were accessed by a 
sequence of amide couplings, deprotection and/or ‘click’ azide-alkyne cycloadditions (Scheme 
8). Issues with copper-catalyzed azide-alkyne cycloadditions (CuAAC) were encountered on a 
related project, the benzylguanine-azo-glutamate (BGAGs) PORTL molecules.28 The BGAGs 
with amides in 4,4’-position of the azobenzene required unusually high catalytic loadings of 
Cu(I) and high temperatures to drive the CuAAC to completion. Even more surprising, the red-
shifted BGAG460, where one amide is changed to a dialkylamine, was entirely unreactive in 
CuAAC under all conditions tested. In the end, BGAG460 was synthesized using strain-
promoted azide-alkyne cycloaddition (SpAAC) with a strained dibenzocyclooctyne. We 
hypothesized that the PEG chains are coordinating to the copper-ions, rendering them 
unavailable for catalysis. To avoid this issues, the synthesis of MOR PORTLs was directly 
planned via SpAAC. Next, the MOR PORTLs 5.14 and 5.15 were tested by electrophysiology. 
HEK293 cells expressing SNAP_MOR and GIRK1/2 were labelled with MOR PORTLs at 
micromolar concentrations (1 - 10 μM) at 37 °C for 30-90 min. The labelling solution was then 
replaced with extracellular buffer, cells were patched and illuminated at the appropriate 
wavelengths to isomerize to cis. If no effect was observed upon illumination, the agonists Leu-
Enkephalin (LE) or DAMGO were washed in as positive control to confirm expression of 
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SNAP_MOR and GIRK1/2. Negative experiments were at least repeated twice and are not 
shown here. Unfortunately, neither 5.14 nor 5.15 showed any light-dependent currents. Both 
compounds feature dibenzocyclooctyne which represents a large hydrophobic moiety. Even at 
low concentrations of 1 μM, precipitation of the compounds in labelling solution was observed. 
Accordingly, we hypothesized that the lack of light-dependent currents could be explained by 
failure to label due to low aqueous solubility of the PORTLs. First, the SpAAC was replaced by 
CuAAC (5.19), but led to incomplete conversion and was replaced by amide couplings (5.16 
and 5.17). 5.16 and 5.17 were both assayed for photoswitching in patch-clamp experiments, 
but again no light-dependent effects were observed. In a last attempt, the PEG tether was 
replaced by a simple C10 carbon chain, and this compound was directly washed in at 50 μM, 
but again, no photoswitching could be observed. 
 
Scheme 8. Final MOR PORTLs. 
5.2.3 Cis-stable Photoswitches 
Ideally, PCLs are inactive in the dark and only elicit a biological effect upon illumination. Since 
PF-II and the related photoswitches 5.8 and 5.13 are trans-active, i.e. dark active, we sought 
to reverse the azobenzene logic. Siewertsen et al. reported a bridged 5,6-
dihydrodibenzo[c,g][1,2]diazocine in 2009.111 In these ‘bridged’ azobenzenes, the cis-isomer 
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is the thermodynamically stable configuration and can be photoisomerized to the trans-
configuration by violet/blue light with wavelengths around 370-400 nm. The thermal back-
isomerization is usually slow for this type of a photoswitch. Green light around 480-550 nm 
triggers the photoisomerization back from the trans- to the cis-isomer.111,112  
While the cis-stable, bridged azobenzenes have been employed for optical control of biological 
systems before,113 it has not yet been shown that a trans-active PCL can be converted into a 
cis-active switch by replacing its azobenzene with the bridged variant. One synthesis by 
Woolley et al.113 exists for the diamino-substituted, cis-stable photoswitch core 5.24. In this 
synthesis, the diazene is formed by intramolecular reductive coupling of the nitro groups. This 
is reported with a mixture of Zn dust and Ba(OH)2 in ethanol followed by treatment with HgO. 
This procedure was attempted multiple times in the Trauner laboratory but was not 
reproducible in our hands. Therefore, we revisited an alternative route towards the cis-stable 
photoswitch that was developed by Dr. David Woodmansee and remains unpublished to date. 
With minor modifications to these procedures, the cis-stable photoswitch 5.24 could be 
accessed through a 4-step reaction sequence with satisfying and reproducible yields.  
The synthesis commenced with a radical bromination of 2,2’-ethylene dianiline. The aniline 
groups were then oxidatively coupled by treatment with mCPBA in DCM. The reaction yielded 
a mixture of the desired azobenzene2 and the further oxidized azoxy byproducts. Theoretically, 
two equivalents of mCPBA are required to oxidize the aniline to the nitroso, which subsequently 
reacts with the other aniline to the azobenzene in an intramolecular Baeyer-Mills-reaction. By 
portion wise addition of 2.0 equivalents of mCPBA to 5.21 in DCM, the amount of azoxy 
byproducuts could be minimized and the desired bridged azobenzene 5.22 could be isolated 
in 30% yield. Finally, by Buchwald-Hartwig coupling of 5.22 with tert-butyl carbamate and Boc-
deprotection in neat TFA, the cis-stable azobenzene 5.24 was accessed. 
 
Scheme 9. Synthesis of cis-stable azobenzene 5.24. 
Single crystals of 5.22 suitable for X-ray crystallography could be obtained (Figure 34). The 4- 
and 4’-positions are 6.1 Å apart, very similar in comparison with normal cis-azobenzene114 (6.2 
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Å). The dihedral angle is 7.9°, very similar to the value of 7.7° for cis-azobenzene. The phenyl 
rings in cis-azobenzene are not arranged planar but are rotated by 57° around the C-N bond, 
an angle of 90° would represent the planar arrangement. In cis-5.22 this angle is 71°. 
Therefore, the phenyl rings in the cis-5.22 are more planar to each other than in cis-
azobenzene, which is the major difference in their geometry.  
Next, the optimal wavelengths for the photoisomerization was determined by changing the 
illumination wavelength while recording the absorbance at the trans-5.22 absorbance 
maximum at 492 nm (Figure 34d). The optimal switching wavelengths for cis-to-trans are 400 
nm and >490 nm for trans-to-cis photoisomerization. 
The photoisomerization leads to a change in absorption (Figure 34e), which can easily 
observed by the color change of the 5.22-solution (Figure 34b). The photoisomerization can 
be performed over multiple cycles with no observable decay or degradation (Figure 34f). In the 
dark, thermal relaxation of 5.22 is slow and it can therefore be considered as bistable 
photoswitch on the timescales that are relevant for MOR-targeting photoswitches (Figure 34g). 
 
Figure 34. Photophysical properites of 5.22. a) X-Ray crystal structure of precursor 5.21. b) 
X-Ray crystal structure of the cis-isomer of 5.22. c) A solution of 5.22 in DMSO. Left: dark-
adapted, cis-configuration; right: after illumination with violet light (λ = 400 nm) in the trans-
configuration. d) Wavelength screen in 10 nm steps from 380 nm to 530 nm. e) UV/Vis 
spectrum in the dark-adapted state of 5.22 (black) and after illumination with violet light (λ = 
400 nm). f) Switching was performed by illumination with violet (λ = 400 nm) and green light (λ 
= 500 nm). g) Dark relaxation proceeds with a time constant of τ = 349 min. All spectrums 
were recorded at a concentration of 0.5 mM 5.22 in DMSO. 
After establishing the synthesis of the cis-stable azobenzene, the final steps towards a cis-
stable PCL were performed. 5.24 was amide coupled with Boc-protected glycine. Then, the 
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phenethylpiperidine moiety was attached via reductive amination to yield 5.26. The final cis-
stable photoswitch 5.27 was obtained after acylation using propionylchloride and deprotection 
by HCl gas in EtOAc. 
 
Scheme 10. Synthesis of the cis-stable photofentanyl 5.27. 
The photoswitch 5.27 was tested at a (high) concentration of 50 μM by patch-clamp 
electrophysiology in HEK-GIRK cells transfected with SNAP_MOR. Unfortunately, no light-
dependent effects could be observed (Supporting Figure 7). 
5.2.4 Further synthesis 
The following compound was synthesized according to the design in Figure 31c by Dr. Ahmed 
Ali.  
 
Scheme 11. Structure of AM-II. 
AM-II was tested for effects in SNAP_MOR expressing HEK-GIRK cells. Unfortunately, no 
wash-in currents and no photoswitching could be observed (n = 5). For electrophysiological 
characterization see Supporting Figure 8. 
In collaboration with Manuel Gailer (Hoffmann-Röder group, LMU Munich), a photoswitchable 
version (AzoDAMGO) of the synthetic enkephalin DAMGO was synthesized. To this end, an 
azobenzene was installed on the phenylalanine of DAMGO (Scheme 12). AzoDAMGO was 
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tested for effects in MOR-transfected HEK-GIRK assays, but no effects were observed (n = 8). 
For electrophysiological characterization see Supporting Figure 9. 
 
Scheme 12. Structure of AzoDAMGO. 
5.3 Summary and Outlook 
A variety of photoswitchable derivatives of fentanyl was synthesized. Some of the freely-
diffusible photoswitches enabled photoswitching of the μ-opioid receptor (MOR). 
Unfortunately, attachment of the PEG chain, that is required to span the distance between 
bioconjugation site and ligand binding site, was deleterious to photoswitching. None of the 
PEGylated photoswitches activated the MOR, neither in their trans- nor in their cis-
configuration. 
In an attempt to reverse the logic of photofentanyl-II, its azobenzene was replaced with a cis-
stable, ethylene-bridged variant to yield 5.27. 5.27 was not active on the MOR receptor in both 
its cis- and trans-configuration.  
In conclusion, future PORTL molecules for the MOR should not be designed based on fentanyl. 
Molecular docking studies were performed with photoswitchable variants of carfentanyl (not 
shown). These molecules adapt a different position in the MOR binding site and molecular 
docking suggests that carfentanyl-based photoswitches might be more amenable to the 
PORTL approach.  
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5.4 Supporting Information 
5.4.1 Synthesis 
 tert-Butyl (E)-(2-((4-((4-aminophenyl)diazenyl)phenyl)amino)-2-oxoethyl)carbamate 
(3.6, 5.10) 
N
N
H
N
H2N
O
NHBoc
 
4,4’-Diazoaniline (1.00 g, 4.71 mmol, 2.0 equiv.), N-Boc-Gly-OH (413 mg, 2.36 mmol, 
1.0 equiv.), HBTU (1.79 g, 4.72 mmol, 2.0 equiv.) and DIPEA (1.64 mL, 9.40 mmol, 4.0 equiv.) 
were added successively to a round bottom flask filled with dry THF (20 mL) at 0 °C. The 
reaction mixture was stirred at 0 °C for 45 min before it was allowed to warm to r.t. After 3 h 
the solvent was removed in vacuo and the residue was partitioned between EtOAc and 1 mM 
HCl. The organic layer was washed with water (1x) and brine (1x) before drying over MgSO4. 
After purification by flash column chromatography (1/2 = EtOAc/DCM) 725 mg (1.96 mmol) of 
the product were obtained as an orange solid in in 83% yield. 
TLC (2/1 = EtOAc/DCM) = 0.61. 
1H NMR (400 MHz, MeOH-d4) δ = 7.67 (d, J = 8.9 Hz, 2H), 7.63 – 7.54 (m, 4H), 6.67 – 6.57 
(m, 2H), 3.79 (s, 2H), 1.38 (s, 9H). 
13C NMR (101 MHz, MeOH-d4): δ = 169.2, 157.2, 151.9, 149.2, 144.3, 139.6, 124.6, 122.4, 
119.8, 113.8, 79.3, 48.2, 48.0, 47.8, 47.6, 47.4, 47.2, 46.9, 43.7, 27.3. 
HRMS (ESI): m/z calc. for C19H24N5O3+ (M+H)+: 370.1874, found: 370.1873. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.52 (cis), 6.67 min 
(trans). 
UV/Vis (LCMS): max = 389 nm. 
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 tert-Butyl (E)-(2-oxo-2-((4-((4-((1-phenethylpiperidin-4-yl)amino)phenyl)diazenyl) 
phenyl)amino)ethyl)carbamate (5.11) 
N
N
H
N
HN
O
NHBoc
N
Ph  
3.6 (200 mg, 0.54 mmol, 1.0 equiv.), N-phenethylpiperidin-4-one1 (110 mg, 0.54 mmol, 
1.0 equiv.), sodium triacetoxyborohydride (160 mg, 0.76 mmol, 1.4 equiv.), AcOH (30 μL, 
0.54 mmol, 1.0 equiv.) were added successively to dry DCE (5 mL). The reaction mixture was 
was stirred for 18 h at r.t. before the solvent was removed in vacuo. The residue was extracted 
with EtOAc against NaHCO3, water and brine. The organic layer was dried over MgSO4. After 
purification by flash column chromatography (3/2 = DCM/EtOAc -> EtOAc) the product was 
obtained as an orange solid (68 mg, 0.12 mmol) in 23% yield. 
TLC (2/3 = EtOAc/DCM) = 0.20 (PAA stain, SM: orange-yellow, product: violet). 
1H NMR (400 MHz, MeOH-d4) δ = 77.70 – 7.54 (m, 6H), 7.22 – 7.03 (m, 5H), 6.65 – 6.52 (m, 
2H), 3.78 (s, 2H), 3.33 (tt, J = 10.1, 4.1 Hz, 1H), 2.94 (d, J = 11.6 Hz, 2H), 2.77 – 2.68 (m, 2H), 
2.57 – 2.48 (m, 2H), 2.25 – 2.14 (m, 2H), 2.03 – 1.93 (m, 2H), 1.55 – 1.41 (m, 2H), 1.38 (s, 
9H). 
13C NMR (101 MHz, MeOH-d4): δ = 175.48, 163.51, 157.28, 155.63, 149.98, 146.13, 145.72, 
134.68, 134.48, 132.11, 131.11, 128.64, 126.13, 118.21, 85.65, 66.57, 58.27, 55.29, 49.98, 
39.12, 37.50, 33.61. 
HRMS (ESI): m/z calc. for C32H41N6O3+ (M+H)+: 557.3235, found: 557.3236. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.99 min. 
UV/Vis (LCMS): max = 420 nm. 
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 tert-Butyl (E)-(2-oxo-2-((4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)carbamate (5.12) 
HN
NN
N
N Ph
O
NHBoc
O
 
5.11 (58 mg, 0.104 mmol, 1.0 equiv.) was dissolved in dry DCM (5 mL) under a nitrogen 
atmosphere before addition of dry DIPEA (45 μL, 0.260 mmol, 2.5 equiv.) and propionyl 
chloride (11 μL, 0.125 mmol, 1.2 equiv.). After stirring at r.t. for 36 h, reaction progress was 
checked by LCMS, judged to be incomplete and more propionyl chloride was added (11 μL, 
0.125 mmol, 1.2 equiv.). After stirring for further 4.5 h at r.t., the reaction was quenched by 
addition of a few drops of MeOH before it was loaded directly on a silica column for purification 
(96/4  95/5 = MeOH/DCM). The product was obtained as an orange solid (50 mg, 81.6 μmol) 
in 79% yield. 
TLC (MeOH/DCM = 95/5) = 0.30. (Product and starting material run co-polar on TLC; PAA 
stain: SM violet, product yellow.). 
1H NMR (400 MHz, CDCl3) δ = 8.86 (s, 1H), 7.90 – 7.80 (m, 4H), 7.70 – 7.60 (m, 2H), 7.21 – 
7.05 (m, 7H), 5.49 (t, J = 5.9 Hz, 1H), 4.63 (tt, J = 11.4, 3.4 Hz, 1H), 3.93 (d, J = 5.8 Hz, 2H), 
2.96 (d, J = 11.2 Hz, 2H), 2.71 – 2.62 (m, 2H), 2.53 – 2.44 (m, 2H), 2.12 (t, J = 11.6 Hz, 2H), 
1.92 (q, J = 7.4 Hz, 2H), 1.78 (d, J = 11.3 Hz, 2H), 1.51 – 1.36 (m, 11H), 0.97 (t, J = 7.4 Hz, 
3H). 
13C NMR (101 MHz, CDCl3): δ = 173.5, 168.2, 156.7, 152.2, 148.9, 140.8, 140.0, 131.1, 128.6, 
128.4, 126.1, 124.2, 123.5, 119.9, 80.8, 60.3, 53.0, 52.5, 45.6, 33.7, 30.5, 28.7, 28.3, 9.7. 
HRMS (ESI): m/z calc. for C35H45N6O4+ (M+H)+: 613.3497, found: 613.3498. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.57 (cis), 5.89 
(trans). 
UV/Vis (LCMS): max = 365 nm. 
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 (E)-N-(4-((4-(2-Aminoacetamido)phenyl)diazenyl)phenyl)-N-(1-phenethylpiperidin-4-
yl)propionamide (5.13) 
HN
NN
N
N Ph
O
NH2
O
 
5.12 (18 mg, 29 μmol) was dissolved in dry EtOAc (1 mL) and sat. HCl in EtOAc (3 mL) was 
added. After stirring for 1 h at r.t., the precipitate was filtered off and dried under HV to yield 
the product as an orange HCl salt in quantitative yield (19 mg). 
1H NMR (400 MHz, D2O) δ = 7.82 (dd, J = 8.6, 5.0 Hz, 4H), 7.70 – 7.60 (m, 2H), 7.33 (ddd, J 
= 7.8, 5.6, 1.9 Hz, 4H), 7.29 – 7.20 (m, 3H), 4.68 (tt, J = 8.6, 3.3 Hz, 1H), 3.99 (s, 2H), 3.60 – 
3.53 (m, 2H), 3.31 – 3.23 (m, 2H), 3.16 – 3.04 (m, 2H), 2.95 (dd, J = 9.8, 6.4 Hz, 2H), 2.11 – 
1.99 (m, 2H), 1.94 (q, J = 7.6 Hz, 2H), 1.61 (qd, J = 12.9, 3.8 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, D2O): δ = 176.7, 165.4, 151.9, 148.6, 140.1, 139.5, 136.1, 130.8, 129.0, 
128.6, 127.3, 123.9, 123.5, 121.0, 57.4, 51.9, 50.2, 41.1, 29.8, 28.3, 27.3, 8.9. 
HRMS (ESI): m/z calc. for C30H37N6O2+ (M+H)+: 513.2973, found:513.2970. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.13 min. 
UV/Vis (LCMS): max = 365 nm. 
 (E)-1-Azido-N-(2-oxo-2-((4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-amide (5.28) 
O
O
HN
N
N
N
N
Ph
O
H
N
O
N3
12
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5.13 (19 mg, 32.4 μmol, 1.0 equiv.) and N3-PEG12-NHS-ester (baseclick #BCL-033, 72 mg, 
97.2 μmol, 3.0 equiv.) were dissolved in dry DMF (1 ml), dry DIPEA (56 μL, 320 μmol, 10 
equiv.) was added and the reaction mixture was stirred at r.t. Reaction progress was monitored 
by LCMS and judged to be complete after 1 h. The reaction mixture was loaded directly on a 
C18 column (Waters Sep-Pak C18 5g) using a gradient of 1 mM HCl and MeCN (100/0  
60/40 = 1 mM HCl/MeCN). Product containing fractions were identified by LCMS, combined 
and freeze-dried to obtain the product as a yellow solid in 66% yield (24.3 mg, 21.3 μmol). 
HRMS (ESI): m/z calc. for C57H86O15N9- (M-H)-: 1136.6249, found: 1136.6252. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.29 min (cis), 5.44 
(trans). 
UV/Vis (LCMS): max1 = 362 nm. 
 BG-DBCO 
N
O
O
HN
O
N
N
N
HN
NH2  
6-((4-(Aminomethyl)benzyl)oxy)-9H-purin-2-amine, BG-NH2, (14.9 mg, 55 μmol, 1.1 equiv.) 
and DBCO-NHS-ester (Jena Bioscience #CLK-A133-100, 20.1 mg, 5´0 μmol, 1.0 equiv.) were 
combined in dry DMF (500 μL) and dry DIPEA (16.7 μL, 100 μmol, 2.0 equiv.) was added. 
Reaction progress was monitored by LCMS and judged to be complete after 5.5 h. The reaction 
mixture was directly loaded on a C8 column (Waters Sep-Pak C8 2g) and eluted with a gradient 
of 1 mM HCl and MeCN (100/0  60/40 = 1 mM HCl/MeCN). Product containing fractions were 
identified by LCMS, conbined and freeze-dried to obtain the product as a colorless solid 
(8.0 mg 14.3 μmol, 29%). 
1H NMR (400 MHz, DMSO-d6) δ = 8.53 (s, 1H), 8.29 (t, J = 5.9 Hz, 1H), 7.74 – 7.60 (m, 2H), 
7.55 – 7.26 (m, 8H), 7.21 (d, J = 7.9 Hz, 2H), 5.53 (s, 2H), 5.04 (d, J = 14.0 jkHz, 1H), 4.18 (d, 
J = 5.9 Hz, 2H), 3.63 (d, J = 14.0 Hz, 1H), 2.61 (t, J = 8.0 Hz, 1H), 2.29 (t, J = 7.6 Hz, 1H), 2.09 
(ddd, J = 15.4, 7.7, 5.7 Hz, 1H), 1.80 (ddd, J = 16.4, 7.6, 5.7 Hz, 1H). 
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13C NMR (101 MHz, DMSO-d6) δ = 171.6, 171.5, 152.0, 148.9, 140.4, 134.4, 132.9, 130.1, 
129.4, 129.3, 128.6, 128.5, 128.2, 127.8, 127.7, 127.3, 125.6, 123.0, 121.9, 114.7, 108.6, 68.5, 
55.4, 42.2, 30.8, 30.1. 
HRMS (ESI): m/z calc. for C32H26O3N7- (M-H)-: 556.2103, found: 556.2109. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.75 min. 
UV/Vis (LCMS): max = 290 nm.  
 (E)-1-(8-(4-((4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-4-oxobutanoyl)-
8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)-N-(2-oxo-2-((4-((4-(N-(1-
phenethylpiperidin-4-yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-amide (5.14) 
O
O
HN
N
N
N
N
Ph
O
H
N
O
N
12 N N
N
O
O
HN
O
N
N
N
HN
NH2
 
5.28 (4.1 mg, 3.9 μmol, 1.0 equiv.) and BG-DBCO (2.2 mg, 3.9 μmol, 1.0 equiv.) were 
combined in dry DMSO (300 μL) and stirred o.n. at r.t. The product was directly loaded on a 
C8 column (Waters Sep-Pak C8 2g) and eluted with a gradient of 1 mM HCl and MeCN (100/0 
 60/40 = 1 mM HCl/MeCN).  Product containing fractions were identified by LCMS, combined 
and freeze dried to obtain the desired product as an orange solid (3.2 mg, 1.9 μmol, 49%). 
 tert-Butyl (3-(methyl(phenyl)amino)propyl)carbamate (5.3) 
N NHBoc
 
N-Methylaniline (338 μL, 3.13 mmol, 1.1 equiv.), N-Boc-3-aminopropanal (400 mg, 2.85 mmol, 
1.0 equiv.), AcOH (171 μL, 3 mmol, 1.1 equiv.) and sodium triacetoxyborohydride (1.02 g, 
4.8 mmol, 1.7 equiv.) were added successively to dry DCE (15 mL). The reaction mixture was 
stirred for 4.5 h at r.t., before it was extracted with DCM against NaHCO3 (aq. sat.). The organic 
layer was washed against NaHCO3 (aq. sat.), brine and dried over MgSO4 before purification 
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by flash column chromatography (98/2 = DCM/MeOH), the product was obtained as colorless 
and viscous oil (298 mg, 1.13mmol) in 40% yield. 
TLC (DCM/MeOH = 98/2) = 0.40. (stain: ninhydrin) 
1H NMR (400 MHz, CDCl3) δ = 7.20 – 7.11 (m, 2H), 6.64 (d, J = 7.7 Hz, 3H), 4.51 (s, 1H), 3.33 
– 3.24 (m, 2H), 3.10 (q, J = 6.7 Hz, 2H), 2.85 (s, 3H), 1.70 (p, J = 7.1 Hz, 2H), 1.37 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ = 156.0, 149.2, 129.2, 116.4, 112.4, 79.3, 50.3, 38.6, 38.5, 28.4, 
27.3. 
HRMS (ESI): m/z calc. for C15H25N2O2+ (M+H)+: 265.1911, found: 265.1916. 
 tert-Butyl (E)-(3-(methyl(4-((4-nitrophenyl)diazenyl)phenyl)amino)propyl)carbamate 
(5.4) 
N NHBoc
N
N
O2N  
5.3 (250 mg, 0.95 mmol, 1.0 equiv.) was dissolved in a mixture of MeCN (10 mL) and 1 M aq. 
NaOAc (10 mL) and cooled to 0 °C. 4-Nitrobenzenediazonium tetrafluoroborate was dissolved 
in MeCN (10 mL), cooled to 0 °C and added dropwise to the solution containing 5.3. After 
complete addition, the reaction mixture was allowed to warm to r.t. and stirred for 20 min. The 
reaction mixture was portioned between DCM (100 mL) and water (30 mL). The organic layer 
was washed with water (2 x 50 mL), brine (50 mL) and dried over MgSO4. After purification by 
flash column chromatography (DCM -> 98/2 = DCM/MeOH), the product was obtained as a 
red solid (358 mg, 0.87 mmol) in 92% yield. 
TLC (DCM/MeOH = 98/2) = 0.33.  
1H NMR (400 MHz, CDCl3) δ = 8.36 – 8.28 (m, 2H), 7.97 – 7.86 (m, 4H), 6.79 – 6.70 (m, 2H), 
4.59 (s, 1H), 3.56 – 3.47 (m, 2H), 3.21 (q, J = 6.8 Hz, 2H), 3.10 (s, 3H), 1.86 (p, J = 7.0 Hz, 
2H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ = 156.8, 156.0, 152.3, 147.4, 143.7, 126.2, 124.7, 122.6, 111.4, 
77.2, 50.1, 38.8, 38.3, 28.4, 27.8. 
HRMS (ESI): m/z calc. for C21H26N5O4- (M-H)-: 412.1990, found: 412.1990. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 9.19 min. 
UV/Vis (LCMS): max = 550 nm (broad).  
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 tert-Butyl (E)-(3-((4-((4-aminophenyl)diazenyl)phenyl)(methyl)amino)propyl) 
carbamate (5.5) 
N NHBoc
N
N
H2N  
5.4 (350 mg, 0.85 mmol) was dissolved in a mixture of THF (20 mL) and water (20 mL). Sodium 
sulfide (65%, monohydrate, 407 mg, 3.39 mmol, 4.0 equiv.) was added and the reaction 
mixture heated to 80 °C for 1 h before it was allowed to cool to r.t. addition of water (75 mL) 
and NaHCO3 (aq. sat., 75 mL). The aqueous phase was extracted with DCM (3x 75 mL). The 
combined organic layers were washed with NaHCO3 (aq. sat., 100 mL), water (100 mL), brine 
(100 mL) and dried over MgSO4. Purification by flash column chromatography (97.5/2.5 = 
DCM/MeOH) gave the product as an orange solid (280 mg, 0.73 mmol) in 86% yield.  
1H NMR (400 MHz, CDCl3) δ = 7.78 – 7.63 (m, 4H), 6.67 (dd, J = 8.8, 2.1 Hz, 4H), 4.52 (s, 1H), 
3.92 (s, 2H), 3.39 (t, J = 7.3 Hz, 2H), 3.12 (q, J = 6.7 Hz, 2H), 2.96 (s, 3H), 1.75 (p, J = 7.1 Hz, 
2H), 1.39 (d, J = 3.3 Hz, 9H). 
13C NMR (101 MHz, CDCl3) δ = 156.0, 150.5, 150.4, 148.2, 124.4, 124.2, 114.8, 111.6, 79.4, 
50.1, 38.7, 38.4, 28.4, 27.6.  
HRMS (ESI): m/z calc. for C21H28O2N5- (M-H)-: 382.2248 found: 382.2251. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 7.73 min. 
UV/Vis (LCMS): max1 = 442 nm.  
 tert-Butyl (E)-(3-(methyl(4-((4-((1-phenethylpiperidin-4-
yl)amino)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.6) 
N NHBoc
N
N
N
H
N
Ph
 
5.5 (96 mg, 0.25 mmol, 1.0 equiv.), N-phenethylpiperidin-4-one (51 mg, 0.25 mmol, 
1.0 equiv.), sodium triacetoxyborohydride (85 mg, 0.40 mmol, 1.6 equiv.) and AcOH (14 μL, 
0.25 mmol, 1.0 equiv.) were combined in dry DCE (5 mL). The reaction mixture was stirred at 
r.t. for 17 h before it was directly purified by flash column chromatography (DCM/MeOH = 98/2 
-> 96/4 -> 94/6). The product was obtained as a red solid (111 mg, 0.19 mmol) in 78% yield. 
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1H NMR (400 MHz, CDCl3) δ = 7.77 (ddd, J = 14.5, 9.2, 2.3 Hz, 4H), 7.35 – 7.26 (m, 2H), 7.22 
(dt, J = 6.7, 2.5 Hz, 4H), 6.77 – 6.69 (m, 2H), 6.68 – 6.60 (m, 2H), 4.58 (s, 1H), 4.06 – 3.53 (m, 
1H), 3.54 – 3.39 (m, 4H), 3.24 – 3.10 (m, 4H), 3.03 (s, 3H), 2.97 – 2.88 (m, 2H), 2.79 (t, J = 
8.2 Hz, 2H), 2.51 – 2.33 (m, 6H), 2.26 – 2.12 (m, 4H), 1.86 – 1.65 (m, 2H), 1.46 (s, 9H).  
13C NMR (101 MHz, CDCl3) δ = 156.1, 150.5, 148.4, 145.3, 144.0, 128.9, 128.7, 126.6, 124.5, 
124.4, 112.9, 111.7, 77.4, 59.9, 52.0, 50.2, 38.8, 38.6, 32.8, 31.4, 28.6, 27.7. 
HRMS (ESI): m/z calc. for C34H47O2N6+ (M+H)+: 571.3755 found: 571.3767. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.70 min. 
UV/Vis (LCMS): max = 458 nm.  
Note: Acetic acid impurity. 
 tert-Butyl (E)-(3-(methyl(4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.7) 
N NHBoc
N
N
N
N
Ph
O
 
5.6 (55 mg, 96 μmol, 1.0 equiv.) was dissolved in dry DCM (1.8 mL) before addition of dry 
DIPEA (42 μL, 240 μmol, 2.5 equiv.) and propionyl chloride (10 μL, 115 μmol, 1.2 equiv.). The 
reaction mixture was stirred overnight at r.t. before it was directly purified by flash column 
chromatography (DCM/MeOH = 96/4) to yield the product as a red solid (56 mg, 89 μmol) in 
93% yield. 
TLC (DCM/MeOH = 96/4) = 0.16. (Product and starting material run copular on TLC, PAA 
stain: SM yellow, product pink.) 
1H NMR (400 MHz, CDCl3) δ = 7.85 – 7.64 (m, 4H), 7.17 (dd, J = 8.9, 2.7 Hz, 2H), 7.14 – 7.05 
(m, 5H), 6.72 – 6.61 (m, 2H), 4.69 – 4.58 (m, 1H), 4.56 (s, 1H), 3.42 (t, J = 7.3 Hz, 2H), 3.13 
(q, J = 6.7 Hz, 2H), 3.00 (s, 3H), 2.94 (dd, J = 8.7, 3.6 Hz, 2H), 2.71 – 2.53 (m, 2H), 2.52 – 
2.42 (m, 2H), 2.16 – 2.02 (m, 2H), 1.92 (q, J = 7.4 Hz, 2H), 1.76 (q, J = 6.7 Hz, 4H), 1.50 – 
1.41 (m, 2H), 1.39 (s, 9H), 0.96 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ = 173.5, 156.0, 152.8, 151.5, 143.5, 140.2, 139.5, 131.0, 128.7, 
128.4, 126.0, 125.4, 122.9, 111.4, 79.5, 60.5, 53.1, 52.4, 50.0, 38.7, 38.4, 33.8, 30.6, 28.7, 
28.4, 27.7, 9.7. 
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HRMS (ESI): m/z calc. for C37H49O3N6- (M-H)-: 625.3872, found: 625.3872 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.67 min. 
UV/Vis (LCMS): max = 455 nm. 
 (E)-N-(4-((4-((3-Aminopropyl)(methyl)amino)phenyl)diazenyl)phenyl)-N-(1-
phenethylpiperidin-4-yl)propionamide dihydrochloride (5.8) 
N NH2
N
N
N
N
Ph
O
x 2 HCl
 
A saturated solution of HCl in dry EtOAc was freshly prepared by bubbling HCl through EtOAc 
for 1 h while stirring. 5.7 (56 mg, 89 μmol) was dissolved in dry EtOAc (2 mL) and HCl sat. in 
dry EtOAc (6 mL) was added. After stirring at r.t. for 3.5 h, the resulting precipitate was filtered 
off, washed with EtOAc and dissolved and transferred with dry MeOH. After solvent removal 
in vacuo, the product was dried under HV and obtained as a violet solid (54 mg, 90 μmol) in 
quantitative yield. 
1H NMR (400 MHz, D2O) δ = 7.87 – 7.79 (m, 2H), 7.77 – 7.69 (m, 2H), 7.34 – 7.23 (m, 4H), 
7.23 – 7.15 (m, 3H), 7.07 – 7.01 (m, 2H), 4.68 – 4.59 (m, 1H), 3.66 (t, J = 7.5 Hz, 2H), 3.54 (d, 
J = 12.6 Hz, 2H), 3.27 – 3.20 (m, 2H), 3.19 (s, 3H), 3.13 – 3.02 (m, 2H), 2.98 (t, J = 8.1 Hz, 
2H), 2.91 (dd, J = 10.0, 6.5 Hz, 2H), 2.12 – 1.81 (m, 6H), 1.57 (tt, J = 14.0, 7.2 Hz, 2H), 0.85 
(t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, D2O) δ = 177.2, 154.5, 147.3, 140.9, 137.4, 136.1, 131.0, 129.0, 128.7, 
128.7, 127.3, 121.0, 115.2, 57.5, 52.0, 50.5, 50.2, 39.6, 36.9, 29.8, 28.3, 27.4, 24.5, 8.9. 
HRMS (ESI): m/z calc. for C32H43ON6+ (M+H)+: 527.3493, found: 527.3498. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.65 min (broad 
peak). 
UV/Vis (LCMS): max = 430 nm. 
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 (E)-1-Azido-N-(3-(methyl(4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-amide (5.29) 
N
H
N
N
N
N
N
Ph
O
O
O
N3
12
 
5.8 (8.1 mg, 14 μmol, 1.0 equiv.), N3-PEG12-NHS-ester (10 mg, 14 μmol, 1.0 equiv.) and dry 
DIPEA (14 μL, 81 μmol, 6.0 equiv.) were combined in dry DMF (1.25 mL). After stirring for 18 h 
at r.t. full conversion was confirmed by LCMS. The product was directly loaded on a C18 
column (Waters Sep-Pak C18 2g) and eluted with a gradient of MeCN and 1 mM HCl (100/0 
 60/40 = 1 mM HCl/MeCN). Product containing fractions were identified by LCMS, combined 
and freeze-dried to obtain the product as a red solid (14.5 mg, 12.6 μmol) in 93% yield. 
HRMS (ESI): m/z calc. for C59H94O14N9+ (M+H)+: 1152.6915, found: 1152.6924; m/z calc. for 
C59H92O14N9- (M-H)-: 1150.6769, found: 1150.6766. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.86 min. 
UV/Vis (LCMS): max = 448 nm. 
 (E)-1-(8-(4-((4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-4-
oxobutanoyl)-8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)-N-(3-((4-((4-
(N-(1-phenethylpiperidin-4-yl)propionamido)phenyl)diazenyl)phenyl)-λ2-
azaneyl)propyl)-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-
amide (5.15) 
N
H
N
N
N
N
N
Ph
O
O
O
N
12 N
N
N
O
NH
O
O
N
N
N
HN
H2N  
5.29 (5.8 mg, 5.0 μmol, 1.0 equiv.) and BG-DBCO (2.8 mg, 5.00 μmol, 1.0 equiv.) were 
combined in DMSO (400 μL) and stirred at r.t. for 3h before LCMS indicated near quantitative 
conversion. The reaction mixture was purified on a 2 g SepPak C18 SPE cartridge (gradient 
0%-40% CH3CN/H2O + 0.1% FA). Product containing fractions were identified by LCMS, 
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combined and freeze-dried to obtain the desired product as orange solid (6.2 mg, 3.6 μmol, 
73%). 
1H NMR (400 MHz, DMSO-d6) δ 7.89 – 7.76 (m, 5H), 7.60 – 7.46 (m, 2H), 7.41 – 7.30 (m, 5H), 
7.33 – 7.14 (m, 7H), 6.88 – 6.79 (m, 2H), 5.84 (dd, J = 21.0, 16.8 Hz, 1H), 5.53 (s, 1H), 4.74 
(d, J = 16.6 Hz, 2H), 4.53 – 4.42 (m, 2H), 4.32 (s, 1H), 4.18 (t, J = 4.9 Hz, 2H), 4.15 – 3.95 (m, 
1H), 3.59 (dt, J = 17.0, 8.5 Hz, 5H), 3.50 – 3.33 (m, 47H), 3.20 (dd, J = 11.8, 5.3 Hz, 2H), 3.19 
– 3.06 (m, 4H), 3.03 (s, 3H), 2.99 – 2.91 (m, 3H), 2.33 (s, 2H), 2.09 – 1.98 (m, 2H), 1.97 (s, 
2H), 1.92 (d, J = 7.8 Hz, 2H), 1.66 (dp, J = 19.8, 7.2 Hz, 4H), 0.91 (t, J = 7.4 Hz, 3H). 
HRMS (ESI): m/z calc. for C91H122O17N162+ (M+2H)2+: 855.4581, found: 855.4594. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.95 min. 
UV/Vis (LCMS): max1 = 280 nm, max2 = 450 nm. 
 (E)-1-(4-(3-((4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-
oxopropyl)-1H-1,2,3-triazol-1-yl)-N-(3-((4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)-λ2-azaneyl)propyl)-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-amide (5.19) 
N
H
N
N
N
N
N
Ph
O
O
O
N
12 N
N
NHO
N
N
N
HN
H2N
O
 
5.29 (8.7 mg, 7.6 μmol, 1.0 equiv.) and N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)pent-
4-ynamide (BG-alkyne, 2.7 mg, 7.6 μmol, 1.0 equiv.) were combined in DMSO (0.5 mL) and 
100 μl of a 10 mM solution of each CuSO4 and TBTA were added. Then sodium ascorbate was 
added in one portion (24 mg, 0.12 μmol, 16.0 equiv.). The reaction mixture was stirred at r.t. 
for several days before it was purified on a 2 g SepPak C18 SPE cartridge (gradient 0%-40% 
CH3CN/H2O + 0.1% FA). Product containing fractions were identified by LCMS, combined and 
freeze-dried to obtain the desired product as orange solid (3.5 mg, 2.3 μmol, 31%). 
HRMS (ESI): m/z calc. for C77H113O16N152+ (M+2H)2+: 751.9239 (100%), 752.4256 (83%); 
found: 751.9255, 752.4272. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.30 min. 
UV/Vis (LCMS): max1 = 224 nm, max2 = 450 nm. 
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 (E)-N1-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)-N43-(3-(methyl(4-((4-(N-
(1-phenethylpiperidin-4-yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)-
4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaoxatritetracontanediamide (5.17) 
N
H
N
N
N
N
N
Ph
O
O
O
O
12
NH
ON
N
NHN
H2N
O
 
5.8 (41 mg, 68 μmol, 1.0 equiv.), PEG13-diacid (polypure #37137-1295, 95 mg, 0.14 mmol, 2.0 
equiv.), DIPEA (71 μL; 0.41 mmol, 6.0 equiv.) and HBTU (31 mg, 82 μmol, 1.2 equiv.) were 
combined in DMF (1 mL). The reaction mixture was stirred for 3.5 h before it was concentrated 
and purified by flash column chromatography (DCM/MeOH/AcOH/water = 90/10/1/1). The 
product was obtained as a dark red solid (75 mg, 63 μmol, 92%). 
The product from the first amide coupling (22 mg, 18 μmol, 1.0 equiv.), 6-((4-
(aminomethyl)benzyl)oxy)-9H-purin-2-amine (BG-NH2, 6.0 mg, 22 μmol, 1.2 equiv.), DIPEA 
(13 μL, 74 μmol, 4 equiv.) and HBTU (8.4 mg, 22 μmol, 1.2 equiv.) were combined in DMF (0.7 
mL) and stirred at r.t. for several hours. Then, the reaction mixture was concentrated and the 
residue purified by flash column chromatography (DCM/MeOH = 90/10  80/20). The product 
was obtained as a red solid (13 mg, 8.8 μmol, 48%). 
HRMS (ESI): m/z calc. for C75H112O17N122+ (M+2H)2+: 726.4129, found: 726.4147. 
tR (LCMS; MeCN/H2O/formic acid = 40/60/0.1  100/0/0.1 over 10 min) = 2.1 min. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 9.8 min. 
UV/Vis (LCMS): max = 455 nm. 
 (E)-1,4-Dioxo-1-((4-((4-(N-(1-phenethylpiperidin-4-yl)propionamido)phenyl) 
diazenyl)phenyl)amino)-7,10,13,16,19,22,25,28,31,34,37,40,43-tridecaoxa-3-
azahexatetracontan-46-oic acid (5.30) 
H
N
N
N
N
N
Ph
O
O
N
H
O
O OH
O
13
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5.13 (17 mg, 30 μmol, 1.0 equiv.), PEG13-diacid (polypure #37137-1295, 20 mg, 30 μmol, 1.0 
equiv.), HBTU (12mg, 31 μmol, 1.05 equiv.) and DIPEA (21 μL, 0.12 mmol, 4.0 equiv.) were 
combined in DMF (0.3 mL) and stirred at r.t. overnight. The reaction mixture was directly 
purified by flash column chromatography (DCM/MeOH/AcOH = 90/10/1  70/30/1). The 
desired product was obtained as an orange solid (11 mg, 9 μmol, 30%). 
HRMS (ESI): m/z calc. for C60H91O18N6- (M-H)-: 1183.6395, found: 1183.6361. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 3.20 min. 
UV/Vis (LCMS): max = 354 nm. 
 (E)-N1-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-N43-(2-oxo-2-((4-((4-(N-
(1-phenethylpiperidin-4-yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)-
4,7,10,13,16,19,22,25,28,31,34,37,40-tridecaoxatritetracontanediamide (5.16) 
H
N
N
N
N
N
Ph
O
O
N
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O
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O
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5.30 (11 mg, 9 μmol, 1.0 equiv.), 6-((4-(aminomethyl)benzyl)oxy)-9H-purin-2-amine (BG-NH2, 
3.2 mg, 12 μmol, 1.3 equiv.), DIPEA (6.5 μL, 38 μmol, 4.0 equiv.) and HBTU (4.3 mg, 11 μmol, 
1.2 equiv.) were combined in DMF (0.5 mL) and stirred at r.t. overnight. The reaction mixture 
was purified on a 2 g SepPak C18 SPE cartridge (0%-30% = CH3CN/H2O + 0.1% FA). Product 
containing fractions were identified by LCMS, combined and freeze-dried to obtain the desired 
product as orange solid (2.0 mg, 1.4 μmol, 16%). 
HRMS (ESI): m/z calc. for C73H106O18N122+ (M+2H)+: 719.3869, found: 719.3886. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 2.99 min. 
UV/Vis (LCMS): max = 355 nm. 
5. Tethered Photopharmacology of the μ-Opioid Receptor 
146 
 (E)-N1-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)-N10-(2-oxo-2-((4-((4-(N-
(1-phenethylpiperidin-4-yl)propionamido)phenyl)diazenyl)phenyl) 
amino)ethyl)decanediamide (5.18) 
H
N
N
N O
N
O
N
Ph
N
H
O H
N
O
O
N
N N
H
N
H2N
 
5.13 (13 mg, 25 μmol, 1.0 equiv.) was combined with dodecandioic acid (23 mg, 98 μmol, 4.0 
equiv.), HBTU (10 mg, 27 μmol, 1.1 equiv.) and DIPEA (43 μL, 250 μmol, 10 equiv.) in DMF 
(0.5 mL). The reaction mixture was allowed to stir at r.t. for o.n., before it was acidified and 
purified on a 2 g SepPak C18 SPE cartridge (0%-40% CH3CN in H2O + 0.1% FA). Product 
containing fractions were identified by LCMS and combined. The product was obtained as an 
orange solid after removal of all volatiles (9.7 mg, 13 μmol, 55%) 
The product from the previous step (9.7 mg, 13 μmol, 1.0 equiv.) was combined with BG-NH2 
(4.0 mg, 15 μmol, 1.1 equiv.), HBTU (5.1 mg, 13 μmol, 1.0 equiv.) and DIPEA (4.7 μL, 27 μmol, 
2.0 equiv.) in DMF (0.5 Ml): The reaction mixture was stirred at r.t. o.n., before it was acidified 
and purified on a 2 g SepPak C18 SPE cartridge (0%-35% CH3CN in H2O + 0.1% FA). Product 
containing fractions were identified by LCMS and combined. The product was obtained as an 
orange solid after removal of all volatiles (4.2 mg, 4.3 μmol, 32%) 
HRMS (ESI): m/z calc. for C55H69O5N12+ (M+H)+: 977.5508, found: 977.5528; m/z calc. for 
C55H67O5N12- (M-H)-: 975.5363, found: 975.5362. 
 2,2'-(Ethane-1,2-diyl)bis(4-bromoaniline) (5.21) 
Br
Br
NH2
NH2
 
2,2'-(Ethane-1,2-diyl)dianiline (1.27 g, 6.0 mmol, 1.00 equiv.) was dissolved in 60 mL MeCN. 
The flask was wrapped in aluminum foil to keep the reaction in the dark and NBS (99%, 2.12 
g, 11.8 mmol, 2.0 equiv.) was added in portions under vigorous stirring over a time of 6 h. After 
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the addition was complete, the reaction mixture was stirred at r.t. overnight. Conversion was 
checked by LCMS and the reaction was judged to be complete. The solution was extracted 
with 50 mL EtOAc against 50 mL of 0.5 M aq. NaOH (4x). The combined aq. layers were back 
extracted with additional 4 x 50 mL EtOAc. All collected organic layers were combined, dried 
over MgSO4 and concentrated in vacuo. The crude product was adsorbed on silica and loaded 
on a 4 x 20 cm column of silica. The product was eluted with 20-100% EtOAc/hexanes, yielding 
5.21 as a yellow-brown solid (2.00 g, 5.4 mmol, 90%). 
1H NMR (400 MHz, DMSO-d6) δ = 7.17 (d, J = 2.3 Hz, 2H), 7.03 (dd, J = 8.5, 2.3 Hz, 2H), 6.57 
(d, J = 8.5 Hz, 2H), 5.12 (s, 4H), 2.61 (s, 4H).  
13C NMR (101 MHz, DMSO-d6) δ = 145.7, 131.1, 129.0, 127.4, 116.3, 106.8, 29.1.  
HRMS (ESI): calc. for C14H15Br2N2+ (M+H)+: 368.9597, found: 368.9598.  
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.55 min. 
UV/Vis (LCMS): λmax1 = 205 nm, λmax2 = 245 nm, λmax3 = 300 nm. 
 (Z)-2,9-Dibromo-11,12-dihydrodibenzo[c,g][1,2]diazocine (5.22) 
N N
BrBr
 
5.21 (371 mg, 1.0 mmol, 1.0 equiv.) was dissolved in 15 mL DCM. mCPBA (77%, 449 mg, 
2.0 mmol, 2.00 equiv.) was added in portions over a time of 1 h under continuous stirring. The 
flask was capped and wrapped in aluminum foil to keep the reaction in the dark and the mixture 
was stirred at r.t. over the weekend. 10 mL of an aq. Na2S2O3 solution (10%) were added, 
followed by extraction with 10 mL DCM and washing with 10 mL of 1 M aq. NaOH (4x). The 
aq. layers were back extracted with additional 5 x 10 mL DCM and the combined organic layers 
were washed against 40 mL water (2x) and 40 mL brine (2x). After drying over MgSO4, all 
volatiles were removed in vacuo. The crude product was adsorbed on silica and loaded on a 
4 x 15 cm column of silica, followed by elution with DCM/hexanes (1/5). The product containing 
impure fractions were combined, concentrated to dryness and purified by flash column 
chromatography another two times under the same conditions but on longer and wider 
2 x 20 cm columns of silica. 5.22 was obtained as a yellow, slightly reddish-orange solid (110 
mg, 0.30 mmol, 30%). 
1H NMR (400 MHz, CDCl3) δ = 7.28 (dd, J = 8.4, 2.0 Hz, 2H), 7.16 (d, J = 2.0 Hz, 2H), 6.72 (d, 
J = 8.3 Hz, 2H), 2.99 – 2.88 (m, 2H), 2.79 – 2.65 (m, 2H).  
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13C NMR (101 MHz, CDCl3) δ = 154.1, 132.6, 130.2, 130.0, 120.8, 120.7, 31.4.  
HRMS (EI): calc. for C14H10Br2N2 (M+): 363.9211, found: 363.9202.  
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.40 min. 
UV/Vis (LCMS): λmax1 = 202 nm, λmax2 = 240 nm, λmax3 = 299 nm, λmax4 = 328 nm. 
 (Z)-di-tert-Butyl-(11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)-dicarbamate 
(5.23) 
N N
H
N
H
N
O
OO
O
 
Pd2dba3 (8.1 mg, 8.8 μmol, 0.05 equiv.) and XantPhos (98%, 10.0 mg, 17 μmol, 0.10 equiv.) 
were transferred into a Schlenk tube. The flask was evacuated and backfilled with argon for 
three times, before 2.0 mL anhydrous 1,4-dioxane were added. The reaction mixture was 
stirred for 30 min. tert-Butyl-carbamate (104 mg, 0.89 mmol, 5.1 equiv.), 5.22 (64.4 mg, 
0.176 mmol, 1.0 equiv.) and Cs2CO3 (347.0 mg, 1.07 mmol, 6.0 equiv.) were added 
sequentially together with an additional 2.0 mL of anhydrous 1,4-dioxane. The reaction was 
capped and stirred overnight at 100 °C. After the reaction mixture was allowed to cool to r.t., it 
was extracted with 20 mL EtOAc against 25 mL water (3x). The aq. layers were back extracted 
with additional 3 x 20 mL EtOAc and the combined organic layers were washed with 30 mL 
aq. sat NaHCO3 (2x), 20 mL brine (3x), dried over MgSO4 and concentrated to dryness. The 
resulting crude material was absorbed on silica and loaded on a 2.5 x 25 cm column of silica, 
followed by elution with DCM/hexanes (2 / 1  1 / 0). TLC (ninhydrin staining) showed that the 
product containing fractions also contained residuals of tert-butyl-carbamate. Therefore, 
product containing fractions were combined, concentrated in vacuo and repurified by flash 
column chromatography (5 / 1 = DCM/EtOAc) on a 2.5 x 20 cm column of silica, whereby the 
sample was loaded adsorbed on silica. 5.23 was obtained as a lemon-yellow solid (45.0 mg, 
103 μmol, 59%). 
1H NMR (400 MHz, CDCl3) δ = 7.14 (s, 2H), 7.03 (dd, J = 8.5, 2.2 Hz, 2H), 6.79 (d, J = 8.4 Hz, 
2H), 6.40 (s, 2H), 2.82 (s, 4H), 1.48 (s, 18H).  
13C NMR (101 MHz, CDCl3) δ = 152.6, 150.8, 137.3, 129.3, 120.4, 118.9, 116.6, 80.9, 32.0, 
28.4.  
HRMS (ESI): calc. for C24H31N4O4+ (M+H)+: 439.2340, found: 439.2345.   
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.90 min. 
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UV/Vis (LCMS): λmax1 = 204 nm, λmax2 = 238 nm, λmax3 = 259 nm, λmax4 = 302 nm, λmax5 = 
333 nm, λmax6 = 408 nm. 
 (Z)-11,12-Dihydrodibenzo[c,g][1,2]diazocine-2,9-diamine (5.24) 
N N
NH2H2N
 
5.23 (44.8 mg, 0.102 mmol) was transferred into a 4 mL dram vial with EtOAc, the solvent was 
removed in vacuo and the sample was dried under HV. 0.75 mL neat TFA were added slowly 
accompanied by red discoloration. The vial was capped and the reaction was monitored by 
LCMS. After 35 min of stirring, the reaction was judged to be complete, and the TFA was 
removed by a stream of nitrogen. The residue was extracted with EtOAc (approx. 1 L) against 
0.2 M aq. NaOH and the aq. layers were back extracted with additional EtOAc. The combined 
organic layers were washed against aq. sat NaHCO3 (2x) and brine, dried over MgSO4 and 
concentrated to dryness. Purification of the crude, red solid by flash column chromatography 
(5% MeOH/DCM) on a 2 x 7 cm column of silica yielded 5.24 as a yellow-brownish solid 
(19.8 mg, 0.0831 mmol, 81%). 
1H NMR (400 MHz, CDCl3) δ = 6.71 (d, J = 8.3 Hz, 2H), 6.45 (dd, J = 8.4, 2.4 Hz, 2H), 6.30 (d, 
J = 2.4 Hz, 2H), 3.59 (s, 4H), 2.72 (s, 4H).  
13C NMR (101 MHz, CDCl3) δ = 147.8, 145.2, 129.8, 121.6, 115.3, 113.3, 32.1. 
HRMS (ESI): calc. for C14H15N4+ (M+H)+: 239.1291, found: 239.1292.  
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 7 min) = 1.51 min. 
UV/Vis (LCMS): λmax1 = 245 nm, λmax2 = 338 nm, λmax3 = 415 nm. 
 tert-Butyl (Z)-(2-((9-amino-11,12-dihydrodibenzo[c,g][1,2]diazocin-2-yl)amino)-
2-oxoethyl)carbamate (5.25) 
N N
H
NH2N
O
NHBoc
 
5.24 (19.8 mg, 0.0831 mmol, 1.00 eq.), N-Boc-Gly-OH (7.6 mg, 0.043 mmol, 0.52 eq.) and 
HBTU (31.7 mg, 0.0836 mmol, 1.01 eq.) were transferred into a 4 mL dram vial. The vial was 
capped, evacuated and backfilled with nitrogen for three times, before 1.0 mL dry THF were 
added. After DIPEA (29.0 μL, 0.166 mmol, 2.00 eq.) was added dropwise, the reaction mixture 
was stirred for 1 h at 0 °C overnight at room temperature. All volatiles were removed in vacuo 
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and the residue was extracted with EtOAc against 1 mM aq. HCl, additional brine was added 
for breaking the emulsion. The collected aq. layers were back extracted with EtOAc and the 
combined organic layers were washed with water and brine. After drying over MgSO4 and 
concentration in vacuo, the crude material was adsorbed on silica and loaded on a 2 x 14 cm 
column of silica. Elution with EtOAc/DCM (1 / 1) yielded the desired product as a yellow, slightly 
brown-greenish solid (14.9 mg, 0.0377 mmol, 45%). 
1H-NMR (400 MHz, CDCl3) δ = 8.14 (bs, 1H), 7.33 (s, 1H), 7.18 (d, J = 8.5 Hz, 1H), 6.79 (d, J 
= 8.5 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 6.44 (dd, J = 8.3, 2.4 Hz, 1H), 6.26 (d, J = 2.3 Hz, 1H), 
5.22 (bs, 1H), 3.86 (d, J = 6.0 Hz, 2H), 3.60 (bs, 2H), 2.80 – 2.65 (m, 4H), 1.46 (s, 10H).  
13C-NMR (101 MHz, CDCl3) δ = 167.9, 152.1, 147.7, 145.6, 136.2, 129.8, 129.3, 121.5, 120.4, 
120.2, 118.0, 115.5, 115.3, 113.4, 81.0, 38.8, 32.2, 31.8, 28.4. 
HRMS (ESI): calc. for C21H26N5O3+ (M+H)+: 396.2030, found: 396.2034.  
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 7 min) = 3.44 min. 
UV/Vis (LCMS): λmax1 = 243 nm, λmax2 = 308 nm, λmax3 = 341 nm, λmax4 = 414 nm. 
 tert-Butyl (Z)-(2-oxo-2-((9-((1-phenethylpiperidin-4-yl)amino)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-2-yl)amino)ethyl)carbamate (5.26) 
N N
H
N
H
N
O
NHBoc
N
Ph  
N-Phenethylpiperidin-4-one (98%, 39.4 mg, 0.190 mmol, 0.99 eq.), NaBH(OAc)3 (97%, 
58.7 mg, 0.269 mmol, 1.41 eq.) and AcOH (10.8 μL, 0.189 mmol, 0.99 eq.) were added to 5.25 
(75.4 mg, 0.191 mmol, 1.00 eq.) in a 4 mL dram vial. The vial was capped, the mixture was 
put under a nitrogen atmosphere and 1.8 mL of anhydrous DCE was added. After the dark 
solution was stirred overnight at r.t., the sample was transferred into a 100 mL round-bottom 
flask with DCM and the grass-green solution was adsorbed on celite, loaded on a 3.5 x 14 cm 
column of silica and eluted with 2-8% MeOH/DCM. The desired product was obtained as a 
yellow, slightly greenish solid (64.7 mg, 0.111 mmol, 58%). 
1H NMR (400 MHz, MeOD-d4) δ = 7.37 (s, 1H), 7.33 – 7.27 (m, 3H), 7.27 – 7.19 (m, 4H), 6.75 
(d, J = 8.5 Hz, 1H), 6.70 (d, J = 8.5 Hz, 1H), 6.47 (dd, J = 8.6, 1.8 Hz, 1H), 6.31 (d, J = 2.3 Hz, 
1H), 3.80 (s, 2H), 3.40 (tt, J = 9.7, 3.9 Hz, 1H), 3.27 (d, J = 12.7 Hz, 2H), 2.97 – 2.90 (m, 4H), 
2.83 – 2.64 (m, 6H), 2.07 (dd, J = 11.5, 2.7 Hz, 2H), 1.58 (q, J = 10.2 Hz, 2H), 1.45 (s, 9H). 
Note:  The signals of two Nsek-H are not observed due solvent proton exchange.  
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13C NMR (101 MHz, MeOD-d4) δ = 170.5, 158.6, 152.7, 148.4, 147.2, 139.4, 138.4, 131.3, 
130.8, 129.8, 129.7, 127.7, 122.7, 121.7, 120.9, 119.3, 114.1, 112.2, 80.7, 60.2, 52.9, 45.0, 
33.2, 32.8, 32.7, 31.4, 28.7. 
Note:  One signal is covered by the MeOD-d4 solvent peaks (see HSQC spectrum). 
HRMS (ESI): calc. for C34H43N6O3+ (M+H)+: 583.3391, found: 583.3378.  
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 3.48 min. 
UV/Vis (LCMS): λmax1 = 205 nm, λmax2 = 246 nm, λmax3 = 309 nm, λmax4 = 357 nm, λmax5 = 
431 nm. 
 tert-Butyl (Z)-(2-oxo-2-((9-(N-(1-phenethylpiperidin-4-yl)propion-amido)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-2-yl)amino)ethyl)carbamate (5.31) 
N N
H
NN
O
NHBoc
N
Ph
O
 
5.26 (44.6 mg, 0.0765 mmol, 1.00 eq.) was dissolved in 3.8 mL anhydrous DCM in a 4 mL 
dram vial under a nitrogen atmosphere. DIPEA (22.8 μL, 0.131 mmol, 1.71 eq.) and a 1.144 M 
solution of propionylchloride in DCM (73.6 μL, 0.0842 mmol, 1.10 eq.) were added 
accompanied by a color change of the solution from green to red. The vial was capped, flushed 
with nitrogen and wrapped in aluminum foil to keep the reaction mixture in the dark. After 
stirring at r.t. for 1.5 h, reaction progress was checked by LCMS, judged to be incomplete and 
more of the propionylchloride solution was added (20.1 μL, 0.0230 mmol, 0.30 eq.). After 
another 2 h of stirring, the reaction was checked again by LCMS, judged to be incomplete and 
more of the propionylchloride solution (10.0 μL, 0.0114 mmol, 0.15 eq.) was added. The 
reaction mixture was stirred at r.t. overnight, followed by loading the sample directly on a 
2.5 x 22 cm column of silica for purification (DCM/MeOH/AcOH/H2O = 90 / 10 / 0.6 / 0.6). The 
desired product was obtained as a yellowish solid (22.4 mg, 0.0351 mmol, 46%). 
Note:  Complex 1H NMR and 13C NMR spectra, possibly because of multiple configurations 
with high energy barriers. The product was clean according to LCMS. 
HRMS (ESI): calc. for C37H47N6O4+ (M+H)+: 639.3653, found: 639.3662.   
tR (LC-MS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 3.40 min. 
UV/Vis (LC-MS): λmax1 = 236 nm, λmax2 = 258 nm, λmax3 = 318 nm, λmax4 = 404 nm. 
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 (Z)-N-(9-(2-Aminoacetamido)-11,12-dihydrodibenzo[c,g][1,2]diazocin-2-yl)-N-
(1-phenethylpiperidin-4-yl)propionamide (5.27) 
N N
H
NN
O
NH2
N
Ph
O
 
5.31 (21.7 mg, 0.0340 mmol) was loaded into a scintillation vial and dissolved in 3 mL 
anhydrous EtOAc under an argon atmosphere. 3 mL of EtOAc saturated with HCl gas were 
added slowly. The reaction mixture was stirred for 1.5 h at r.t. accompanied by a discoloration 
from green to red and by formation of a red precipitate. The reaction progress was checked by 
LCMS, judged to be incomplete and 0.5 mL HCl saturated EtOAc were added. After another 
45 min of stirring, LCMS was measured again and 0.5 mL HCl saturated EtOAc were added 
once again. The reaction mixture was stirred for a further 1 h, followed by filtration through a 
cotton wool filled pipette and washing of the remaining red precipitate with anhydrous EtOAc. 
The precipitate was eluted with anhydrous MeOH and concentrated to dryness, yielding a 
brown-yellow solid. The solid was resolved in 0.5 mL of DMSO and filtered through a syringe 
filter (PTFE 0.4) which was rinsed with additional 0.5 mL DMSO. Purification by HPLC yielded 
the desired product as a pale yellow solid (9.9 mg, 0.018 mmol, 53%). 
1H NMR (400 MHz, DMSO-d6) δ 10.45 (s, 1H), 9.25 (s, 1H), 8.11 (s, 3H), 7.45 – 7.19 (m, 7H), 
7.10 – 6.81 (m, 4H), 4.65 (s, 1H), 3.72 (d, J = 5.8 Hz, 2H), 3.56 (s, 2H), 3.27 – 3.06 (m, 4H), 
2.99 – 2.70 (m, 6H), 1.94 (d, J = 13.5 Hz, 2H), 1.71 – 1.47 (m, 2H), 1.28 (d, J = 30.9 Hz, 2H), 
0.67 (s, 3H). 
Note: Doubly charged FA salt. 
HRMS (ESI): calc. for C32H39N6O2+ [M+H]+: 539.3129, found: 539.3136.   
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 2.20 min. 
UV/Vis (LCMS): λmax1 = 236 nm, λmax2 = 257 nm, λmax3 = 317 nm, λmax4 = 404 nm. 
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5.4.2 Crystallographic Data 
Crystallographic data of 2,2'-(ethane-1,2-diyl)bis(4-bromoaniline). 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
μ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
C14H14Br2N2 
370.09 
0.040 × 0.030 × 0.020 
100.(2) 
MoKα 
'Bruker D8 Venture TXS' 
monoclinic 
'P 1 21/c 1' 
7.2468(2) 
13.6374(5) 
6.8983(3) 
90 
100.3960(10) 
90 
670.55(4) 
2 
1.833 
6.028 
Multi-Scan 
0.6749–0.7457 
6842 
0.0392 
0.0358 
3.354–27.482 
1323 
0.0071, 0.5928 
H(C) constr, H(N) refall 
1533 
90 
0 
0.0232 
0.0532 
1.098 
0.001 
0.461 
−0.331 
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Crystallographic data of (Z)-2,9-dibromo-11,12-dihydrodibenzo[c,g][1,2]diazocine. 
net formula 
Mr/g mol−1 
crystal size/mm 
T/K 
radiation 
diffractometer 
crystal system 
space group 
a/Å 
b/Å 
c/Å 
α/° 
β/° 
γ/° 
V/Å3 
Z 
calc. density/g cm−3 
μ/mm−1 
absorption correction 
transmission factor range 
refls. measured 
Rint 
mean σ(I)/I 
θ range 
observed refls. 
x, y (weighting scheme) 
hydrogen refinement 
refls in refinement 
parameters 
restraints 
R(Fobs) 
Rw(F2) 
S 
shift/errormax 
max electron density/e Å−3 
min electron density/e Å−3 
C14H10Br2N2 
366.06 
0.030 × 0.030 × 0.010 
100.(2) 
MoKα 
'Bruker D8 Venture TXS' 
monoclinic 
'P 1 21/c 1' 
9.0147(3) 
17.1183(5) 
8.4172(3) 
90 
99.8120(10) 
90 
1279.91(7) 
4 
1.900 
6.315 
Multi-Scan 
0.6740–0.7457 
14150 
0.0356 
0.0318 
3.285–28.280 
2700 
0.0145, 0.9564 
constr 
3161 
163 
0 
0.0235 
0.0488 
1.034 
0.003 
0.483 
−0.430 
 
 
5.4.3 Plasmids, Cell Culture and Electrophysiology 
HEK-GIRK cells were a kind gift of Sonja Kleinlogel.110 They were maintained in standard 
growth medium DMEM/10% FCS with 400 ug/mL G418. Transfections were performed as 
described previously.115  
The SNAP-MOR plasmids featured: 
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SNAP_MOR (from Helen Farrants): mGluR5 non-cleavable signal peptide, HA-epitope, SNAP-
tag, PGLG linker, MOR (rat) 
SNAP_(MOR) (J.T. Williams): HA cleavable signal peptide, FLAG-tag without enterokinase 
cleavage site, SNAP-tag 8x GS linker, MOR (mouse) 
Patch solutions contained the following: 
 
 
 
Supporting Figure 6. HEK-GIRK transfected with SNAP_MOR (from JT Williams). DAMGO 
was washed in as positive control to confirm functional expression of SNAP_MOR.  
F4', internal Kgluconate, dilute 80:10:10 for end conc
substrate c (mM) M (g/mol) V (L) n (mmol) m (mg) final conc
KCl 15 74.55 0.05 0.75 55.9125 12
Kgluconat 175 234.25 0.05 8.75 2049.688 140
HEPES 12.5 238.31 0.05 0.625 148.9438 10
NaCl 5 58.44 0.05 0.25 14.61 4
MgATP 40 507.18 0.01 0.4 202.872 4
Na2GTP 4 567.14 0.01 0.04 22.6856 0.4
osmo 330.8
HEK_GIRK external solution, high K+, pH 7.4 with KOH, updated Josh recipe
10x 
substrate c (mM) M (g/mol) V (L) n (mmol) m (mg) (m in g)
NaCl 25 58.44 0.5 12.5 730.5 7.305
KCl 120 74.55 0.5 60 4473 44.73
MgCl2 1 203.3 0.5 0.5 101.65 1.0165
CaCl2 2 147.02 0.5 1 147.02 1.4702
HEPES 10 238.31 0.5 5 1191.55 11.9155
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Supporting Figure 7. HEK-GIRK transfected with SNAP_MOR (from JT Williams). 5.27 (50 μM) 
was washed in. Then, photoswitching was attempted using various wavelengths. The 
switching was performed at a holding potential of -80 mV to maximize GIRK currents. No light-
dependent current was observed. DAMGO was washed in at the end of the experiment as a 
positive control to confirm expression of SNAP_MOR and GIRK. The spikes are capacitive 
currents from changing the membrane potential, or from interference from the perfusion system 
and are not edited out.  
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Supporting Figure 8. Electrophysiological characterization of AM-II. 
 
Supporting Figure 9. Electrophysiological characterization of AzoDAMGO. 
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5.4.4 Spectral Data 
 tert-Butyl (E)-(2-((4-((4-aminophenyl)diazenyl)phenyl)amino)-2-oxoethyl)carbamate 
(3.6) 
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 tert-Butyl (E)-(2-oxo-2-((4-((4-((1-phenethylpiperidin-4-yl)amino)phenyl)diazenyl) 
phenyl)amino)ethyl)carbamate (5.11) 
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 tert-Butyl (E)-(2-oxo-2-((4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)amino)ethyl)carbamate (5.12) 
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  (E)-N-(4-((4-(2-Aminoacetamido)phenyl)diazenyl)phenyl)-N-(1-phenethylpiperidin-4-
yl)propionamide (5.13) 
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 BG-DBCO  
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 tert-Butyl (3-(methyl(phenyl)amino)propyl)carbamate (5.3) 
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 tert-Butyl (E)-(3-(methyl(4-((4-nitrophenyl)diazenyl)phenyl)amino)propyl)carbamate 
(5.4) 
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 tert-Butyl (E)-(3-((4-((4-aminophenyl)diazenyl)phenyl)(methyl)amino) 
propyl)carbamate (5.5) 
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 tert-butyl (E)-(3-(methyl(4-((4-((1-phenethylpiperidin-4-
yl)amino)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.6) 
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 tert-butyl (E)-(3-(methyl(4-((4-(N-(1-phenethylpiperidin-4-
yl)propionamido)phenyl)diazenyl)phenyl)amino)propyl)carbamate (5.7) 
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 (E)-N-(4-((4-((3-aminopropyl)(methyl)amino)phenyl)diazenyl)phenyl)-N-(1-
phenethylpiperidin-4-yl)propionamide dihydrochloride (5.8) 
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 (E)-1-(8-(4-((4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-4-
oxobutanoyl)-8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)-N-(3-((4-((4-
(N-(1-phenethylpiperidin-4-yl)propionamido)phenyl)diazenyl)phenyl)-λ2-
azaneyl)propyl)-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-
amide (5.15) 
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 2,2'-(Ethane-1,2-diyl)bis(4-bromoaniline) (5.21) 
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 (Z)-2,9-dibromo-11,12-dihydrodibenzo[c,g][1,2]diazocine (5.22) 
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 (Z)-di-tert-butyl-(11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diyl)-dicarbamate 
(5.23) 
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 (Z)-11,12-dihydrodibenzo[c,g][1,2]diazocine-2,9-diamine (5.24) 
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 tert-butyl (Z)-(2-((9-amino-11,12-dihydrodibenzo[c,g][1,2]diazocin-2-yl)amino)-
2-oxoethyl)carbamate (5.25) 
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  tert-Butyl (Z)-(2-oxo-2-((9-((1-phenethylpiperidin-4-yl)amino)-11,12-
dihydrodibenzo[c,g][1,2]diazocin-2-yl)amino)ethyl)carbamate (5.26) 
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 (Z)-N-(9-(2-aminoacetamido)-11,12-dihydrodibenzo[c,g][1,2]diazocin-2-yl)-N-
(1-phenethylpiperidin-4-yl)propionamide (5.27) 
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6 Optical Control of the Smoothened Receptor 
6.1 Introduction 
Most of our understanding of how genes drive development of animals stems from pioneering 
work on embryogenesis of the fruit fly Drosophila melanogaster,116 which was awarded with 
the 1995 Nobel prize in physiology or medicine to Lewis, Nüsslein-Volhard and Wieschaus. 
Multiple genes were isolated that are vital for Drosophila embryogenesis by mutational studies 
and were named after the according mutants phenotype. Mutants with impaired genes involved 
in the Hedgehog (Hh) signaling pathway loose polarity of the evolving body segments, leading 
to flies with pronounced ‘spikes’ sticking out of their unusually short body. Today, the molecular 
components of the Hh signaling axis are identified: in absence of ligand, the Patched receptor 
is inhibiting Smoothened, keeping it sequestered in vesicles. After activation of Patched by the 
ligand Hh and the cell-surface co-receptor iHog, Smoothened is recruited to the plasma 
membrane where it activates Gli transcription regulator proteins, which in turn trigger 
transcription of target genes (Figure 35b).63 
 
Figure 35. Design of azovismodegib and the Hedgehog signaling pathway. a) 
Azologization strategy for azovismodegib. b) In its inactive state, smoothened remains 
sequestered in vesicles by inhibition through patched. Upon stimulation of Patched by iHog 
and Hedgehog, the inhibition of Smoothened is relieved. Smoothened is then recruited to the 
plasma membrane where it recruits a protein complex and activates Gli transcription regulator 
proteins, ultimately leading to transcription of hedgehog target genes. 
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In humans, mutations of Smoothened are involved in basal cell carcinomas (BCC), which is 
the most prevalent form of cancer in Caucasians.117 Vismodegib (Erivedge®) is a small-
molecule antagonist which was approved for treatment of BCC in 2012, representing the first 
therapeutic targeting the Hh signaling pathway.118 Vismodegib contains a N-aryl benzamide, 
which is a structural motif suitable for replacement by a diazene according to Trauner’s 
azologization strategy (Figure 35a).78 Furthermore, the conformation adopted by Vismodegib 
in the crystal structure with Smoothened suggest that azovismodegib should be 
accommodated in the proteins binding pocket in its trans- but not in its cis-configuration.119  
6.2 Results and Discussion 
Commencing with a Sandmeyer reaction of aniline 6.1 with potassium iodide afforded the 
iodoarene 6.2 in 44% yield. The 2-pyridyl ring was attached by Negishi-coupling with 2-
bromopyridine yielded the biaryl 6.3 in 27%; this reaction proved to be a bottleneck due to the 
complex and tedious preparation of the reactive zinc species and unreliable yields. Attempts 
to improve the synthesis by using 2-pyridyl boronic acids or boronic esters to access the 
desired product via Suzuki coupling were tried and proved unsuccessful. 6.3 was reduced to 
aniline 6.4 in 90% yield by a suspension of powdered iron in a mixture of ethanol and acetic 
acid. Finally, azovismodegib (6.6) was obtained after Baeyer-Mills reaction of 6.4 with 1-
(methylsulfonyl)-4-nitrosobenzene in 76% yield. 
 
Figure 36. Synthesis and UV/Vis-spectroscopy of azovismodegib. a) Synthesis of 
azovismodegib in a four-step reaction sequence. b) UV/Vis spectra of azovismodegib (50 μM 
in DMSO) were recorded in the dark and under illumination with the optimal wavelength for 
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switching to the cis-isomer (360 nm) or to the trans-isomer (420 nm). c) Switching was 
performed in aqueous buffer (50 μM in 95/5 = PBS/DMSO) while recording the absorbance at 
the absorbance maximum (330 nm) over time (τ(360 nm) = 3.73 ± 0.04 min, τ(420 nm) = 1.33 
± 0.002 min).  
Azovismodegib was then tested for photoswitching. After performing a wavelength screen, 
optimal wavelengths for cis/trans-photoswitching were determined to be 360 nm and 420 nm. 
UV/Vis Spectra of azovismodegib were then recorded in the dark and under illumination with 
UV (360 nm) or blue light (420 nm). In addition, the kinetics of photoswitching were measured 
by recording the extinction at the absorbance maximum while switching UV/blue light (Figure 
36c).  
6.3 Summary and Outlook 
Azovismodegib was accessed through a brief synthesis in four steps from commercially 
available starting materials. Azovismodegib behaves like a ‘normal’ photoswitch with bistable 
photostationary states and photoswitching kinetics as expected for azobenzenes with this 
electronic substitution pattern. At this stage, azovismodegib is being investigated for biological 
activity by collaborators (Ben Myers, University of Utah). To this end, NIH/3t3 cells stably 
expressing a Gli-responsive Firefly luciferase reporter (Shh LIGHT2 cells)120 will be stimulated 
by the smoothened agonist SAG in presence of azovismodegib and under illumination with 
light of the appropriate wavelengths. 
If azovismodegib exhibits light-dependent antagonism on Smoothened, it will be employed in 
more complex settings. The Hedgehog signaling axis gives the developing animal polarity, e.g. 
determines where the anterior (head) or posterior (tail) ends are. There are still many gaps in 
our knowledge of how this polarity arises.121,122 With azovismodegib, we want to provide a tool 
which allows for a spatially defined inhibition of Smoothened. This could break down details of 
Hedgehog signaling in dependence of location in the developing animal, e.g. in Drosophila.  
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6.4 Supporting Information 
6.4.1 Synthesis 
 1-Chloro-2-iodo-4-nitrobenzene (6.2) 
I
Cl
NO2
 
2-Chloro-5-nitroaniline (2.00 g, 11.6 mmol, 1.0 equiv.) was dissolved in 2.4 M H2SO4 (32 mL) 
and a NaNO2 (0.91 g, 13.2 mmol, 1.1 equiv.) solution in water (130 mL) was added dropwise 
over 10 min at 0 °C. The resulting mixture was stirred for 1h at 0 °C. Then a KI (3.47 g, 
13.2 mmol, 1.8 equiv.) solution in water (14 mL) was added dropwise over 15 min via dropping 
funnel at 0 °C. After addition of KI was completed, the mixture was stirred for another 2 h at 
room temperature. The reaction mixture was extracted with EtOAc against sodium thiosulfat 
solution three times. The combined organic layers were washed against brine, dried over 
MgSO4 and concentrated in vacuo. The crude product was recrystallized from a mixture of hot 
iPrOH (13.6 mL) and hexane (5.40 mL). 6.2 was obtained as a tan powder in a yield of 44% 
(1.44 g, 5.10 mmol).  
1H-NMR (400 MHz, CDCl3) δ = 8.71 (d, J = 2.5 Hz, 1H), 8.17 (dd, J = 8.8, 2.6 Hz, 1H), 7.61 (d, 
J = 8.8 Hz, 1H).  
13C-NMR (101 MHz, CDCl3) δ = 145.9, 135.1, 129.6, 124.2, 100.0, 98.0.  
HRMS (EI): m/z calc. for C6H3ClINO2 (M+)+: 282.8897, found: 282.8892. 
Note: Too unpolar for LCMS, no elution.  
 (2-Chloro-5-nitrophenyl)pyridine (6.3) 
Cl
NO2
N  
2-Bromopyridine (0.43 mL, 4.52 mmol, 1.6 equiv.) was added to dry THF (5 mL) under argon 
and iPrMgCl (3.47 mL, 4.52 mmol, 1.6 equiv.) was added dropwise at 0 °C. The mixture was 
stirred for 1 h at room temperature. ZnCl2 (717 mg, 4.52 mmol, 1.6 equiv.) was sublimated 
under argon, and dissolved in dry THF (5 mL). The pyridine-2-ylmagnesium bromide solution 
was added to the ZnCl2 solution and heated to 50 °C for 1h (solution 1). 1-Chloro-2-iodo-4-
nitrobenzene (800 mg, 2.82 mmol, 1 equiv., 6.2), bis(triphenylphosphine)palladium-(II)-
chloride (60 mg, 0.09 mmol, 0.03 equiv.) and triphenylphosphine (89 mg, 0.34 mmol, 
0.12 equiv.) were dissolved in dry DMF (5 mL) under argon (Solution 2). Solution 1 was added 
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to solution 2 and heated to 60 °C overnight. The reaction mixture was cooled to room 
temperature, ethyl acetate (100 mL) and 2 M NaOH (100 mL) were added and stirred for 
10 min. The solution was filtered over celite and washed with ethyl acetate (50 mL). The 
organic layer was separated and the aq. layer was extracted with ethyl acetate (3 x 100 mL). 
The combined organic layers were washed with brine and dried over MgSO4. The product was 
purified by flash column chromatography (EtOAc/hexanes = 1/9). 2-(2-chloro-5-
nitrophenyl)pyridine (6.3) was obtained as brown crystals in a yield of 26% (173 mg, 
0.73 mmol).  
TLC (EtOAc/hexanes = 1/9) = 0.35. 
1H-NMR (400 MHz, CDCl3) δ (d, J = 4.9 Hz, 1H), 8.45 (d, J = 2.8 Hz, 1H), 8.14 (dd, J = 8.8, 
2.8 Hz, 1H), 7.78 (td, J = 7.7, 1.7 Hz, 1H), 7.67 – 7.57 (m, 2H), 7.33 (dd, J = 7.6, 4.9 Hz, 1H).  
HRMS (ESI): m/z calc. for C11H8ClN2O2+ (M+H)+: 235.0269, found: 235.0269. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 7.53 min. 
UV/Vis (LCMS): λmax1 = 194 nm, λmax2 = 226 nm, λmax3 = 270 nm.  
 4-Chloro-3-(pyridine-2-yl)aniline (6.4) 
Cl
NH2
N  
2-(2-Chloro-5-nitrophenyl)pyridine (20 mg, 0.09 mmol, 1.0 equiv., 6.3) was dissolved in a 
mixture of acetic acid/ethanol (1:1, 2 ml) and added to a suspension of Fe (29mg, 0.51 mmol, 
6.0 equiv.) in acetic acid/ethanol (1:2; 5 ml). The reaction mixture was heated to 60 °C for 4 h. 
The reaction mixture was allowed to cool to room temperature, filtered over celite, washed with 
EtOAc (30 mL) and concentrated in vacuo. The oily residue was diluted in EtOAc (30 mL), 
washed with aq. sat. NaHCO3 (2 x 25 mL), water (2 x 10 mL), brine (30 mL) and dried over 
MgSO4. The crude material was purified by flash column chromatography (EtOAc/ hexanes = 
4:1). The desired product was obtained in a yield of 90%.  
TLC (EtOAc/hexanes = 4/1) = 0.30. 
1H-NMR (400 MHz, CDCl3) δ = 8.69 (d, J = 4.5 Hz, 1H), 7.82 – 7.70 (m, 1H), 7.66 (d, J = 7.9 
Hz, 1H), 7.29 – 7.26 (m, 1H), 7.22 (d, J = 8.5 Hz, 1H), 6.92 (d, J = 2.8 Hz, 1H), 6.65 (dd, J = 
8.5, 2.8 Hz, 1H), 3.74 (s, 2H).  
13C-NMR (101 MHz, CDCl3) δ = 155.9, 148.4, 144.4, 138.5, 134.8, 129.7, 123.9, 121.3, 120.0, 
116.7, 115.4.  
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HRMS (ESI): m/z calc. for C11H10ClN2+ (M+H)+: 205.0527, found: 205.0527.  
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 3.20 min.  
UV/Vis (LCMS): λmax1 = 193 nm, λmax2 = 231 nm, λmax3 = 270 nm.  
Notes: Impurities (silicon grease). 
 (E)-2-(2-Chloro-5-((4-(methylsulfonyl)phenyl)diazenyl)phenyl)pyridine (6.6) 
Cl
N
N
N
S
O O  
4-(Methylsulfonyl)aniline (1.71 g, 10 mmol, 1.0 equiv.) was dissolved in a biphasic mixture of 
DCM/water (40 mL / 40 mL) and Oxone® (6.18 g, 10 mmol) was added in one portion. The 
reaction mixture was stirred vigorously at r.t. for 2h while it changed color to a bright green. 
The reaction mixture was diluted with water (100 mL) and DCM (100 mL). The organic layer 
was separated and dried over MgSO4 and concentrated in vacuo. A part of the solid residue 
(48 mg, 0.26 mmol, 1.5 equiv.) was used without further purification for the next step. It was 
added to 6.4 (56 mg, 0.17 mmol, 1.0 equiv.) dissolved in AcOH (5 mL). The reaction mixture 
was stirred at r.t. for 2 days before it was neutralized with aq. sat. NaHCO3 and extracted with 
DCM. The organic layer was washed with aq. sat. NaHCO3, water and brine for it was dried 
over MgSO4 and concentrated in vacuo. The crude material was purified by flash column 
chromatography (DCM / EtOAc = 9 / 1). The desired product was obtained as an orange solid 
in 76% yield (47 mg, 0.13 mmol). 
TLC (DCM/EtOAc = 1/9) = 0.52. 
1H NMR (400 MHz, CDCl3) δ 8.77 (d, J = 4.8 Hz, 1H), 8.23 (d, J = 2.4 Hz, 1H), 8.07 (q, J = 8.5 
Hz, 4H), 7.95 (dd, J = 8.6, 2.4 Hz, 1H), 7.82 (td, J = 7.7, 1.7 Hz, 1H), 7.72 (d, J = 7.9 Hz, 1H), 
7.66 (d, J = 8.5 Hz, 1H), 7.35 (dd, J = 7.5, 4.9 Hz, 1H), 3.11 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 155.9, 155.1, 150.8, 149.8, 142.0, 140.2, 136.1, 136.0, 131.2, 
128.6, 126.4, 124.8, 124.1, 123.6, 122.9, 44.6. 
HRMS (ESI): m/z calc. C18H15ClN3O2S+ (M+H)+:  372.0568, found: 372.0564. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 5.20. 
UV/Vis (LCMS): max1 = 235nm, max2 = 226 nm, max3 = 273 nm, max4 = 327 nm. 
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6.4.2 Spectral Data 
 1-Chloro-2-iodo-4-nitrobenzene (6.2) 
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 2-(2-Chloro-5-nitrophenyl)pyridine (6.3) 
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 4-Chloro-3-(pyridine-2-yl)aniline (6.4) 
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 (E)-2-(2-Chloro-5-((4-(methylsulfonyl)phenyl)diazenyl)phenyl)pyridine (6.6) 
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7 Photoswitchable Receptor Tyrosine Kinase Inhibitors 
7.1 Introduction 
Cancer is one of the biggest challenges of modern societies. According to Siegel et al., more 
than one out of three individuals in the US are likely to suffer from some kind of invasive cancer 
in their lifetime, and one out of four deaths in the US is caused by cancer.123 Cancer is a 
disease characterized by uncontrolled cell growth and the spread of its cells from the site of 
origin to other sites in the body.124 The development of human cancer is multistep process 
during which several distinct biological capabilities are acquired: the so-called hallmarks of 
cancer. Defined by Hanahan and Weinberg in 2000, these hallmarks are characteristics shared 
by most types of cancer, namely the capability for autonomous growth signaling, evasion of 
growth inhibitory signals, evasion of apoptotic cell death, unlimited replicative potential, 
angiogenesis (the formation of new blood vessels), and invasion and metastasis.125 Since 
RTKs are key regulators of cell growth and cell cycle growth, mutation or overexpression of 
RTKs is often closely linked to mutagenesis. As such, they constitute an important drug target 
for cancer therapy.126 Tyrosine-kinase-inhibitors (TKIs) can be ATP-mimetics, which block the 
ATP binding pocket of the tyrosine kinase (TK) domain, therefore blocking auto-
phosphorylation and locking the RTK in its auto-inhibited state. 
A major drawback of TKIs is the lack of selectivity against tumor cells versus normal cells. As 
a result, chemotherapy with TKIs is often accompanied by harsh side-effects.127 Indeed, 
photoswitchable drugs could offer a solution to this issue. After systemic application of a 
photoswitchable drug by oral uptake, it is distributed in the body in its dark adapted, inactive 
form. Tumor cells would then be locally exposed to light, and the photoswitchable drug is turned 
ON, resulting in RTK inhibition. Only the illuminated area, i.e. the tumor, is exposed to the 
active drug, limiting off-target effects in healthy, surrounding tissue. This approach combines 
the precision of radiotherapy with the efficacy of chemotherapy and represents another leap 
that photopharmacology could take. 
Axitinib is a small molecule TKI which showed promising results in the treatment of various 
cancer types. For instance, it reduced growth of breast cancer in xenograft tumor mouse 
models and is now approved by the FDA for treatment of metastatic renal cell carcinoma 
(mRCC). It is acting through inhibition of the vascular endothelial growth factor receptors 
(VEGFR) 1-3, mast/stem cell growth factor receptor (c-KIT) and the platelet-derived growth 
factor receptor (PDGFR).128,129 Axitinib is a TKI that blocks the ATP-binding site. For productive 
binding of ATP, the juxtamembrane domain (JM) has to switch from JMin to JMout, which allows 
the DFG motif to switch from its inactive ‘out’ to its active ‘in’ position. Crystal structures of 
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Axitinib in complex with non-phosporylated VEGFR2 revealed that it acts by blocking the JMin 
to JMout transition, thereby locking the RTK in its auto-inhibited state.130 Key interactions of 
Axitinib with the protein are two hydrogen bonds and one hydrophobic stabilization between 
the amide head group with D146, E885 and I804 of VEGFR2. The pyrazol nitrogen atoms are 
acting as hydrogen bond donor or acceptor to the protein backbone.130 The vinylpyridine moiety 
is mostly responsible for solubility an the metabolic and pharmacokinetic properties of the drug. 
We envisioned that Axintinib could be turned into a photoswitchable drug by replacing the 
diarylethene moiety by a diazene. 
7.2 Results and Discussion 
First, unsuccessful syntheses were aimed at installing phenylhydrazine via cross-coupling with 
the 3-halogenated benzopyrazol. Subsequent oxidation of the resulting diarylhydrazine would 
then give the diazene. Therefore, the synthetic route was changed (Scheme 13). 7.1 was 
condensed with hydrazine to yield the aminoindazole 7.2. 7.2 was reacted with 2-
nitrosopyridine131 in a Baeyer-Mills reaction to give access to the heterocyclic azobenzene 7.3. 
The final AzoAxitinib 7.5 was then obtained by Pd-catalyzed cross-coupling with aryl thiol 7.4. 
To fine tune photophysical properties, one diazene with a benzene instead of the pyridine and 
one red-shifted variant were synthesized. Since cross couplings with 7.10, the benzene-
analogue of 7.3 were unsuccessful. Therefore, the reaction sequence was reversed. To this 
end, 7.1 was cross-coupled to aryl thiol 7.4 to yield diaryl sulfide 7.6. Subsequent condensation 
with hydrazine gave access to 7.7. Sandmeyer reaction with potassium iodide yielded the 3-
iodo derivative that was used for X-ray crystallography after recrystallization from ethanol. 7.7 
was then reacted in a Baeyer-Mills reaction with nitrosobenzene to yield 7.8: The red-shifted 
variant 7.9 was obtained by diazotation of 7.7 and subsequent capture with N,N-diethylaniline.  
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Scheme 13. Synthesis of AzoAxitinibs 7.5, 7.8 and 7.9. 
The three photoswitches were then evaluated for their photophysical properties by UV/Vis 
spectroscopy (Figure 36). The photoswitches behave very similar, they all relax back to the 
trans-isomer in the dark. The optimal wavelengths for the cis-isomerization of pyridine-diazene 
7.5 is 380 nm, which is the same wavelength for the phenyl-diazene 7.8. Both absorption 
spectra are very similar, but the kinetics of photoisomerization are different. 7.5 cis-isomerizes 
significantly slower with τ = 0.22 min compared to τ = 0.14 min for 7.8. Both 7.5 and 7.8 
isomerize back to the trans under thermal conditions in the dark. The trans-isomerization of 
7.5 is slower with τ = 0.17 min compared to τ = 0.10 min for 7.8. For azobenzenes, substitution 
in para-position of the diazene bond with an electron-donating substituent leads to red-shifting 
of the cis-isomerization while the thermal backrelaxation to trans is proceeding faster. This is 
not the0 case for the heterocyclic azobenzenes shown here, when an electron-donating 
diethylamine is installed on 7.8, the rate of back-relaxation is slowed. The red-shifted 7.9 is 
isomerized to cis with blue light (460 nm), with τ = 0.13 min. The backrelaxation to trans in the 
dark is significantly slower with τ = 0.42 min. 
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Figure 37. UV/Vis spectroscopy of AzoAxitinibs 7.5, 7.9 and 7.8. 7.5 τ(cis) = 0.22 ± 0.001 
min, τ(trans) = 0.17 ± 0.0002 min; 7.9 τ(cis) = 0.13 ± 0.007 min, τ(trans) = 0.42 ± 0.001 min; 
7.8 τ(cis) = 0.14 ± 0.003 min, τ(trans) = 0.10 ± 0.0001 min;  
7.5 was evaluated for light-dependent bioactivity by a proliferation (MTT) assay of HUVEC cells 
(human umbilical vein endothelial cells, kind gift from Carlo Mümmler, CPC Munich). In the 
dark, 7.5 inhibited cell proliferation with IC50 = 67 nM (Figure 38). Under illumination with violet 
light (390 nm), the IC50 decreased to 183 nM. 
 
Figure 38. MTT assay with HUVEC cells and 7.5. Red: 390 nm, black: dark; error bars 
represent standard deviation. Survival was normalized to vehicle control (0.2% DMSO). IC50 
(dark) = 67 nM; IC50 (390 m) = 183 nM. 
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7.3 Summary and Outlook 
Here, photoswitchable variants of the cancer drug Axitinib were described. Proliferation assays 
indicated that the installation of the photoswitch was not deleterious to the inhibitory effects of 
Axitinib. Nevertheless, the difference in IC50 between trans- and cis- isomers of AzoAxitinib 7.5 
is only ~3-fold. As an assay method, proliferation is a downstream phenotypic effect, is 
dependent on many effects, and can lead to misleading conclusions. To better understand the 
structure-activity relationship (SAR) of cis- and trans-AzoAxitinib, more simple assays, such 
as phosphorylation assays should be employed. This could help with the design of improved 
photoswitches with higher differences in affinity upon photoisomerization. 
AzoAxitinib 7.5 represents a new type of photoswitch that features an indazole and a pyridine. 
Indeed, the photophysical properties of AzoAxitinib 7.5 are very similar to common 
azobenzene derivatives. This class of indazole-containing diazene was only recently described 
by Travieso-Puente et al.132 Their synthesis featured a nucleophilic aromatic substitution to 
form the 5-membered indazole-ring and is limited to strongly electron-deficient aromatics. On 
the other hand, the azo-bonds of AzoAxitinibs 7.5, 7.8 and 7.9 were installed via well-known 
Baeyer-Mills reactions or diazotation from the 3-amino indazole derivative. As such, these 
syntheses represent a facile method of constructing this type of photoswitch and expands the 
‘azologable’ space even further. 
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7.4 Supporting Information 
HUVEC cells were grown in EGM2 medium (Lonza), supplemented with 10% FCS. Cells were 
seeded on two 96w plates (5000 cells/well). After 1d, cells were starved in 1%FCS/EBM2 
(Lonza). Compound was applied, one plate was kept in the dark and one was illuminated by 
an LED array at 390 nm (72 LEDs) from above, 50 ms light pulses every 3 seconds. 1-2h after 
compound application, 2 μL/well VEGF (human, 1 ng/μL) was added. The next day, 10 μL 
MTT/PBS was added, and the MTT assay was performed as previously described.62 
7.4.1 Synthesis 
 2-Mercapto-N-methylbenzamide (7.4) 
O NH
SH
 
Synthesis of 7.4 was carried out according to a literature procedure.133 Briefly, methylamine-
hydrochloride (2.00 g, 29.6 mmol, 2.0 equiv.) was suspended in dry DCM (20 mL) and cooled 
to 0°C. AlMe3 (2 M in toluene, 14.9 mL, 29.8 mmol, 2.0 equiv.) was added dropwise. The 
mixture was stirred at 0 °C for 15 min and allowed to warm to r.t. After the gas evolution ceased, 
N-methyl thiosalicylate (2.50 g, 14.86 mmol, 1.0 equiv.) was added dropwise. The yellow 
reaction mixture was heated to reflux for 6 h. Then, the reaction mixture was cooled to r.t. and 
carefully quenched with 1 M aq. HCl. The organic layer was separated and the aqueous layer 
was extracted with DCM (3 x 30 mL). The combined organic layers were dried over MgSO4 
and evaporated. Recrystallization from diethyl ether yielded 7.4 as colorless crystals (1.33 g, 
7.92 mmol, 53%) suitable for single-crystal X-ray diffraction.  
1H NMR (400 MHz, CDCl3) δ = 7.39 (dd, J = 7.7, 1.4 Hz, 1H), 7.28 (dd, J = 7.9, 1.3 Hz, 1H), 
7.21 (td, J = 7.6, 1.5 Hz, 1H), 7.08 (td, J = 7.5, 1.3 Hz, 1H), 6.33 (s, 1H), 4.73 (s, 1H), 2.94 (d, 
J = 4.9 Hz, 3H).  
13C NMR (101 MHz, CDCl3) δ = 169.5, 132.9, 132.9, 130.8, 130.5, 128.0, 125.0, 26.7.  
HRMS (ESI): m/z calc. for C8H8NOS- [M-H]-: 166.0332, found: 166.0321.  
tR (LCMS, MeCN/H2O/formic acid = 90/10/0.1  10/90/0.1 over 7 min) = 2.57 min.  
UV/Vis (LCMS): λmax = 297 nm. 
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 6-Bromo-1H-indazol-3-amine (7.2) 
Br
HN N
NH2
 
7.2 was synthesized according to a patent procedure.134 Briefly, 4-bromo-2-fluoro-benzonitrile 
(1.00 g, 5.00 mmol, 1.0 equiv.) and hydrazine hydrate (785 μL, 25.0 mmol, 5 equiv.) were 
dissolved in n-butanol (6 mL) and refluxed for 2 h. The reaction mixture was allowed to cool to 
r.t., before filtering over a glass frit. The colorless crystals were washed with EtOAc and dried 
in vacuo to yield the desired product (1.01 g, 4.76 mmol, 95%). 
1H NMR (400 MHz, DMSO-d6) d = 7.64 (d, J = 8.5 Hz, 1H), 7.47–7.38 (m, 1H), 7.02 (d, J = 8.7 
Hz, 1H), 5.48 (s, 2H). 
13C NMR (101 MHz, DMSO-d6) d = 149.8, 142.5, 122.6, 120.8, 120.3, 113.5, 112.3.  
HRMS (ESI): m/z calc. for C7H7BrN3+ [M+H]+: 211.9818, found: 211.9817. 
 (E)-6-Bromo-3-(pyridin-2-yldiazenyl)-1H-indazole (7.3) 
Br
HN N
N
N
N  
The 2-nitrosopyridine was prepared according to a published procedure.131 The crude nitroso 
compound was extracted and washed according to the original procedure. The product 
containing DCM layers were then carefully concentrated to dryness with the rotary evaporator 
at ~25 °C and the crude tan material was stored at -20°C until further use.  
7.2 (500 mg, 2.4 mmol, 1.0 equiv.) was suspended in AcOH (15 mL) and crude 2-
nitrosopyridine (384 mg, th. 3.6 mmol, th. 1.5 equiv.) was added in one portion. The reaction 
mixture immediately turned green. The reaction mixture was allowed to stir for a few hours 
before it was extracted with DCM against sat. aq. NaHCO3 (3x). The combined organic layers 
were concentrated in vacuo before purification by flash column chromatography (dry load on 
silica) to yield the product as a yellow solid (98 mg, 0.32 mmol, 13%). 
1H NMR (400 MHz, DMSO-d6) δ 14.27 (s, 1H), 8.80 – 8.72 (m, 1H), 8.25 (d, J = 8.6 Hz, 1H), 
8.08 (td, J = 7.7, 1.7 Hz, 1H), 7.94 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.60 (dd, J = 7.3, 4.8 Hz, 
1H), 7.56 (dd, J = 8.6, 1.5 Hz, 1H). 
13C NMR (101 MHz, DMSO) δ 163.7, 155.6, 150.0, 142.7, 139.4, 128.2, 126.3, 124.7, 121.4, 
114.1, 113.4, 112.3. 
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HRMS (ESI): m/z calc. for C12H9BrN5+ [M+H]+: 302.0036, found: 302.0037. 
tR (LCMS, MeCN/H2O/formic acid = 90/10/0.1  10/90/0.1 over 7 min) = 4.16 min.  
UV/Vis (LCMS): λmax = 361 nm. 
 (E)-N-Methyl-2-((3-(pyridin-2-yldiazenyl)-1H-indazol-6-yl)thio)benzamide (7.5) 
S
HN N
N
N
N
OHN
 
7.3 (90 mg, 0.30 mmol, 1.0 equiv.), 7.4 (50 mg, 0.30 mmol, 1.0 equiv.), Pd2(dba)3 (5.5 mg, 6 
μmol, 0.02 equiv.), XantPhos (7.0 mg, 12 μmol, 0.04 equiv.) and NaHCO3 (28 mg, 0.33 mmol, 
1.1 equiv.) were combined in a Schlenk flask. The flask was evacuated and backfilled with 
nitrogen for three times, before dry DMF (1 mL) was added. The reaction mixture was heated 
to 120 °C for 24 h before it was allowed to cool to r.t. The reaction mixture was extracted with 
EtOAc against sat. aq. NaHCO3 (3x). The combined organic layers were washed with water 
and brine, dried over MgSO4 and concentrated in vacuo. The desired product was obtained 
after flash column chromatography (dry load, 5% MeOH/DCM) as an orange solid (38 mg, 98 
μmol, 33%). 
1H NMR (400 MHz, DMSO-d6) δ 14.19 (s, 1H), 8.75 (dd, J = 4.9, 1.6 Hz, 1H), 8.42 (q, J = 4.6 
Hz, 1H), 8.30 (d, J = 8.4 Hz, 1H), 8.08 (td, J = 7.8, 1.8 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.65 
(s, 1H), 7.59 (dd, J = 7.4, 4.8 Hz, 1H), 7.51 (dd, J = 7.0, 2.1 Hz, 1H), 7.39 – 7.28 (m, 3H), 7.11 
(dd, J = 7.3, 1.7 Hz, 1H), 2.76 (d, J = 4.5 Hz, 3H). 
13C NMR (101 MHz, DMSO) δ 168.3, 163.7, 155.7, 149.9, 142.5, 139.4, 138.0, 135.2, 135.1, 
131.1, 130.9, 128.9, 128.3, 127.1, 126.2, 123.9, 114.7, 113.4, 112.5, 40.6, 40.6, 40.4, 40.4, 
40.2, 40.2, 39.9, 39.7, 39.5, 39.3, 26.6. 
HRMS (ESI): m/z calc. for C20H17N6OS+ [M+H]+: 389:1179, found: 389.1178. 
tR (LCMS, MeCN/H2O/formic acid = 90/10/0.1  10/90/0.1 over 7 min) = 3.53 min.  
UV/Vis (LCMS): λmax = 380 nm. 
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 2-((4-Cyano-3-fluorophenyl)thio)-N-methylbenzamide (7.6) 
S
F
N
HN O
 
7.4 (600 mg, 3.00 mmol, 1.0 equiv.), Pd2(dba)3 (28 mg, 30 μmol, 0.01 equiv.), XantPhos (35 
mg, 60 μmol, 0.02 equiv.) and NaHCO3 (277 mg, 3.30 mmol, 1.1 equiv.) were combined in a 
Schlenk flask. The flask was evacuated and backfilled with nitrogen for three times, before dry 
N-methylpyrrolidinone (3 mL) was added. The reaction mixture was stirred at r.t. for 30 min 
before 4-bomo-2-fluorobenzonitrile 7.1 (506 mg, 3.00 mmol, 1.0 equiv.; dissolved in 3 mL N-
methylpyrrolidinone) was added dropwise. The reaction mixture was heated to 50 °C for 5 h 
before it was allowed to cool to r.t. The reaction mixture was extracted with DCM against water 
(3x). The combined organic layers were washed with water, sat aq. LiCl, brine, dried over 
MgSO4 and concentrated in vacuo. The desired product was obtained after flash column 
chromatography (2% MeOH/DCM) as a white solid (670 mg, 2.34 mmol, 78%). 
1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 5.6, 2.6 Hz, 1H), 7.44 (dt, J = 16.4, 5.9 Hz, 4H), 
6.99 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 9.5 Hz, 1H), 6.29 (s, 1H), 3.04 – 2.70 (m, 3H). 
13C NMR (101 MHz, CDCl3) δ 168.2, 164.4, 161.8, 147.9, 147.8, 140.6, 135.8, 133.3, 131.3, 
129.9, 128.9, 128.4, 123.8, 123.8, 115.3, 115.1, 113.9, 98.3, 98.1, 77.4, 77.1, 76.8, 26.8. 
HRMS (ESI): m/z calc. for C15H12FN2OS+ [M+H]+: 287.0649, found: 287.0650. 
 2-((3-Amino-1H-indazol-6-yl)thio)-N-methylbenzamide (7.7) 
S
HN O
HN N
NH2
 
7.6 (573 mg, 2.00 mmol, 1.0 equiv.) and hydrazine hydrate (0.5 mL; 10.0 mmol, 5 equiv.) were 
combined in nBuOH (~7 mL). The reaction mixture was refluxed overnight before it was allowed 
to cool to r.t. The reaction mixture was extracted with EtOAc against sat. aq. NaHCO3 (3x). 
The combined organic layers were washed with brine, dried over MgSO4 and concentrated to 
dryness. The crude material was purified by C18 reverse-phase column chromatography 
(100/0  60/40 = 1 mM aq. HCl/MeCN) to yield the product as colorless crystals (311 mg, 1.04 
mmol, 52%). 
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For X-Ray crystallography, the product was dissolved in MeCN and tBuONO was added. After 
30 min, aq. KI solution was added. Single crystals suitable for X-Ray crystallography were 
obtained by crystallization from hot EtOH.  
1H NMR (400 MHz, Methanol-d4) δ 7.52 (d, J = 8.3 Hz, 1H), 7.33 – 7.26 (m, 1H), 7.24 (s, 1H), 
7.18 – 7.08 (m, 2H), 7.04 – 6.97 (m, 1H), 6.83 (dd, J = 8.4, 1.6 Hz, 1H), 3.97 (q, J = 7.1 Hz, 
1H), 2.74 (s, 3H), 1.89 (s, 1H), 1.18 – 1.06 (m, 1H). 
13C NMR (101 MHz, Methanol-d4) δ 170.4, 149.2, 142.3, 137.0, 135.7, 133.8, 130.8, 130.2, 
127.5, 126.2, 122.6, 120.6, 113.6, 113.2, 48.3, 48.1, 47.9, 47.8, 47.6, 47.4, 47.2, 47.0, 25.4. 
HRMS (ESI): m/z calc. for C15H15N4OS+ [M+H]+: 299.0961, found: 299.0962. 
 (E)-N-Methyl-2-((3-(phenyldiazenyl)-1H-indazol-6-yl)thio)benzamide (7.8) 
S
HN N
N
N
OHN
 
7.7 (52 mg, 0.17 mmol, 1.0 equiv.) was dissolved in 2 mL AcOH and nitrosobenzene (21 mg, 
0.20 mmol, 1.2 equiv.) was added in one portion. The reaction mixture was heated overnight 
at 60 °C before it was allowed to cool to r.t. and extracted with DCM against aq. sat. NaHCO3 
(3x). The combined organic layers were washed with brine, dried over MgSO4 and 
concentrated in vacuo. Purification by flash column chromatography (5% MeOH/DCM) yielded 
the product as an orange solid (14 mg, 37 μmol, 21%). 
1H NMR (400 MHz, DMSO-d6) δ 13.97 (s, 1H), 8.42 (q, J = 4.6 Hz, 1H), 8.34 (d, J = 8.4 Hz, 
1H), 7.98 (d, J = 7.5 Hz, 2H), 7.67 – 7.55 (m, 4H), 7.54 – 7.48 (m, 1H), 7.37 – 7.26 (m, 3H), 
7.08 (d, J = 7.4 Hz, 1H), 2.77 (d, J = 4.3 Hz, 3H). 
HRMS (ESI): m/z calc. for C21H18N5OS+ [M+H]+: 388.1223, found: 388.1226.  
 (E)-2-((3-((4-(Diethylamino)phenyl)diazenyl)-1H-indazol-6-yl)thio)-N-
methylbenzamide (7.9) 
S
HN N
N
N
OHN
N
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7.7 (30 mg, 0.10 mmol, 1.0 equiv.) and TFA (23 μL, 0.30 mmol, 3.0 equiv.) were combined in 
MeCN (15 mL). The reaction mixture was cooled to 0 °C before tBuONO (16 μL, 0.12 mmol, 
1.2 equiv.) was added. After 45 min, N,N-diethylaniline (0.16 mL, 1.00 mmol, 10.0 equiv.) was 
added dropwise. Stirring was continued at 0 °C for 45 min, before the reaction mixture was 
allowed to warm to r.t. and all volatiles were removed in vacuo. The residue was purified by 
flash column chromatography (DCM  5%MeOH/DCM) to yield the product as an orange-red 
solid (43 mg, 94 μmol, 94%). 
1H NMR (400 MHz, CDCl3) δ 12.37 (s, 0H), 8.31 (d, J = 8.4 Hz, 1H), 7.91 – 7.83 (m, 2H), 7.72 
(s, 1H), 7.49 – 7.41 (m, 1H), 7.19 (s, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.13 – 6.97 (m, 4H), 6.63 
(d, J = 8.8 Hz, 2H), 6.51 (q, J = 4.9 Hz, 1H), 3.35 (q, J = 7.1 Hz, 4H), 2.88 (d, J = 4.7 Hz, 3H), 
1.13 (t, J = 7.0 Hz, 7H). 
13C NMR (101 MHz, CDCl3) δ 169.2, 156.3, 150.3, 143.5, 142.5, 135.6, 135.5, 133.0, 131.0, 
130.9, 128.4, 126.8, 126.6, 125.4, 124.6, 114.8, 113.8, 111.0, 44.7, 27.0, 12.7. 
HRMS (ESI): m/z calc. for C25H27N6OS+ [M+H]+: 459.1962, found: 459.1967. 
tR (LCMS, MeCN/H2O/formic acid = 90/10/0.1  10/90/0.1 over 7 min) = 5.33 min.  
UV/Vis (LCMS): λmax = 482 nm. 
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7.4.2 Spectral Data 
 2-Mercapto-N-methylbenzamide (7.4) 
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 6-Bromo-1H-indazol-3-amine (7.2) 
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 (E)-6-Bromo-3-(pyridin-2-yldiazenyl)-1H-indazole (7.3) 
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 (E)-N-Methyl-2-((3-(pyridin-2-yldiazenyl)-1H-indazol-6-yl)thio)benzamide (7.5) 
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 2-((4-Cyano-3-fluorophenyl)thio)-N-methylbenzamide (7.6) 
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 2-((3-Amino-1H-indazol-6-yl)thio)-N-methylbenzamide (7.7) 
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 (E)-N-Methyl-2-((3-(phenyldiazenyl)-1H-indazol-6-yl)thio)benzamide (7.8) 
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 (E)-2-((3-((4-(Diethylamino)phenyl)diazenyl)-1H-indazol-6-yl)thio)-N-
methylbenzamide (7.9) 
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7.4.3 Crystallographic Data 
 2-Mercapto-N-methylbenzamide (7.4) 
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 4-Bromo-2-fluoro-benzonitrile (7.1) 
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 6-Bromo-1H-indazol-3-amine (7.2) 
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 2-((3-Iodo-1H-indazol-6-yl)thio)-N-methylbenzamide 
 
8 Further Synthesis and Biology 
8.1 ExONatide 
This work was published as: 
Podewin, T.; Ast, J.; Broichhagen, J.; Fine, N.H.F., Nasteska, D.; Leippe, P.; Gailer, M., 
Buenaventura, T.; Kanda, N.; Jones, B.J., M’Kadmi, C.; Baneres, J.-L.; Marie, J.; Tomas, A., 
Trauner, D.; Hoffmann-Röder, A.; Hodson, D.J. Conditional and Reversible Activation of Class 
A and B G Protein-Coupled Receptors Using Tethered Pharmacology. ACS Cent. Sci. 2018, 4 
(2), 166–179. 
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8.1.1 Supporting Information 
N-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)-1-(3-(pyridin-2-yldisulfanyl)propanamido)-
3,6,9,12-tetraoxapentadecan-15-amide (BG-PEG4-SSpy) 
 
6-((4-(Aminomethyl)benzyl)oxy)-9H-purin-2-amine (12.0 mg, 44 μmol, 1.1 equiv.), PEG4-
SDPD (ThermoScientific #26128, 22.0 mg, 44.0 μmol, 1.0 equiv.) and DIPEA (10.5 μL, 
60 μmol, 1.5 equiv.) were combined in anhydrous DMF (1.0 mL) under a nitrogen atmosphere. 
After stirring for 1 h at r.t., the crude reaction mixture was syringe filtered and subjected to RP-
HPLC. The product containing fractions were combined, concentrated in vacuo and freeze-
dried to obtain 17.0 mg (24.0 μmol) of the desired product as a white solid in 60% yield.  
Note: The multiplet at 2.52 – 2.45 ppm was obscured by the solvent signal and was assigned 
by 2D-COSY analysis. 
1H NMR (800 MHz, DMSO-d6) δ [ppm] 12.44 (s, 1H), 8.45 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 8.35 
(t, J = 6.0 Hz, 1H), 8.04 (t, J = 5.7 Hz, 1H), 7.82 (ddd, J = 8.0, 7.5, 1.9 Hz, 1H), 7.80 (d, J = 4.3 
Hz, 1H), 7.76 (dt, J = 8.1, 1.1 Hz, 1H), 7.44 (d, J = 7.7 Hz, 2H), 7.26 (d, J = 7.9 Hz, 2H), 7.24 
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 6.28 (s, 2H), 5.45 (s, 2H), 4.27 (d, J = 5.9 Hz, 2H), 3.62 (t, J = 
6.4 Hz, 2H), 3.48 (d, J = 4.6 Hz, 12H), 3.39 (t, J = 5.9 Hz, 2H), 3.19 (q, J = 5.8 Hz, 2H), 3.00 
(t, J = 7.1 Hz, 2H), 2.53 – 2.52 (m, 2H), 2.37 (t, J = 6.4 Hz, 2H). 
13C NMR (201 MHz, DMSO-d6) δ [ppm] 170.1, 169.8, 159.8, 159.6, 159.2, 155.2, 149.6, 139.3, 
137.8, 135.2, 128.5, 127.2, 121.1, 119.1, 113.5, 109.5, 69.8, 69.7, 69.5, 69.5, 69.0, 66.9, 66.5, 
41.8, 39.9, 38.6, 36.1, 34.5, 34.1. 
HRMS (ESI): m/z calc. for C32H41N8O7S2- [M-H]-: 713.2545, found: 713.2545. 
UV/VIS (LCMS): λmax1 = 197 nm; λmax2 = 214 nm; λmax3 = 286 nm. 
tR (LCMS, MeCN/H2O/formic acid = 10/90/0.1 → 100/0/0.1 over 10 min) = 4.479 min. 
tR (RP-HPLC, MeCN/H2O/TFA = 5/95/0.1 →  80/20/0.1 over 60 min) = 21.1 min. 
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8.2 APCs for mGluR2 
Similar to the ideas outlined in chapter 3.2.2, an APC for the mGluR2 was synthesized. 
Synthesis and characterization is summarized in Figure 39.  
Electrophysiological characterization was carried out in HEK293T cells transfected with 
GIRK1/2 and mGlur2 (rat). No photoswitchable effects of the APC were observed, the data is 
not shown here. One reason for these negative experiments might be bad quality of the anti-
mGluR2 antibody, multiple unspecific bands were detected by immunoblotting of HEK293T 
cells transfected with mGluR2 (see Figure 39e). 
 
Figure 39. APCs for mGluR2. a) Synthesis of the photoswitchable NOAG molecule b) APC 
conjugation reactions. c) The APC binds to the native mGluR2 and illumination with light of 
different wavelengths enables optical control. d) Coomassie stained SDS-PAGE gel verifies 
successful synthesis of APC (OximeAG-mGluR2). e) Lysate of HEK293T cells transfected with 
mGluR2 was subjected to immunoblotting. 
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8.2.1 Supporting Information 
Synthesis of NOAG 
Azoglutamate28 (4.0 mg, 6.1 μmol, 1.0 equiv.) was combined with Phth-NO-PEG12-(CH2)2-
C(O)NHS (Iris Biotech #PEG4630, 6.3 mg, 7.3 μmol, 1.2 equiv.) and DIPEA (4.2 μL, 24 μL, 
4.0 equiv.) in dry DMF (0.5 mL). The reaction mixture was stirred at r.t. for 3h. The reaction 
mixture was acidified by addition of a few drops of FA and charged on a Waters Sep-Pack 2g 
C18 column. Elution with a gradient of H2O/MeCN +0.1% FA yielded the product as an orange 
glaze (1.1 mg). 
TFA (200 μL) was then added and allowed to stand for 15 min before the TFA was removed 
in a gentle stream of nitrogen. For deprotection of the phthalimide, 2M MeNH2 in THF (500 μL) 
was added and sonicated for 30 min. The residue was acidified by addition of FA and charged 
on a Waters Sep-Pack 2g C18 column. Elution with a gradient of H2O/MeCN +0.1% FA yielded 
the product as an orange glaze (1.2 mg, 1.09 μmol, 18% over 3 steps). 
For HRMS analysis, the product was reacted with a drop of acetone to form the oxime. 
HRMS (ESI): calc. for C53H86N7O20+ (M+acetone+H)+: 1140.5922, found: 1140.5960; calc. for 
C53H84N7O20- (M+acetone-H)+: 1138.5777, found: 1138.5773. 
Synthesis of Keto-mGluR2  
Stock solutions: 
 A 0.1 mg/mL stock solution of anti-mGluR2 (ATSBio #AB-N32) was prepared by 
diluting 77 L of 1.3 mg/mL stock (100 g, 6.4110-10 mol) with 923 L of 0.25M pH 7.3 
TRIS buffer.  
• A 20 mg/mL stock solution of dichloroacetone (DCA, Sigma-Aldrich #168548) was 
prepared by dissolving 39.2 mg of DCA in 1.96 mL DMSO.  
• A 4 mM stock solution of TCEP.HCl was prepared by diluting 10 L of 0.5M TCEP.HCl 
with 1.25 mL milliQ water. The 0.5M stock solution of TCEP.HCl was prepared by 
dissolving 37.4 mg of TCEP.HCl in 0.260 mL milliQ water.  
In a 1.5 mL Eppendorf tube at room temperature, 17 L of 20 mg/mL DCA was combined with 
1000 L of 0.1 mg/mL mGluR2-IgG 4000:1 DCA:IgG). The tube was vortexed, spun down and 
cooled to 4°C. In a separate microcentrifuge tube, 50 L of 4mM TCEP.HCl was added and 
cooled to 4°C. Using a pipette, the entire volume of the mGluR2-IgG/DCA solution was added 
to the TCEP.HCl solution and the resulting solution was mixed thoroughly by repeated pipetting 
(300:1 TCEP:IgG). The reaction mixture was stored at 4°C overnight. The antibody was purified 
the next morning by membrane filtration using an Amicon centrifugal filter with 10kDa MWCO 
(10min, 14000rcf). After concentration, the retentate was diluted to ~500uL with PBS pH 7.4 
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and concentration was repeated. In total, seven concentration steps were performed, using 
PBS pH 7.4 as diluent each time. The final retentate was collected via centrifugation according 
to the manufacturer’s instructions into a tared tube and then weighed to determine the retentate 
volume (47.9 mg = 47.9 L, assuming d = 1 mg/uL). The concentration of Keto-mGluR2 was 
determined by absorbance spectroscopy: A280 = 0.882, corresponding to 0.65 mg/mL using 
ε280 of 1.36 mL mg-1 cm-1. Recovery of Keto-mGluR2 was 31% (31.1 g). 
Synthesis of Azo-mGluR2 
Stock solutions: 
• A 1M stock solution of 3,5-diaminobenzoic acid (DABA, Sigma-Aldrich #D12805) 
was freshly prepared by dissolving 49.6 mg DABA in 326uL DMSO. 
A 1.5 mL Eppendorf tube was charged sequentially with PBS (18.9 L), DMSO (7.5 L, final 
conc.: 30vol/vol%), DABA (6 L, final conc.: 0.1 M), AoAG (AminooxyAzoGlutamate, PL421C, 
4.5 L of 6.5 mM DMSO stock, 29 nmol, 300 equiv.) and Keto-mGluR2 (23 L, 15 g, 96 pmol, 
1 equiv.). The resulting solution was mixed thoroughly by repeated pipetting and stored at room 
temperature overnight. The reaction mixture was stored at room temperature, protected from 
light, overnight. The next morning, the reaction was diluted to ~500 L by addition of PBS pH 
7.4 and the antibody was purified by membrane filtration using an Amicon centrifugal filter with 
10kDa MWCO (10min, 14000rcf) using the same procedure as described for Keto-mGluR2 
purification. The final retentate was collected via centrifugation according to the manufacturer’s 
instructions into a tared tube and then weighed to determine the retentate volume (43.0 mg = 
43.0 L, assuming d = 1 mg/L). The concentration of OximeAG-mGluR2 was determined by 
absorbance spectroscopy: A280 = 0.245, corresponding to 180 g/mL using ε280 of 1.36 mL·mg-
1·cm-1. A second absorbance peak at 380 nm was observed, indicative of successful 
conjugation: A378 = 0.090 corresponding to 4.59 M using ε378 of 19611 L·mg-1·cm-1. The 
calculated conjugation ratio of photoswitch is OximeAG/IgG = (4.59 M * 43.0 L) / (180 g * 
43.0 L/156 kDa) = 3.97. Recovery of OximeAG-mGluR2 was 16% (7.74ug) over two steps 
(ketone insertion and oxime condensation). 
Absorptionspectra 
Keto-mGluR2 
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OximeAG-mGluR2 
 
SDS-PAGE of Keto-mGluR2 and OximeAG-mGluR2 
Samples (1   g/lane) were analyzed by SDS-PAGE on a NuPage 4-12% Bis-Tris gel with MES 
running buffer at 180V for ca. 45min: 
The gel was removed from its plastic casing and stained using InstantBlue Coomassie 
(Expedeon). Both unmodified and modified antibodies were observed to migrate near the 
165kDa MW marker, consistent with an intact IgG (~156 kDa). The reduced mGluR2-IgG 
migrated as two bands near the 24kDa and 57kDa MW markers, consistent with complete 
reduction of the interchain disulfide bonds yielding separate HC (~50kDa) and LC (~25kDa). 
The reduced Keto-mGluR2 migrated near the 165kDa MW marker, consistent with successful 
crosslinking with DCA, where reduction-insensitive thioether bonds have replaced disulfides. 
1.0
0.8
0.6
0.4
0.2
0.0
Ab
so
rba
nc
e
700600500400300
wavelength [nm]
0.4
0.3
0.2
0.1
Ab
so
rba
nc
e
700600500400300
wavelength [nm]
 221 
 
The band for the OximeAG-mGluR2 conjugate migrates slightly slower than the starting IgG, 
indicative of an increase in molecular weight after conjugation (see zoom-in). 
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8.3 Photocleavable dimerizers and oligomerizers 
Coumarins are widely used as photoremovable ‘photocaging’ groups. Usually, payloads are 
attached in 4-position and released upon irradiation with UV-light (Figure 40a). In comparison 
with other photoremovable groups, e.g. o-nitrobenzyl, coumarin cages exhibit high absorbance 
coefficients at reasonably long wavelengths, together with fast release-rates.135 
Other uses can be envisioned. Often, biological processes are driven by proximity alone, which 
can be taken advantage of by chemical tools, i.e. rapamycin induced dimerization.136 However, 
most chemical tools are irreversible. Recently, we reversibly enabled conditional control over 
SNAP-tagged GLP1-R and GHS-R1a by inclusion of a reductively-cleavable disulfide bridge 
into the designs of benzylguanine-linked peptide agonists, termed ExONatide and GhrelON.137 
An improvement over this method could involve the use of photolabile groups, to allow the 
cleavage to proceed by illumination (Figure 40b). To this end, a few building blocks were 
synthesized to allow for further modification.  
 
Figure 40. Design of photocleavable dimerizers or oligomerizers. BG = benzyl guanine, 
BC = benzyl cytosine, HTL = Halo-tag ligand. 
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8.3.1 Synthesis 
 tert-Butyl (3-((4-(Chloromethyl)-2-oxo-2H-chromen-7-yl)(methyl)amino)propyl) 
carbamate (8.1) 
O O
Cl
N
BocHN  
7-amino-4-(chloromethyl)-2H-chromen-2-one was prepared according to a published 
synthesis route.138 N-(tert-Butoxycarbonyl)-3-aminopropionaldehyde was prepared by 
standard Boc-protection of 3-aminopropanol and subsequent DMP oxidation. 
7-Amino-4-(chloromethyl)-2H-chromen-2-one (245 mg, 1.2 mmol, 1.0 equiv.), 
triacetoxyborohydride (447 mg, 2.8 mmol, 2.3 equiv.), glacial acetic acid (127 μL, 2.2 mmol, 
1.8 equiv.) and N-(tert-Butoxycarbonyl)-3-aminopropionaldehyde were mixed in DCE (10 mL). 
The reaction mixture was stirred at r.t. for 3 h before addition of aq. formaldehyde (37%, 95 μL, 
1.3 mmol, 1.1 equiv.), glacial acetic acid (57 μL, 1.0 mmol, 0.8 eq) and triacetoxyborohydride 
(160 mg, 1.2 mmol, 1.0 eq.). The reaction mixture was stirred at r.t. for a further 4.5 h before it 
was extracted with DCM against sat. NaHCO3 (2x), water (1x) and brine (1x). The organic layer 
was dried over MgSO4, concentrated in vacuo and purified by flash column chromatography 
(2/98 = MeOH/DCM) to obtain 160 mg (0.42 mmol) of a light yellow solid in 35% yield.  
1H NMR (400 MHz, CDCl3): δ 7.45 (d, J = 9.0 Hz, 1H), 6.64 (dd, J = 9.0, 2.6 Hz, 1H), 6.52 (d, 
J = 2.6 Hz, 1H), 6.21 (t, J = 0.9 Hz, 1H), 4.57 (d, J = 0.8 Hz, 2H), 3.46 (dd, J = 14.7, 7.3 Hz, 
2H), 3.19 (q, J = 6.6 Hz, 2H), 3.03 (s, 3H), 1.81 (p, J = 7.0 Hz, 2H), 1.45 (s, 9H). 
13C NMR (101 MHz, CDCl3): δ 161.6, 156.3, 156.0, 151.8, 149.8, 125.1, 109.7, 109.0, 106.8, 
98.4, 79.6, 50.0, 41.5, 38.7, 31.0, 28.4, 27.5. 
HRMS (ESI): calc. for C19H26ClN2O4+ (M+H)+: 381.1576, found: 381.1578. 
 tert-Butyl (2-(methyl(4-methyl-2-oxo-2H-chromen-7-yl)amino)ethyl)carbamate (8.2) 
O ON
NHBoc  
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7-Bromo-4-methylcoumarin was prepared according to a published procedure.139 tert-Butyl (2-
(methylamino)ethyl)carbamate was prepared according to a published procedure.140 
7-Bromo-4-methylcoumarin (46.6 mg, 195 μmol, 1.0 equiv.), tert-butyl (2-
(methylamino)ethyl)carbamate (40.8 mg, 234 μmol, 1.2 equiv.), cesium carbonate 
(190.6 mg585 μmol, 3.0 equiv.), RuPhos (9.1 mg, 19.5 μmol, 0.1 equiv.) and RuPhos Pd G3 
(16.3 mg, 19.5 μmol, 0.1 equiv.) were combined in a schlenk tube. The schlenk tube was 
evacuated and backfilled three times with argon before addition of dry 1,4-dioxane (1 mL). The 
reaction mixture was heated to 100°C and stirred for 3.5 h before LCMS analysis indicated 
consumption of all starting material. The reaction mixture was filtered over celite, the filter cake 
was washed with EtOAc. The solvent was removed in vacuo and the crude residue was purified 
by flash column chromatography (EtOAc/hexanes = 1/3 -> 1/2 -> 1/1) to yield the product as a 
white solid (31.5 mg, 94.8 μmol) in 49% yield. 
1H NMR (599 MHz, CDCl3): δ 7.37 (d, J = 9.0 Hz, 1H), 6.69 – 6.64 (m, 1H), 6.50 (d, J = 2.6 Hz, 
1H), 5.95 (d, J = 1.2 Hz, 1H), 4.78 (s, 1H), 3.53 (t, J = 6.7 Hz, 2H), 3.31 (q, J = 6.5 Hz, 2H), 
3.03 (s, 3H), 2.32 (d, J = 1.2 Hz, 3H), 1.42 (s, 9H). 
13C NMR (151 MHz, CDCl3): δ [ppm] = 162.1, 156.1, 155.9, 152.9, 152.0, 125.6, 109.9, 109.5, 
108.8, 98.2, 79.7, 51.8, 38.8, 38.2, 28.5, 18.6. 
HRMS (ESI): calc. for C18H25N2O4+ (M+H)+: 333.1809, found: 333.1808. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 7.723 min. 
UV/Vis (LCMS): max1,2,3 = 278, 314, 369 nm.  
 tert-Butyl (2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-yl)(methyl)amino)ethyl) 
carbamate (8.3) 
O ON
NHBoc
OH
 
8.2 (276 mg, 0.830 mmol, 1.0 equiv.) and SeO2 (184 mg, 1.66 mmol, 2.0 equiv.) were 
combined in dry meta-xylene. The reaction mixture was heated to reflux for 7 h before the 
reaction was judged to be incomplete by LCMS. More SeO2 (55.0 mg, 0.495 mmol, 0.6 equiv.) 
was added and the reaction mixture heated to reflux 16 h. The reaction mixture was allowed 
to cool to r.t. and filtered over celite. The celite was washed with a copious amount of EtOAc 
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before the organic layer was concentrated in vacuo. The blackish residue was redissolved in 
MeOH (10 mL), cooled to 0 °C and NaBH4 (53.0 mg, 1.40 mmol, 1.6 equiv.) was added in 
portions. After stirring for 1 h, the reaction was quenched by addition of a few drops of water. 
The reaction mixture was extracted with EtOAc (3x) and DCM (3x) against water. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified on a Waters Sep-Pak© 5g C18 column (water/MeCN + 0.1% FA, 100/0 -> 80/20, 5% 
increments). Product containing fractions were identified by LCMS, combined and freeze-dried. 
The tan product was obtained in 10% yield over 2 steps (30 mg, 0.086 mmol). 
1H NMR (400 MHz, CDCl3): δ  7.33 (d, J = 9.0 Hz, 1H), 6.68 (d, J = 10.0 Hz, 1H), 6.55 (d, J = 
2.4 Hz, 1H), 6.30 (s, 1H), 4.83 (s, 2H), 4.72 (s, 1H), 3.54 (t, J = 6.8 Hz, 2H), 3.32 (q, J = 6.5 
Hz, 2H), 3.05 (s, 3H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3): δ 162.2, 156.1, 155.9, 154.3, 151.7, 124.4, 109.0, 107.2, 106.3, 
98.5, 79.7, 61.0, 51.8, 38.8, 38.0, 28.4. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) = 6.23 min. 
UV/Vis (LCMS): max1,2,3 = 209, 246, 374 nm. 
HRMS (ESI): calc. for C18H25N2O5+ (M+H)+: 349.1758, found: 349.1764. 
 (9H-Fluoren-9-yl)methyl (2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-
yl)(methyl)amino)ethyl)carbamate (8.4) 
O ON
NHFmoc
OH
 
To 8.3 (30.0 mg, 0.086 mmol, 1.0 equiv.) was added neat TFA (1 mL). After 10 min at r.t., 
volatiles were removed by a gentle stream of nitrogen. The residue was redissolved in DMF 
(0.5 mL), DIPEA (0.060 mL, 0.344 mmol, 4.0 equiv.) and Fmoc-OSu (35.0 mg, 0.103 mmol, 
1.2 equiv.)O were added. The reaction was stirred for 30 min before the crude mixture was 
loaded on a Waters Sep-Pak© 2g C18 column and eluted with a gradient of water and MeCN 
(water/MeCN + 0.1% FA, 100/0 -> 80/40, 5% increments). Product containing fractions were 
identified by LCMS, combined and freeze-dried. The product was obtained as a tan solid in 
46% yield over 2 steps (19.0 mg, 0.040 mmol). 
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1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 7.6 Hz, 2H), 7.44 (d, J = 7.5 Hz, 2H), 7.31 (t, J = 7.4 
Hz, 2H), 7.20 (d, J = 9.2 Hz, 2H), 6.62 – 6.54 (m, 1H), 6.47 (s, 1H), 6.17 (s, 1H), 4.90 (d, J = 
7.6 Hz, 1H), 4.62 (s, 2H), 4.33 (d, J = 6.8 Hz, 2H), 4.02 (t, J = 6.8 Hz, 1H), 3.49 (t, J = 6.5 Hz, 
2H), 3.32 (q, J = 6.4 Hz, 2H), 2.93 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 156.5, 155.9, 154.3, 151.8, 143.8, 141.3, 127.7, 127.1, 125.0, 
124.4, 120.0, 108.8, 107.1, 106.3, 98.4, 66.7, 60.9, 51.5, 47.3, 38.6, 38.4. 
HRMS (ESI): calc. for C28H27N2O5+ (M+H)+: 471.1915, found: 471.1917. 
tR (LCMS; MeCN/H2O/formic acid = 10/90/0.1  100/0/0.1 over 10 min) =7.76 min. 
UV/Vis (LCMS): max1,2,3 = 207, 256, 301, 372 nm. 
8.3.2 Spectral Data 
 tert-Butyl (3-((4-(Chloromethyl)-2-oxo-2H-chromen-7-yl)(methyl)amino)propyl) 
carbamate (8.1) 
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 tert-Butyl (2-(methyl(4-methyl-2-oxo-2H-chromen-7-yl)amino)ethyl)carbamate (8.2) 
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 tert-Butyl (2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-yl)(methyl)amino)ethyl) 
carbamate (8.3) 
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 (9H-Fluoren-9-yl)methyl (2-((4-(hydroxymethyl)-2-oxo-2H-chromen-7-
yl)(methyl)amino)ethyl)carbamate (8.4) 
 
9. Appendix 
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9 Appendix 
9.1 General Remarks Regarding Synthetic Procedures Including Spectroscopy and 
Spectrometry 
All reactions were carried out with magnetic stirring and, if moisture- or air- sensitive, under 
nitrogen or argon atmosphere using standard Schlenk techniques in oven-dried glassware 
(140 °C oven temperature). External bath temperatures were used to record all reaction 
temperatures. Low temperature reactions were carried out in a Dewar vessel filled with distilled 
water/ice (0 °C). High temperature reactions were conducted using a heated silicon oil bath in 
reaction vessels equipped with a reflux condenser or in a sealed flask. Tetrahydrofuran (THF) 
was distilled over sodium and benzophenone prior to use. Dichloromethane (CH2Cl2), 
triethylamine (Et3N), diisopropylethylamine (DIPEA) and diisopropylamine (DIPA) were distilled 
over calcium hydride under a nitrogen atmosphere. All other solvents were purchased from 
Acros Organics as ‘extra dry’ reagents. All other reagents with a purity > 95% were obtained 
from commercial sources (Sigma Aldrich, Acros, Alfa Aesar and others) and used without 
further purification.  
Normal phase flash column chromatography was carried out with Merck silica gel 60 
(0.040-0.063 mm). Reverse phase flash column chromatography was carried out with 
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Macherey-Nagel POLYGOPREP® 100-50 C18 silica gel or on Waters Sep-Pak® C8 or C18 
columns. Analytical thin layer chromatography (TLC) was carried out using Merck silica gel 
60 F254 glass-backed plates and visualized under UV light at 254 nm. 
NMR spectra (1H NMR and 13C NMR) were recorded in deuterated chloroform (CDCl3) on a 
Bruker Avance III HD 400 MHz spectrometer equipped with a CryoProbe™, a Varian VXR400 
S spectrometer, a Bruker AMX600 spectrometer or a Bruker Avance III HD 800 MHz 
spectrometer equipped with a CryoProbe™ and are reported as follows: chemical shift δ in 
ppm (multiplicity, coupling constant J in Hz, number of protons) for 1H NMR spectra and 
chemical shift δ in ppm for 13C NMR spectra. Multiplicities are abbreviated as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, quint = quintet, br = broad, m = multiplet, or 
combinations thereof. Residual solvent peaks of CDCl3 (H = 7.26 ppm, C = 77.16 ppm), d4-
MeOH (H = 3.31 ppmC = 49.00 ppm) were used as an internal reference. NMR spectra 
were assigned using information ascertained from COSY, HMBC, HSQC and NOESY 
experiments. 
High resolution mass spectra (HRMS) were recorded on a Varian MAT CH7A or a Varian 
MAT 711 MS instrument by electron impact (EI) or electrospray ionization (ESI) techniques at 
the Department of Chemistry, Ludwig-Maximilians-University Munich.  
LCMS was performed on an Agilent 1260 Infinity HPLC System, MS-Agilent 1100 Series, Type: 
1946D, Model: SL, equipped with an Agilent Zorbax Eclipse Plus C18 (100 x 4.6 mm, particle 
size 3.5 micron) RP column with a constant flow-rate of 1 or 2 mL/min. 
X-ray data collections were performed either on an Oxford Diffraction Xcalibur diffractometer, 
on a Bruker D8Quest diffractometer or on a Bruker D8Venture at 100 K or at 173 K using 
MoKα-radiation (λ = 0.71073 Å, graphite monochromator). The CrysAlisPro software (version 
1.171.33.41) [CrysAlisPro, Oxford Diffraction Ltd., Version 1.171.33.41 (release 06-05-2009 
CrysAlis171.NET)] was applied for the integration, scaling and multi-scan absorption correction 
of the data. The structures were solved by direct methods with SIR97218 and refined by least-
squares methods against F2 with SHELXL-97. All non-hydrogen atoms were refined 
anisotropically. The hydrogen atoms were placed in ideal geometry riding on their parent atoms 
UV/Vis spectroscopy was performed using a VARIAN Cary 50 Scan UV/Vis spectrometer. 
Compound solution was placed in a standard quartz cuvette (d = 1 cm) illuminated by a light 
fiber cable from above. 
All yields are isolated, unless otherwise specified. 
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9.2 Abbreviations 
A Ampere 
Å Angstrom 
a.u.  Arbitrary units 
Ac Acetyl 
ADC antibody-drug conjugate 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor, GluA 
ANP atrial natriuretic peptide 
APC antibody-photoswitch conjugate 
Asc Ascorbate 
BC 2-((4-(aminomethyl)benzyl)oxy)pyrimidin-4-amine, benzyl 
cytosine 
BG 6-((4-(aminomethyl)benzyl)oxy)-7H-purin-2-amine, benzyl 
guanine 
BGAG Benzyl guanine azobenzene glutamate 
BINA Biphenyl-indanone A  
BME β-mercaptoethanol 
Boc tert-butoxycarbonyl 
br broad 
brsm based on recovered starting material 
BSA bovine serum albumin 
Bu butyl 
C Celsius 
COSY correlation spectroscopy 
CRD cysteine-rich domain 
CuAAC Copper-catalyzed azide-alkyne-cylcoaddition 
DABA 3,5-diaminobenzoic acid 
DBCO dibenzocyclooctyne 
DCA 1,3-dichloroacetone 
DCE 1,2-dichloroethane 
DCM dichloromethane 
DIPEA ethyldiisopropylamine 
DMEM Dulbecco’s modified eagle medium 
DMF N,N-dimethylformamide 
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DMSO Dimethylsulfoxide 
DNA desoxyribonculeic acid 
EC50 half-maximal effective concentration 
EGFR epidermal growth factor receptor 
EI electron impact 
equiv. equivalents 
ESI electrospray ionization 
Et ethyl 
FA formic acid 
 
FBS ftal bovine serum 
FCS Fetal calf serum 
Fmoc fluorenylmethoxycarbonyl 
FP Fluorescent proteinj 
g gram 
GFP green fluorescent protein 
GHS-R1a growth hormone secretagogue receptor 1a 
GIRK G protein-coupled inward rectifying receptor 
GLP1-R glucagon-like peptide 1 receptor 
GLP-1R glucagon-like peptide-1 receptor 
GPCR G protein-coupled receptor 
GVBD germinal vesicle breakdown 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRMS high-resolution mass spectrometry 
HRP Horseradish peroxidase 
HV High vacuum 
Hz Hertz 
IC50 half-maximal inhibitory concentration 
IR Insulin Receptor 
LB luria broth 
LBD ligand binding domain 
LCMS liquid chromatography–mass spectrometry 
LF lipofectaime 
MAG maleimide azobenzene glutamate 
MAP mitogen-activated protein 
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Meff effective molarity 
Met hepatocyte growth factor receptor 
mGluR metabotropic glutamate receptor 
NMDA N-methyl-D-aspartate receptor 
NMR nuclear magnetic resonance 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCL Photochromic ligand 
PEG polyethylene glycol 
Ph phenyl 
PORTL Photoswitchable orthogonal remotely-tethered ligand 
ppm parts per million 
PTL Photoswitchable tethered ligand 
RGCs retinal ganglion cells 
s seconds 
SAR structure-activity relationship 
SM small molecule 
SpAAC Strain-promoted azide-alkyne-cycloaddition 
TEA Triethylamine 
TFA trifluoroacetic acid 
TK tyrosine kinase 
TLC  thin layer chromatography 
TM transmembrane 
VFT Venus flytrap 
VKR venus kinase receptor 
WB western blot 
  
 235 
 
9.3 References 
1. Lerch, M. M., Hansen, M. J., van Dam, G. M., Szymanski, W. & Feringa, B. L. Emerging 
Targets in Photopharmacology. Angew. Chem. Int. Ed. 55, 10978–10999 (2016). 
2. Laprell, L. et al. Restoring Light Sensitivity in Blind Retinae Using a Photochromic AMPA 
Receptor Agonist. ACS Chem. Neurosci. 7, 15–20 (2016). 
3. Barber, D. M. et al. Optical control of AMPA receptors using a photoswitchable quinoxaline-
2,3-dione antagonist. Chem. Sci. 8, 611–615 (2016). 
4. Laprell, L. et al. Optical control of NMDA receptors with a diffusible photoswitch. Nat. 
Commun. 6, 8076 (2015). 
5. Schönberger, M. & Trauner, D. A Photochromic Agonist for μ-Opioid Receptors. Angew. 
Chem. Int. Ed. 53, 3264–3267 (2014). 
6. Banghart, M. R. et al. Photochromic Blockers of Voltage-Gated Potassium Channels. 
Angew. Chem. Int. Ed. 48, 9097–9101 (2009). 
7. Mourot, A. et al. Rapid optical control of nociception with an ion-channel photoswitch. Nat. 
Methods 9, 396–402 (2012). 
8. Podewin, T. et al. Optical control of a receptor-linked guanylyl cyclase using a 
photoswitchable peptidic hormone. Chem. Sci. 8, 4644–4653 (2017). 
9. Fehrentz, T., Schönberger, M. & Trauner, D. Optochemical Genetics. Angew. Chem. Int. 
Ed. 50, 12156–12182 (2011). 
10. Merino, E. & Ribagorda, M. Control over molecular motion using the cis–trans 
photoisomerization of the azo group. Beilstein J. Org. Chem. 8, 1071–1090 (2012). 
11. Levitz, J. et al. Optical control of metabotropic glutamate receptors. Nat. Neurosci. 16, 
507–516 (2013). 
12. Berlin, S. et al. A family of photoswitchable NMDA receptors. Elife 5, e12040 (2016). 
13. Donthamsetti, P. et al. Optical Control of Dopamine Receptors Using a Photoswitchable 
Tethered Inverse Agonist. J. Am. Chem. Soc. (2017). doi:10.1021/jacs.7b07659 
9. Appendix 
236 
14. Banghart, M., Borges, K., Isacoff, E., Trauner, D. & Kramer, R. H. Light-activated ion 
channels for remote control of neuronal firing. Nat. Neurosci. 7, 1381–1386 (2004). 
15. Sandoz, G., Levitz, J., Kramer, R. H. & Isacoff, E. Y. Optical Control of Endogenous 
Proteins with a Photoswitchable Conditional Subunit Reveals a Role for TREK1 in GABAB 
Signaling. Neuron 74, 1005–1014 (2012). 
16. Janovjak, H., Szobota, S., Wyart, C., Trauner, D. & Isacoff, E. Y. A light-gated, 
potassium-selective glutamate receptor for the optical inhibition of neuronal firing. Nat. 
Neurosci. 13, 1027–1032 (2010). 
17. Volgraf, M. et al. Allosteric control of an ionotropic glutamate receptor with an optical 
switch. Nat. Chem. Biol. 2, 47–52 (2006). 
18. Tochitsky, I. et al. Optochemical control of genetically engineered neuronal nicotinic 
acetylcholine receptors. Nat. Chem. 4, 105–111 (2012). 
19. Lemoine, D. et al. Optical control of an ion channel gate. Proc. Natl. Acad. Sci. 110, 
20813–20818 (2013). 
20. Szobota, S. et al. Remote Control of Neuronal Activity with a Light-Gated Glutamate 
Receptor. Neuron 54, 535–545 (2007). 
21. Caporale, N. et al. LiGluR Restores Visual Responses in Rodent Models of Inherited 
Blindness. Mol. Ther. 19, 1212–1219 (2011). 
22. Wyart, C. et al. Optogenetic dissection of a behavioural module in the vertebrate spinal 
cord. Nature 461, 407–410 (2009). 
23. Stephanopoulos, N. & Francis, M. B. Choosing an effective protein bioconjugation 
strategy. Nat. Chem. Biol. 7, 876–884 (2011). 
24. Hermanson, G. T. Bioconjugate techniques. (Elsevier/AP, 2013). 
25. DuBay, K. H. et al. A Predictive Approach for the Optical Control of Carbonic Anhydrase 
II Activity. ACS Chem. Biol. 13, 793–800 (2018). 
 237 
 
26. Tsai, Y.-H., Essig, S., James, J. R., Lang, K. & Chin, J. W. Selective, rapid and optically 
switchable regulation of protein function in live mammalian cells. Nat. Chem. 7, 554–561 
(2015). 
27. Blackman, M. L., Royzen, M. & Fox, J. M. Tetrazine Ligation: Fast Bioconjugation 
Based on Inverse-Electron-Demand Diels−Alder Reactivity. J. Am. Chem. Soc. 130, 13518–
13519 (2008). 
28. Broichhagen, J. et al. Orthogonal Optical Control of a G Protein-Coupled Receptor with 
a SNAP-Tethered Photochromic Ligand. ACS Cent. Sci. 1, 383–393 (2015). 
29. Lang, K. & Chin, J. W. Bioorthogonal Reactions for Labeling Proteins. ACS Chem. Biol. 
9, 16–20 (2014). 
30. Keppler, A. et al. A general method for the covalent labeling of fusion proteins with 
small molecules in vivo. Nat. Biotechnol. 21, 86–89 (2003). 
31. Cisbio. http://www.cisbio.com/usa/drug-discovery/start-pre-clonedplasmids (accessed 
July 12, 2017). 
32. Shields, B. C. et al. Deconstructing behavioral neuropharmacology with cellular 
specificity. Science 356, eaaj2161 (2017). 
33. Niswender, C. M. & Conn, P. J. Metabotropic Glutamate Receptors: Physiology, 
Pharmacology, and Disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322 (2010). 
34. Krishnamurthy, V. M., Semetey, V., Bracher, P. J., Shen, N. & Whitesides, G. M. 
Dependence of Effective Molarity on Linker Length for an Intramolecular Protein−Ligand 
System. J. Am. Chem. Soc. 129, 1312–1320 (2007). 
35. Levitz, J. et al. Dual optical control and mechanistic insights into photoswitchable group 
II and III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. 201619652 (2017). 
doi:10.1073/pnas.1619652114 
36. Courtesy of and adapted from Dr. Johannes Broichhagen. 
37. Berry, M. H. et al. Restoration of patterned vision with an engineered photoactivatable 
G protein-coupled receptor. Nat. Commun. 8, 1862 (2017). 
9. Appendix 
238 
38. Gaub, B. M. et al. Restoration of visual function by expression of a light-gated 
mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc. Natl. Acad. Sci. 
111, E5574–E5583 (2014). 
39. Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a 
pioneering price | FiercePharma. Available at: https://www.npr.org/sections/health-
shots/2017/12/19/571962226/first-gene-therapy-for-inherited-disease-gets-fda-approval. 
(Accessed: 12th April 2018) 
40. Chudasama, V., Maruani, A. & Caddick, S. Recent advances in the construction of 
antibody–drug conjugates. Nat. Chem. (2016). doi:10.1038/nchem.2415 
41. Helma, J., Cardoso, M. C., Muyldermans, S. & Leonhardt, H. Nanobodies and 
recombinant binders in cell biology. J. Cell Biol. 209, 633–644 (2015). 
42. Schumacher, D., Helma, J., Schneider, A. F. L., Leonhardt, H. & Hackenberger, C. P. 
R. Nanobodies: Chemical Functionalization Strategies and Intracellular Applications. 
Angew. Chem. Int. Ed. 57, 2314–2333 (2018). 
43. Farrants, H. et al. SNAP-tagged nanobodies enable reversible optical control of a G 
protein-coupled receptor via a remotely tethered photoswitchable ligand. (2018). 
doi:10.1101/266247 
44. Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. 
Nat. Struct. Mol. Biol. 17, 133–138 (2010). 
45. Scholler, P. et al. Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor 
homodimers in contextual fear consolidation. Nat. Commun. 8, 1967 (2017). 
46. Group II mGlu Receptors | mGlu2 | mGlu3. Tocris Bioscience Available at: 
https://www.tocris.com/pharmacology/glutamate-metabotropic-group-ii-receptors. 
(Accessed: 12th April 2018) 
47. Lemmon, M. A. & Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases. Cell 
141, 1117–1134 (2010). 
 239 
 
48. Vicogne, J. et al. An unusual receptor tyrosine kinase of Schistosoma mansoni contains 
a Venus Flytrap module. Mol. Biochem. Parasitol. 126, 51–62 (2003). 
49. Vanderstraete, M. et al. Venus Kinase Receptors Control Reproduction in the 
Platyhelminth Parasite Schistosoma mansoni. PLOS Pathog. 10, e1004138 (2014). 
50. Vogel, K. J., Brown, M. R. & Strand, M. R. Ovary ecdysteroidogenic hormone requires 
a receptor tyrosine kinase to activate egg formation in the mosquito Aedes aegypti. Proc. 
Natl. Acad. Sci. 112, 5057–5062 (2015). 
51. Vanderstraete, M. et al. The venus kinase receptor (VKR) family: structure and 
evolution. BMC Genomics 14, 1 (2013). 
52. Goodsell, D. S. Insulin Receptor. RCSB Protein Data Bank (2015). 
doi:10.2210/rcsb_pdb/mom_2015_2 
53. Ferrell, J. E. Building a cellular switch: more lessons from a good egg. BioEssays 21, 
866–870 (1999). 
54. El-Etr, M., Schorderet-Slatkine, S. & Baulieu, E. E. Meiotic maturation in Xenopus laevis 
oocytes initiated by insulin. Science 205, 1397–1399 (1979). 
55. Felder, C. B., Graul, R. C., Lee, A. Y., Merkle, H.-P. & Sadee, W. The Venus flytrap of 
periplasmic binding proteins: an ancient protein module present in multiple drug receptors. 
AAps Pharmsci 1, 7–26 (1999). 
56. Ahier, A. et al. A New Family of Receptor Tyrosine Kinases with a Venus Flytrap 
Binding Domain in Insects and Other Invertebrates Activated by Aminoacids. PLoS ONE 4, 
e5651 (2009). 
57. Li, E. & Hristova, K. Receptor tyrosine kinase transmembrane domains. Cell Adhes. 
Migr. 4, 249–254 (2010). 
58. Ward, C. W., Menting, J. G. & Lawrence, M. C. The insulin receptor changes 
conformation in unforeseen ways on ligand binding: Sharpening the picture of insulin 
receptor activation. BioEssays 35, 945–954 (2013). 
9. Appendix 
240 
59. Ye, Z. C. & Sontheimer, H. Astrocytes protect neurons from neurotoxic injury by serum 
glutamate. Glia 22, 237–248 (1998). 
60. mGlu2 receptor | Metabotropic glutamate receptors | IUPHAR/BPS Guide to 
PHARMACOLOGY. Available at: 
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=290. 
(Accessed: 20th April 2018) 
61. Libermann, T. A. et al. Amplification, enhanced expression and possible rearrangement 
of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144–147 
(1985). 
62. Borowiak, M. et al. Photoswitchable Inhibitors of Microtubule Dynamics Optically 
Control Mitosis and Cell Death. Cell 162, 403–411 (2015). 
63. Alberts, B. et al. Molecular Biology of the Cell. (Garland Science, 2002). 
64. Carpi, N., Carpi, N., Piel, M., Azioune, A. & Fink, J. Micropatterning on glass with deep 
UV. Protoc. Exch. (2011). doi:10.1038/protex.2011.238 
65. Pitaval, A., Christ, A., Curtet, A., Tseng, Q. & Théry, M. Probing Ciliogenesis Using 
Micropatterned Substrates. in Methods in Enzymology 525, 109–130 (Elsevier, 2013). 
66. Malherbe, P. et al. Identification of Essential Residues Involved in the Glutamate 
Binding Pocket of the Group II Metabotropic Glutamate Receptor. Mol. Pharmacol. 60, 944–
954 (2001). 
67. Mahen, R. et al. Comparative assessment of fluorescent transgene methods for 
quantitative imaging in human cells. Mol. Biol. Cell 25, 3610–3618 (2014). 
68. Regot, S., Hughey, J. J., Bajar, B. T., Carrasco, S. & Covert, M. W. High-Sensitivity 
Measurements of Multiple Kinase Activities in Live Single Cells. Cell 157, 1724–1734 
(2014). 
69. Kudo, T. et al. Live-cell measurements of kinase activity in single cells using 
translocation reporters. Nat. Protoc. 13, 155–169 (2017). 
 241 
 
70. Bindels, D. S. et al. mScarlet: a bright monomeric red fluorescent protein for cellular 
imaging. Nat. Methods 14, 53–56 (2016). 
71. Hodgkin, A. L. & Huxley, A. F. Action Potentials Recorded from Inside a Nerve Fibre. 
Nature 144, 710–711 (1939). 
72. Wulff, H., Castle, N. A. & Pardo, L. A. Voltage-gated potassium channels as therapeutic 
targets. Nat. Rev. Drug Discov. 8, 982–1001 (2009). 
73. Garcia, M. L. & Kaczorowski, G. J. Potassium Channels as Targets for Therapeutic 
Intervention. Sci. Signal. 2005, pe46–pe46 (2005). 
74. Fortin, D. L. et al. Photochemical control of endogenous ion channels and cellular 
excitability. Nat. Methods (2008). doi:10.1038/nmeth.1187 
75. Tochitsky, I. et al. Restoring Visual Function to Blind Mice with a Photoswitch that 
Exploits Electrophysiological Remodeling of Retinal Ganglion Cells. Neuron 81, 800–813 
(2014). 
76. Tochitsky, I. et al. How Azobenzene Photoswitches Restore Visual Responses to the 
Blind Retina. Neuron 92, 100–113 (2016). 
77. Goodsell, D. https://pdb101.rcsb.org/motm/38, accessed on 20180322. 
78. Broichhagen, J., Frank, J. A. & Trauner, D. A Roadmap to Success in 
Photopharmacology. Acc. Chem. Res. 48, 1947–1960 (2015). 
79. Barber, D. M. et al. Optical control of neuronal activity using a light-operated GIRK 
channel opener (LOGO). Chem. Sci. 7, 2347–2352 (2016). 
80. French, R. J. & Shoukimas, J. J. Blockage of squid axon potassium conductance by 
internal tetra-N-alkylammonium ions of various sizes. Biophys. J. 34, 271–291 (1981). 
81. Honoré, E. The neuronal background K2P channels: focus on TREK1. Nat. Rev. 
Neurosci. 8, 251–261 (2007). 
82. Fink, M. et al. Cloning, functional expression and brain localization of a novel 
unconventional outward rectifier K+ channel. EMBO J. 15, 6854–6862 (1996). 
9. Appendix 
242 
83. Vivier, D., Bennis, K., Lesage, F. & Ducki, S. Perspectives on the Two-Pore Domain 
Potassium Channel TREK-1 (TWIK-Related K + Channel 1). A Novel Therapeutic Target?: 
Miniperspective. J. Med. Chem. 59, 5149–5157 (2016). 
84. Göb, E. et al. The two-pore domain potassium channel KCNK5 deteriorates outcome 
in ischemic neurodegeneration. Pflüg. Arch. - Eur. J. Physiol. 467, 973–987 (2015). 
85. Steinberg, E. A., Wafford, K. A., Brickley, S. G., Franks, N. P. & Wisden, W. The role 
of K2P channels in anaesthesia and sleep. Pflüg. Arch. - Eur. J. Physiol. 467, 907–916 
(2015). 
86. Piechotta, P. L. et al. The pore structure and gating mechanism of K2P channels: K2P 
channel gating. EMBO J. 30, 3607–3619 (2011). 
87. Koh, D.-S., Jonas, P., Bräu, M. E. & Vogel, W. A TEA-insensitive flickering potassium 
channel active around the resting potential in myelinated nerve. J. Membr. Biol. 130, 149–
162 (1992). 
88. Lein, E. S. et al. Genome-wide atlas of gene expression in the adult mouse brain. 
Nature 445, 168–176 (2007). 
89. Sack, J. T., Stephanopoulos, N., Austin, D. C., Francis, M. B. & Trimmer, J. S. Antibody-
guided photoablation of voltage-gated potassium currents. J. Gen. Physiol. 142, 315–324 
(2013). 
90. Beck, S. et al. Fluorophore‐assisted light inactivation: A high‐throughput tool for direct 
target validation of proteins. PROTEOMICS 2, 247–255 (2002). 
91. Hu, Q. Y. & Allan, M. Methods for making conjugates from disulfide-containing proteins. 
(Google Patents, 2017). 
92. Hu, Q. Y. & Imase, H. Methods for oxime conjugation to ketone-modified polypeptides. 
(Google Patents, 2016). 
93. Kienzler, M. A. et al. A Red-Shifted, Fast-Relaxing Azobenzene Photoswitch for Visible 
Light Control of an Ionotropic Glutamate Receptor. J. Am. Chem. Soc. 135, 17683–17686 
(2013). 
 243 
 
94. Hammond, C. Cellular and molecular neurophysiology. (Elsevier/AP, Academic Press 
is an imprint of Elsevier, 2015). 
95. Traynelis, S. F. et al. Glutamate Receptor Ion Channels: Structure, Regulation, and 
Function. Pharmacol. Rev. 62, 405–496 (2010). 
96. Schmitz, L. J. M. et al. The AMPA receptor-associated protein Shisa7 regulates 
hippocampal synaptic function and contextual memory. eLife 6, (2017). 
97. Tomita, S. et al. Stargazin modulates AMPA receptor gating and trafficking by distinct 
domains. Nature 435, 1052–1058 (2005). 
98. Choi, C. & Nitabach, M. N. Membrane-Tethered Ligands: Tools for Cell-Autonomous 
Pharmacological Manipulation of Biological Circuits. Physiology 28, 164–171 (2013). 
99. Los, G. V. et al. HaloTag: A Novel Protein Labeling Technology for Cell Imaging and 
Protein Analysis. ACS Chem. Biol. 3, 373–382 (2008). 
100. Sobolevsky, A. I., Rosconi, M. P. & Gouaux, E. X-ray structure, symmetry and 
mechanism of an AMPA-subtype glutamate receptor. Nature 462, 745–756 (2009). 
101. Chang, P. K.-Y., Verbich, D. & McKinney, R. A. AMPA receptors as drug targets in 
neurological disease – advantages, caveats, and future outlook. Eur. J. Neurosci. 35, 1908–
1916 (2012). 
102. Henley, J. M. & Wilkinson, K. A. Synaptic AMPA receptor composition in development, 
plasticity and disease. Nat. Rev. Neurosci. 17, 337–350 (2016). 
103. Yamashita, T. & Kwak, S. The molecular link between inefficient GluA2 Q/R site-RNA 
editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis 
patients. Brain Res. 1584, 28–38 (2014). 
104. Greger, I. H., Watson, J. F. & Cull-Candy, S. G. Structural and Functional Architecture 
of AMPA-Type Glutamate Receptors and Their Auxiliary Proteins. Neuron 94, 713–730 
(2017). 
105. Wolter, M., Klapars, A. & Buchwald, S. L. Synthesis of N-Aryl Hydrazides by Copper-
Catalyzed Coupling of Hydrazides with Aryl Iodides. Org. Lett. 3, 3803–3805 (2001). 
9. Appendix 
244 
106. Li, S. et al. Synthesis and biological evaluation of fentanyl acrylic derivatives. RSC Adv. 
7, 20015–20019 (2017). 
107. Salam, M. The Opioid Epidemic: A Crisis Years in the Making. The New York Times 
(2018). 
108. Smydo, J. Delayed respiratory depression with fentanyl. Anesth. Prog. 26, 47–48 
(1979). 
109. Williams, J. T. et al. Regulation of -Opioid Receptors: Desensitization, Phosphorylation, 
Internalization, and Tolerance. Pharmacol. Rev. 65, 223–254 (2013). 
110. Wyk, M. van, Pielecka-Fortuna, J., Löwel, S. & Kleinlogel, S. Restoring the ON Switch 
in Blind Retinas: Opto-mGluR6, a Next-Generation, Cell-Tailored Optogenetic Tool. PLOS 
Biol. 13, e1002143 (2015). 
111. Siewertsen, R. et al. Highly Efficient Reversible Z−E Photoisomerization of a Bridged 
Azobenzene with Visible Light through Resolved S 1 (nπ*) Absorption Bands. J. Am. Chem. 
Soc. 131, 15594–15595 (2009). 
112. Sell, H., Näther, C. & Herges, R. Amino-substituted diazocines as pincer-type 
photochromic switches. Beilstein J. Org. Chem. 9, 1–7 (2013). 
113. Samanta, S., Qin, C., Lough, A. J. & Woolley, G. A. Bidirectional Photocontrol of Peptide 
Conformation with a Bridged Azobenzene Derivative. Angew. Chem. Int. Ed. 51, 6452–6455 
(2012). 
114. Mostad, A. et al. A Refinement of the Crystal Structure of cis-Azobenzene. Acta Chem. 
Scand. 25, 3561–3568 (1971). 
115. Frank, J. A. et al. Photoswitchable fatty acids enable optical control of TRPV1. Nat. 
Commun. 6, 7118 (2015). 
116. Nüsslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity 
in Drosophila. Nature 287, 795–801 (1980). 
117. Ruat, M., Hoch, L., Faure, H. & Rognan, D. Targeting of Smoothened for therapeutic 
gain. Trends Pharmacol. Sci. 35, 237–246 (2014). 
 245 
 
118. Gunzner, J. L. et al. Pyridyl inhibitors of hedgehog signalling. (2011). 
119. Byrne, E. F. X. et al. Structural basis of Smoothened regulation by its extracellular 
domains. Nature 535, 517 (2016). 
120. Taipale, J. et al. Effects of oncogenic mutations in Smoothened and Patched can be 
reversed by cyclopamine. Nature 406, 1005–1009 (2000). 
121. Ingham, P. W., Nakano, Y. & Seger, C. Mechanisms and functions of Hedgehog 
signalling across the metazoa. Nat. Rev. Genet. 12, 393–406 (2011). 
122. Briscoe, J. & Thérond, P. P. The mechanisms of Hedgehog signalling and its roles in 
development and disease. Nat. Rev. Mol. Cell Biol. 14, 416–429 (2013). 
123. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA. Cancer J. Clin. 63, 
11–30 (2013). 
124. Pecorino, L. Molecular biology of cancer: mechanisms, targets, and therapeutics. 
(Oxford University Press, 2016). 
125. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. Cell 144, 
646–674 (2011). 
126. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of Cancer Therapy: Oncogene and 
Non-oncogene Addiction. Cell 136, 823–837 (2009). 
127. Schmidinger, M. & Bellmunt, J. Plethora of agents, plethora of targets, plethora of side 
effects in metastatic renal cell carcinoma. Cancer Treat. Rev. 36, 416–424 (2010). 
128. Wilmes, L. J. et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, 
inhibits breast cancer growth and decreases vascular permeability as detected by dynamic 
contrast-enhanced magnetic resonance imaging. Magn. Reson. Imaging 25, 319–327 
(2007). 
129. Escudier, B. & Gore, M. Axitinib for the Management of Metastatic Renal Cell 
Carcinoma. Drugs R. D. 11, 113–126 (2011). 
9. Appendix 
246 
130. McTigue, M. et al. Molecular conformations, interactions, and properties associated 
with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc. Natl. Acad. 
Sci. 109, 18281–18289 (2012). 
131. Taylor, E. C., Tseng, C. P. & Rampal, J. B. Conversion of a primary amino group into a 
nitroso group. Synthesis of nitroso-substituted heterocycles. J. Org. Chem. 47, 552–555 
(1982). 
132. Travieso-Puente, R. et al. Arylazoindazole Photoswitches: Facile Synthesis and 
Functionalization via S N Ar Substitution. J. Am. Chem. Soc. 139, 3328–3331 (2017). 
133. Correa, A., Tellitu, I., Domínguez, E. & SanMartin, R. Novel Alternative for the N−S 
Bond Formation and Its Application to the Synthesis of Benzisothiazol-3-ones. Org. Lett. 8, 
4811–4813 (2006). 
134. Gray, N., Zhou, W. & Deng, X. Indazole compounds and their uses. (Google Patents, 
2013). 
135. Klán, P. et al. Photoremovable Protecting Groups in Chemistry and Biology: Reaction 
Mechanisms and Efficacy. Chem. Rev. 113, 119–191 (2013). 
136. Stanton, B. Z., Chory, E. J. & Crabtree, G. R. Chemically induced proximity in biology 
and medicine. Science 359, eaao5902 (2018). 
137. Podewin, T. et al. Conditional and Reversible Activation of Class A and B G Protein-
Coupled Receptors Using Tethered Pharmacology. ACS Cent. Sci. 4, 166–179 (2018). 
138. Cürten, B., Kullmann, P. H. M., Bier, M. E., Kandler, K. & Schmidt, B. F. Synthesis, 
Photophysical, Photochemical and Biological Properties of Caged GABA, 4-[[(2H-1-
Benzopyran-2-one-7-amino-4-methoxy) carbonyl] amino] Butanoic Acid¶. Photochem. 
Photobiol. 81, 641 (2005). 
139. Liu, X. et al. Aziridinyl Fluorophores Demonstrate Bright Fluorescence and Superior 
Photostability by Effectively Inhibiting Twisted Intramolecular Charge Transfer. J. Am. 
Chem. Soc. 138, 6960–6963 (2016). 
 247 
 
140. Li, H., Hao, M., Wang, L., Liang, W. & Chen, K. Preparation of Mono Boc-Protected 
Unsymmetrical Diamines. Org. Prep. Proced. Int. 41, 301–307 (2009). 
 
